Development of health models in Pediatric Infectious Diseases by Nicastro, Emanuele
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! X$!
B(+(0,(0&+3!+/+3<,),!6)-)!1)-;.-5)7!60(4!(4)!,(+(0,(0&+3!&.51'(0/*!)/=0-./5)/(!a!G=)-,0./!f8Y8VW!a!\.'/7+(0./!;.-!B(+(0,(0&+3!P.51'(0/*A!c0)//+A!%',(-0+H8!L+(+!;.-!&./(0/'.',!=+-0+23),!6)-)!):1-),,)7!+,!5)+/,!l!,(+/7+-7!7)=0+(0./8!L+(+!;.-!&+()*.-0&+3!=+-0+23),!6)-)!1-),)/()7!+,!;-)K')/&0),!+/7!1)-&)/(+*),8!!R/!'/0=+-0+()!+/+3<,0,A!(4)!70;;)-)/&),!0/!(4)!(4).-)(0&+3!N/.63)7*)!.;!PCD!-)&.55)/7+(0./,!+/7!0/!(4)!+=)-+*)!+74)-)/&)!,&.-)A!2);.-)!+/7!+;()-!(4)!&.'-,)A!6)-)!)=+3'+()7!',0/*!(4)!?03&.:./!,0*/)7J-+/N!(),(!;.-!1+0-)7!,+513),8!!9.!):+50/)!(4)!051+&(!./!+74)-)/&)!.;!;+&(.-,!-)3+(0/*!(.!)0(4)-!14<,0&0+/`,!+/7!1+(0)/(`,!3)=)3A!+!(6.J3)=)3!-+/7.5!0/()-&)1(!5'3(03)=)3!3.*0,(0&!-)*-),,0./!+/+3<,0,!Gd^a%H!6+,!',)7!(.!1-.1)-3<!+&&.'/(!;.-!&3',()-0/*!.;!%D@!&+,),!+5./*!14<,0&0+/,8!d^a%!6+,!+1130)7!,)1+-+()3<!./!(4)!1-)J)7'&+(0./!*-.'1!GC-)@DH!+/7!1.,(J)7'&+(0./!*-.'1!GC.,(@DH!7+(+!0/!.-7)-!(.!0/=),(0*+()!64)(4)-!;+&(.-,!+,,.&0+()7!(.!/./J+74)-)/&)!(.!PCD!1-0.-!(.!(4)!)J3)+-/0/*!&.'-,)!+3,.!3)7!(.!0/+11-.1-0+()!0/()-=)/(0./,!+;()-!(4)!&.'-,)8!%7M',()7!.77,!-+(0.!+/7!&.--),1./70/*!OXk!&./;07)/&)!0/()-=+3,!6)-)!.2(+0/)7!60(4!(4)!d^a!5)(4.78!!%33!(),(,!6)-)!(6.J(+03)7A!+/7!?!=+3'),!hY8YX!6)-)!&./,07)-)7!,0*/0;0&+/(8!!
!<BKN;B'S/)! 4'/7-)7! +/7! ;.-(<J/0/)! 14<,0&0+/,! ,0*/)7! '1! (.! (4)! )J3)+-/0/*! &.'-,)! +/7! 6)-)!&./,07)-)7! )/-.33)78! F0/)(<! GgYkH! 6)-)! ):&3'7)7! 2)&+',)! (4)<! 707! /.(! &.513)()! +33! (4)!5.7'3),! 60(40/! (4)! ),(+230,4)7! 7)+730/)8! \0;(<J/0/)! G"YkH! .;! (4)! )/-.33)7! 14<,0&0+/,! G"X!;)5+3),A!5)70+/!+*)!"Y!<)+-,A! -+/*)!TgJXOH! &.513)()7! (4)! &.'-,)!+/7!6)-)! &./,07)-)7! ;.-!;'-(4)-!+/+3<,0,!+/7!(4)0-!2+,)30/)!&4+-+&()-0,(0&,!+-)!,4.6/!0/!9+23)!V8!96)/(<J,)=)/!.;!XO!1+-(0&01+/(,!G"gkH!4+7! 3),,!(4+/!VY!<)+-,!.;!+&(0=0(<8!94)<!6)-)!;-.5!B3.=)/0+!GVTHA!D-))&)!GVVHA!F)(4)-3+/7,!GOHA!C.-('*+3A!a.5+/0+A!a',,0+!GX!)+&4HA!9'-N)<A!R(+3<!Gf!)+&4HA!])3*0'5!+/7!D)-5+/<! GT! )+&4H8! %5./*! (4)! 1+-(0&01+/(,A! (4)-)! 6)-)! fO! 14<,0&0+/,! GggkH! 6.-N0/*! 0/!
! XO!
4.,10(+3! ,)((0/*! +/7! TY! Gf"kH! 0/! .'(1+(0)/(! &30/0&8! F.! 70;;)-)/&)! 0/! +*)A! *)/7)-A! <)+-,! +/7!,)((0/*!.;!+&(0=0(<A!1-)=0.',!):1)-0)/&)!60(4!)J3)+-/0/*!+/7!1-)=0.',!N/.63)7*)!.;!PCD!6+,!.2,)-=)7!2)(6))/!(4)!14<,0&0+/,!64.!&.513)()7!(4)!&.'-,)!+/7!(4.,)!64.!707!/.(8!!L+(+! .;! X"X! &4037-)/! 60(4! %D@! Gf"T! ;)5+3),W! 5)70+/! +*)! TV! 5./(4,A! -+/*)! VJgTH! 6)-)!&.33)&()7! 2<! (4)! 1+-(0&01+/(,A! T$V! 2);.-)! GC-)@DA! XVkH! +/7! Tg"! +;()-! (+N0/*! (4)! &.'-,)!GC.,(@DA!"OkH8!94-))!4'/7-)7!+/7!;.-(<J(4-))!1+(0)/(,!GgXkH!6)-)!5+/+*)7!0/!4.,10(+3!+/7!VOT! GfXkH! 0/! .'(1+(0)/(! ,)((0/*8! 94)! 1-),)/&)! .;! +/! '/7)-3<0/*! &4-./0&! 70,)+,)! .-! +!&./&.50(+/(!+&'()!033/),,!6+,!-)1.-()7!0/!"X!G$kH!+/7!g#!GVTkH!&+,),A!-),1)&(0=)3<8!%!(.(+3!.;!TX! .'(! .;! X"X! &4037-)/! GXkH! 1-),)/()7! 60(4! ,)=)-)! 7)4<7-+(0./! +&&.-70/*! (.! 14<,0&0+/`,!),(05+()!G9+23)!TH8!94)-)!6+,!/.!,0*/0;0&+/(!70;;)-)/&)!0/!&30/0&+3!;)+('-),!2)(6))/!C-)@D!+/7!C.,(@D!+(!./,)(!.;!%D@A!60(4!(4)!):&)1(0./!.;!,(..3!.'(1'(!G1mY8YVgH8!_/.63)7*)!+2.'(!(4)!PCD!./!%D@!0/&-)+,)7!+;()-!(4)!)J3)+-/0/*!&.'-,)!+,!M'7*)7!2<!(4)!VXJK'),(0./!N/.63)7*)!(),(!,&.-),!2);.-)!G$8glT8#!1.0/(,H!+/7!+;()-!(4)!&.'-,)!GVT8$lT8V!1.0/(,A!1hY8YYVH8!94)!-),1./,)!(05)!+3,.!7)&-)+,)7!+;()-!(4)!&.'-,)!GX#Olf#O!=,!$#$lXYf!,)&./7,A!1hY8YYVH!0/!(4)!XO!)/-.33)7!14<,0&0+/,!G\0*'-)!VH8!!94)!1-.1.-(0./!.;!1+(0)/(,!5+/+*)7!0/!;'33!+74)-)/&)!G/.!0/+11-.1-0+()!0/()-=)/(0./,!.-!./3<!./)! 50/.-! =0.3+(0./H! 0/&-)+,)7! ;-.5! ff8glfV8#k! (.! "f8Olfg8Vk! G1mY8Yf#H8! B0503+-3<A! (4)!+=)-+*)!+74)-)/&)!0/&-)+,)7!;-.5!$#8Yl#8#k!(.!OY8gl#8Vk!G1mY8YYVH!G\0*'-)!TH8!!94)!5)+/!1-.1.-(0./!.;!1+(0)/(,!5+/+*)7!60(4! 0/+11-.1-0+()! 0/()-=)/(0./,! 0/!)+&4!7.5+0/!6+,! &+3&'3+()78! 94)! 5.,(! &.55./! =0.3+(0./,! (.! (4)! PCD! 6)-)! (4)! 1-),&-01(0./! .;! ,(..3!&'3('-),! 0/! (4)! +2,)/&)! .;! 23..7<! 70+--4.)+! +/7Q.-! '/7)-3<0/*! &4-./0&! 70,)+,),A! 70)(+-<!&4+/*),! +/7! 0/&./,0,()/(! ),(05+()! .;! 7)4<7-+(0./! &.51+-)7!60(4! .2M)&(0=)! 1+-+5)()-,8! %,!,4.6/! 0/! \0*'-)! fA! (4)! )J3)+-/0/*! &.'-,)! -)7'&)7! 0/+11-.1-0+()! 0/()-=)/(0./,! 0/! +33! (4)!7.5+0/,8!E.,10(+3!+750,,0./!6+,!/.(!+11-.1-0+()!0/!TTk!.;!(4)!C-)@D!+/7!VXk!.;!(4)!C.,(@D!G1mY8TH8! R/7))7A! (4)!1-.1.-(0./!.;! 4.,10(+30>)7! &4037-)/!60(4!iXk!6)0*4(! *+0/! +(! 70,&4+-*)!
! gY!
6+,! ./3<! TXk! +5./*! (4)! C-)@D! +/7! Tg8Xk! +5./*! (4)! C.,(@D! G1mY8$"VHA! 0/70&+(0/*! +! 3.6!1-.1.-(0./!.;! &4037-)/!60(4!%D@!60(4!+(! 3)+,(!5.7)-+()!7)*-))!.;!7)4<7-+(0./! 0/!4.,10(+3,A!+/7!(40,!7+(+!707!/.(!&4+/*)!+;()-!(4)!)J3)+-/0/*!&.'-,)8!94)!d^a%!5.7)3!0,!,4.6/!0/!9+23)!f8!?0(4!,'&4!5.7)3A!6)!+,,),,)7!(4)!30/N!2)(6))/!,1)&0;0&!;+&(.-,! -)3+()7! (.! 14<,0&0+/,! .-A! -),1)&(0=)3<A! (.! &30/0&+3! ;)+('-),! .;! &4037-)/A! +/7! (4)!70,&-)1+/&0),! 60(4! (4)! *'07)30/),! -)&.55)/7+(0./,8! ?)! +3,.! 0/=),(0*+()7! 64)(4)-! (4),)!;+&(.-,!6)-)!,(033!+,,.&0+()7!60(4!0/+11-.1-0+()!0/()-=)/(0./,!+;()-!(4)!&.'-,)8!C4<,0&0+/,!64.!4+7!+!1-)=0.',!N/.63)7*)!.;! (4)!*'07)30/),!6)-)!5.-)! ! 30N)3<!(.!2)! !+74)-)/(!60(4!(4)!PCD!nSamY8TO!GOXkPRmY8VJY8$gHA!1mY8YTgo8!E.6)=)-!!(4)!)J3)+-/0/*!&.'-,)!;033)7!(4)!*+1!2)(6))/!(4.,)! 64.! +3-)+7<! N/.6! (4)! PCD! +/7! (4.,)! 64.! 707! /.(! nSamV8OT! GOXkPRmY8X$Jg8f#HA!1mY8T$Oo8! P.50/*! (.! (4)! 1+(0)/(,`! ;)+('-),A! &4037-)/! 0/! (4)! C-)@D! 60(4! 23..7<! 70+--4)+!nSamX8#X! GOXkPRmV8fOJTf8$OHA! 1mY8YVgo! +/7! +27.50/+3! 1+0/! nSamV8$$! GOXkPRmV8VJf8T"HA!1mY8YTo!6)-)!5.-)!30N)3<!(.!-)&)0=)!0/+11-.1-0+()!0/()-=)/(0./,A!2'(!(40,!-0,N!6+,!+2.30,4)7!+;()-! (4)! &.'-,)! nSamV8O! GOXkPRmY8"gJ#8$"HA! 1mY8f#! +/7! SamY8gV! GOXkPRmY8TXJV8"OHA!1mY8T#OA!-),1)&(0=)3<A!0/!(4)!C.,(@Do8!R/,()+7A!;-)K')/(!=.50(0/*!)10,.7),!GiXQ7+<H!-)5+0/)7!+,,.&0+()7! 60(4! 0/+11-.1-0+()! 5+/+*)5)/(! )0(4)-! 2);.-)! nSam"8Y#! GOXkPRmV8fOJVV8$OHA!1mY8YVo!+/7!+;()-!(4)!&.'-,)!nSamX8TT!GOXkPRmV8g"JVg8gOHA!1mY8YYXo8!P4-./0&!70,)+,),!6)-)!+! 1-.()&(0=)! ;+&(.-! +*+0/,(! /./J+74)-)/&)! ./3<! 0/! (4)!C-)@D! *-.'1! nSamY8T"! GOXkPRmY8Y#JY8$gHA!1mY8YT$o8!!
J*B:KBB*A='@J3)+-/0/*! 0,! +! 3.*0&+3! ,(-+()*<! (.! 051-.=)! 1-+&(0&)A! 7')! (.! 0(,! '/0=)-,+3! +=+03+2030(<A!+,</&4-./.',! +&&),,02030(<A! 0/()-+&(0=0(<A! 1-),)/&)! .;! 0513)5)/(+(0./! (..3,! G,'&4! +,!&4)&N30,(,A!6)2!-);)-)/&),A!)(&8HA! +/7! (4)! 3.6!&.,(,! ;.-! (4)! 3)+-/)-TY!TV8!E.6)=)-A! (4)-)! 0,!/.!1-..;!.;! 0(,!);;0&+&<! 0/! 051-.=0/*!&30/0&+3!1-+&(0&)8!d+/<!,('70),!',)7!,'--.*+()!.'(&.5),!(.!
! gV!
`,!7+03<!1-+&(0&)8!94)!.=)-+33!+74)-)/&)!(.!PCD!!,0*/0;0&+/(3<!051-.=)7A!+,!M'7*)7!2<!2.(4!+=)-+*)!+74)-)/&)!.;!5)70&+3! 0/()-=)/(0./,! +/7! (4)! 5)+/! 1-.1.-(0./! .;! &4037-)/! 5+/+*)7! +&&.-70/*! (.! (4)!-)&.55)/7+(0./,8!E.6)=)-A!6)!/.(!./3<!0/=),(0*+()7!(4)!,1)&0;0&!*+1,!+/7!(4)!70,&-)1+/&0),!60(4! (4)! +1130&+(0./! .;! -)&.55)/7+(0./,A! 2'(! +3,.! )=+3'+()7! (4)0-! 7)()-50/+/(,! (4-.'*4! +!,1)&0;0&+33<!7)=)3.1)7!3.*0,(0&!-)*-),,0./!5.7)3!+/7!):+50/)7!(4)!-.3)!.;!2.(4!14<,0&0+/,`!+/7!1+(0)/(,`
! gT!
fJTg
! gf!

!<E<!<=:<B'V8!]+3+,!@%8!\-.5!+11-.1-0+()!&+-)!(.!)=07)/&)J2+,)7!5)70&0/)8!C)70+(-!%//!VOO$WT#GOHUX$VJ"8!T8!^+//./!PdA!\3.6)-!_A!L'/&+/!CA!)(!+38!94)!]-0*4(!\'('-),!9-+0/0/*!R/()-=)/(0./!C-.M)&(U!0513)5)/(0/*!,<,()5,!(.!,'11.-(!1-)=)/(0=)!+/7!7)=)3.15)/(+3!,)-=0&),!0/!1-+&(0&)8!C)70+(-0&,!TYY$WVTTGVHU)VgfJ#V8!f8!^.!c)&&40.!%A!D0+//+((+,0.!%A!L'**+/!PA!)(!+38!@=+3'+(0./!.;!(4)!K'+30(<!.;!*'07)30/),!;.-!+&'()!*+,(-.)/()-0(0,!0/!&4037-)/!60(4!(4)!%Da@@!0/,(-'5)/(8!e!C)70+(-!D+,(-.)/()-.3!F'(-!TYVVWXTGTHUV$fJO8!"8!^)*07.Jp'0*3)<!EA!C+/()30!LA!]-',+5)/(.!BA!)(!+38!P30/0&+3!*'07)30/),!0/!(4)!@'-.1)+/!I/0./U!5+110/*!(4)!-)*'3+(.-<!2+,0,A!7)=)3.15)/(A!K'+30(<!&./(-.3A!0513)5)/(+(0./!+/7!)=+3'+(0./!+&-.,,!5)52)-!,(+(),8!E)+3(4!C.30&<!TYVTWVY#GTJfHUV"gJXg8!
! g"!
X8!C-0.-!dA!D')-0/!dA!D-055)-JB.5)-,!_8!94)!);;)&(0=)/),,!.;!&30/0&+3!*'07)30/)!0513)5)/(+(0./!,(-+()*0),JJ+!,</(4),0,!.;!,<,()5+(0&!-)=0)6!;0/70/*,8!e!@=+3!P30/!C-+&(!TYY$WV"GXHU$$$JO#8!g8!C.6)33!Pc@8!E.6!(.!0513)5)/(!&4+/*)!0/!&30/0&+3!1-+&(0&)8!C+)70+(-!a),10-!a)=!TYYfW"G"HUf"YJg8!#8!L.4)-(<!BA!e./),!CA!B()=)/,!EA!)(!+38!q@=07)/&)J2+,)7!0513)5)/(+(0./q!.;!1+)70+(-0&!+,(45+!*'07)30/),!0/!+!-'-+3!)5)-*)/&<!7)1+-(5)/(8!e!C+)70+(-!P4037!E)+3(4!TYY#W"fGOHUgVVJg8!$8!%32+/.!\A!^.!c)&&40.!%A!D'+-0/.!%8!94)!+1130&+2030(<!+/7!);;0&+&<!.;!*'07)30/),!;.-!(4)!5+/+*)5)/(!.;!+&'()!*+,(-.)/()-0(0,!0/!.'(1+(0)/(!&4037-)/U!+!;0)37J-+/7.50>)7!(-0+3!./!1-05+-<!&+-)!1)70+(-0&0+/,8!e!C)70+(-!TYVYWVXgGTHUTTgJfY8!O8!\-))75+/!B]A!D.'0/!BA!]4+((!dA!)(!+38!C-.,1)&(0=)!+,,),,5)/(!.;!1-+&(0&)!1+(()-/!=+-0+(0./,!0/!(4)!(-)+(5)/(!.;!1)70+(-0&!*+,(-.)/()-0(0,8!C)70+(-0&,!TYVVWVT#GTHU)T$#JOX8!VY8!\-))75+/!B]A!94'33J\-))75+/!eLA!a'5+/(0-!dA!)(!+38!@5)-*)/&<!L)1+-(5)/(!a)=0,0(,!0/!P4037-)/!?0(4!D+,(-.)/()-0(0,U!+!a)(-.,1)&(0=)!S2,)-=+(0./+3!P.4.-(!B('7<8!e!C)70+(-!D+,(-.)/()-.3!F'(-!TYVf8!VV8!90)7)-!eBA!a.2)-(,./!%A!D+--0,./!dd8!C)70+(-0&!4.,10(+3!+74)-)/&)!(.!(4)!,(+/7+-7!.;!&+-)!;.-!+&'()!*+,(-.)/()-0(0,8!C)70+(-0&,!TYYOWVT"GgHU)VY$VJ#8!VT8!d+/*0./)JB50(4!aA!L)P-0,(.;+-.!%EA!B)(.7M0!PdA!)(!+38!94)!K'+30(<!.;!+52'3+(.-<!&+-)!7)30=)-)7!(.!&4037-)/!0/!(4)!I/0()7!B(+(),8!F!@/*3!e!d)7!TYY#WfX#GVXHUVXVXJTf8!Vf8!C+(4+N!LA!C+(4+N!%A!d+--./)!DA!)(!+38!%74)-)/&)!(.!(-)+(5)/(!*'07)30/),!;.-!+&'()!70+--4.)+!0/!&4037-)/!'1!(.!VT!<)+-,!0/!IMM+0/A!R/70+JJ+!&-.,,J,)&(0./+3!1-),&-01(0./!+/+3<,0,8!]dP!R/;)&(!L0,!TYVVWVVUfT8!V"8!D.-7./!dA!P4+/7-+(03+N)!dA!]+N)-!C8!R51-.=)7!M'/0.-!1+)70+(-0&!1-),&-020/*!,N033,!+;()-!+!,4.-(!)J3)+-/0/*!0/()-=)/(0./U!+!-+/7.50,)7!&./(-.33)7!(-0+38!%-&4!L0,!P4037!TYVVWOgGVTHUVVOVJ"8!
! gX!
VX8!Sq^)+-<!\d8!C+)70+(-0&!-),',&0(+(0./!(-+0/0/*U!0,!)J3)+-/0/*!(4)!+/,6)-j!%!2);.-)!+/7!+;()-!103.(!,('7<8!e!C+)70+(-!P4037!E)+3(4!TYVTW"$GgHUXTOJff8!Vg8!%,+-2+N4,4!dA!B+/7+-,!e8!@J3)+-/0/*U!(4)!),,)/(0+3!',+2030(<!1)-,1)&(0=)8!P30/!9)+&4!TYVfWVYGVHU"#JXY8!V#8!D'+-0/.!%A!?0/()-!EA!B+/74'!]A!)(!+38!%&'()!*+,(-.)/()-0(0,!70,)+,)U!a)1.-(!.;!(4)!\RBCDE%F!?.-N0/*!D-.'18!e!C)70+(-!D+,(-.)/()-.3!F'(-!TYVTWXXGXHUgTVJg8!V$8!D'+-0/.!%A!%32+/.!\A!%,4N)/+>0!BA!)(!+38!@'-.1)+/!B.&0)(<!;.-!C+)70+(-0&!D+,(-.)/()-.3.*<A!E)1+(.3.*<A!+/7!F'(-0(0./Q@'-.1)+/!B.&0)(<!;.-!C+)70+(-0&!R/;)&(0.',!L0,)+,),!)=07)/&)J2+,)7!*'07)30/),!;.-!(4)!5+/+*)5)/(!.;!+&'()!*+,(-.)/()-0(0,!0/!&4037-)/!0/!@'-.1)8!e!C)70+(-!D+,(-.)/()-.3!F'(-!TYY$W"g!B'113!TUB$VJVTT8!VO8!9@@FJ%D@!,('7<!&.'-,)U!@=07)/&)J2+,)7!*'07)30/),!;.-!(4)!5+/+*)5)/(!.;!+&'()!*+,(-.)/()-0(0,!0/!&4037-)/!0/!@'-.1)8!4((1UQQ6668)J3)+-/0/*8')*8)'Q&.'-,),Q&.'-,)J,'55+-<84(53j)1-,kX]-kXLmV"#Xg8!TY8!E+/,)/!dd8!c)-,+(03)A!055)-,0=)A!&-)+(0=)!+/7!7</+50&!=0-('+3!fJL!4)+3(4&+-)!3)+-/0/*!)/=0-./5)/(,U!+!-)=0)6!.;!(4)!30()-+('-)8!e!d)7!R/()-/)(!a),!TYY$WVYGfHU)Tg8!TV8!_0/7!98!94)!R/()-/)(!+,!+/!+7M'/&(!;.-!1)70+(-0&!1-05+-<!&+-)8!P'--!S10/!C)70+(-!TYYOWTVGgHU$YXJVY8!TT8!_'30)-!aA!Dr35)>.*3'!%dA!b+5.-+!eA!)(!+38!@;;)&(0=)/),,!.;!+!&30/0&+33<!0/()*-+()7!)J3)+-/0/*!&.'-,)!0/!)=07)/&)J2+,)7!5)70&0/)!;.-!-)1-.7'&(0=)!4)+3(4!(-+0/0/*U!+!-+/7.50>)7!(-0+38!e%d%!TYVTWfY$GTVHUTTV$JTX8!Tf8!]-'>>),)!@A!^.!c)&&40.!%A!D'+-0/.!%8!E.,10(+3!5+/+*)5)/(!.;!&4037-)/!60(4!+&'()!*+,(-.)/()-0(0,8!P'--!S10/!D+,(-.)/()-.3!TYVfWTOGVHUTfJfY8!T"8!@75./7,!d8!S/7+/,)(-./!-)7'&)7!(4)!/))7!;.-!0/(-+=)/.',!4<7-+(0./!0/!&4037-)/!60(4!+&'()!*+,(-0(0,Q*+,(-.)/()-0(0,!+/7!7)4<7-+(0./8!@=07!]+,)7!d)7!TYYOWV"GTHU""8!
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Recovery of graft steatosis and protein-
losing enteropathy after biliary diversion
in a PFIC 1 liver transplanted child
PFIC constitutes a heterogeneous group of
autosomal recessive disorders caused by muta-
tions in genes involved in bile formation leading
to cholestastis of hepatocellular origin (1). PFIC
1, previously called Byler disease, is caused by
mutations in ATP8B1 gene, encoding the ‘‘flip-
pase’’ FIC1 expressed on the canalicular pole of
the hepatocyte responsible for the enrichment of
phosphatidylserine and phosphatidylethanol-
amine on the inner leaflet of the plasma mem-
brane. FIC1 is also expressed on cholangiocytes
and enterocytes, where it is likely to be involved
in intestinal bile acid reabsorption and in enter-
ohepatic bile acid circulation. PFIC 1 patients
usually present with cholestasis characterized by
pruritus and jaundice, often accompanied by
intractable diarrhea and growth retardation, and
they invariably progress to liver cirrhosis before
adulthood; in some patients, gastrointestinal
symptoms predominate (2–4). Patients with end
stage liver disease, severe pruritus or severe
growth retardation are candidates for LT,
whereas either PEBD or ileal bypass are consid-
ered in cases without cirrhosis (5). It is well
known that the liver allograft can be affected by
severe steatosis. A variable percentage of patients
with post-transplant steatosis progress to steato-
hepatitis and cirrhosis with possible need of
retransplantation (6, 7). Another recognized
feature in transplant course of patients with
PFIC 1 is the onset or the exacerbation of
diarrhea. Interestingly, post-transplant steatosis
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has been documented primarily in patients with
diarrhea, and it has been hypothesized that the
fatty liver disease spectrum affecting the allograft
could be the result of the interaction between the
native bowel and the graft liver by diverse
mechanisms. Indeed, in a patient with post-
transplant diarrhea, symptoms disappeared
during a transitional biliary diversion performed
for a bile leakage (6).
We describe for the first time the successful
treatment of post-transplant refractory diarrhea
and secondary protein-losing enteropathy, along
with histologically documented graft recovery
from post-transplant steatohepatitis, with an
EBD in a child with PFIC 1.
Case report
Amale infant was born at term to healthy parents,
with no familial history of liver disease, and a
birth weight of 3660 g. At five months of age, he
developed jaundice with dark urine. Growth and
development were normal on breast feeding. He
had mild hepatomegaly and otherwise normal
clinical examination. Liver function tests showed
hyperbilirubinemia (TB and CB 5.7 and 1.5 mg/
dL, respectively) and mild elevation of amino-
transferases (AST 85 IU/L; ALT 58 IU/L); cGT
was in the normal range; hepatic synthetic func-
tion was normal. Serology for infectious hepatitis
was negative. Alpha-1 antitrypsin deficiency
and cystic fibrosis were ruled out. Serum total
bile salts reached 147 lm (NV < 10). Ophthal-
mologic examination and spine radiography were
unremarkable. Liver ultrasound revealed normal
texture and dimension with no focal lesions.
Normal gallbladder and biliary tree were shown
at cholangio-MRI. Histology showed features of
intrahepatic cholestasis with no ductular prolif-
eration. A diagnosis of ‘‘low-cGT PFIC’’ (PFIC 1
or 2) was established and the patient was given
UDCA at a dose of 20 mg/kg/day.
The child was referred to our center at the
age of 42 months, with intractable pruritus
despite UDCA and rifampicin; he was otherwise
in good general condition. He had generalized
scratch lesions, with no hepatomegaly and no
sign of portal hypertension. Blood test showed
mild hyperbilirubinemia (TB/CB 3.1/1.8 mg/dL)
with normal hepatobiliary enzymes, as well as
normal serum total proteins, albumin, and
coagulation tests. Liver Doppler ultrasound
showed heterogeneous parenchymal structure
suggesting fibrosis, with no signs of portal
hypertension. Liver histology confirmed portal
fibrosis, with mild ductular proliferation, and
marked cholestasis.
Living-related donor LT (maternal donor)
was performed at the age of 43 months (3.6 yr),
with tacrolimus, daclizumab, and mycophenolic
acid immunosuppression. Immunohistochemis-
try showed normal BSEP canalicular staining
(courtesy Prof. Tania Roskams). Molecular
analysis for ATP8B1 documented double hetero-
zygosis for the missense mutations p.D554N
(c.1660 G>A, exon 16) and p.D734A (c.2199
A>C, exon 19), the latter being novel, according
to the diagnosis of PFIC 1 (Dr. Christiane
Baussan).
Following LT, pruritus disappeared and serum
bilirubin concentration normalized. However,
diarrhea appeared progressively within one
month following LT, with 6–7 liquid stools/
day, and limited improvement with fasting.
Repeated stool cultures and parasite examination
remained negative, and there was no response
to bowel decontamination using oral adminis-
tration of metronidazole and paromomycin.
Although raised values of vasoactive intestinal
peptide (VIP) (297 pg/mL, NV 15–65) and NSE
(27.2 lg/L, NV < 15) were observed, the ab-
sence of abnormal uptake at In111-penteotride
and I123-MIBG scintigraphy ruled out a neuro-
endocrine tumor as the cause of secretory diar-
rhea. Urinary catecholamines were normal.
Abdominal ultrasound examining the bowel wall
was unremarkable. Liver ultrasound showed
progressive hyperechogenicity of the liver paren-
chyma. Diarrhea was proposed to be secondary
to restored bile flow through the native bowel,
and treatment with cholestyramine was adminis-
tered at a dose of 2 g four times per day. UDCA
and mycophenolic acid were discontinued. This
led to improvement of the diarrhea (less liquid)
and decreased stool output (3–4 stools/day).
Liver biopsies at two and three months after
LT showed severe macrovacuolar steatosis with
mild fibrotic enlargement of the portal spaces
(Fig. 1a).
The child returned to his home country on
cholestyramine 8 g/day in four doses, with an
output of four stools/day, and tacrolimus mono-
therapy as immunosuppression. Nine months
after LT, the child lost weight and developed
hypoalbuminemia requiring substitutive treat-
ment and frequent admissions to a university
hospital in his home country.
He was referred again to our department
two yr after LT, with worsening diarrhea and
severe hypoalbuminemia (1.4 g/dL). Serum total
protein and immunoglobulin levels were also
diminished, along with elevation of the hepato-
biliary enzymes (ALT 201 IU/L; cGT 94 IU/L).
There was no urinary protein excretion, with
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normal renal function and kidney morphology
on ultrasound. Echocardiography was unre-
markable. Stool cultures were negative for bac-
teria, parasites, and amoeba. Upper endoscopic
examination was normal, with normal duodenal
and gastric biopsies, and negative tests for
Giardia spp. and Helicobacter pylori. Fecal Clos-
tridium difficile enterotoxin A was negative on
immunoassay. Fecal pancreatic elastase-1 was
normal. In111-transferrin scintigraphy detected
diffuse activity in the small intestine that reached
the colon one h post-injection, and the protein
loss calculated as a fraction of the whole body
retention after 72 h was 108 mL plasma equiva-
lent/day. This confirmed the diagnosis of protein-
losing enteropathy, which was attributed to the
restored bile flow in the native PFIC 1 small
bowel. Liver histology was characterized by
fibrous septa of centrilobular origin, associated
with the severe macrovacuolar steatosis previ-
ously observed (Fig. 1b).
An EBD of the Roux-en-Y loop was carried
out 28 months after LT. Briefly, the distal part
of the Roux loop was disconnected from the
bowel tract and open as a terminal jejunostomy
in the right hypochondrium (Fig. 2). The intes-
tinal biopsies performed intraoperatively resulted
normal.
Stool frequency normalized within one wk
after EBD. Serum albumin and total protein
concentrations, as well as immunoglobulin levels
returned to normal. Intestinal protein loss
assessed at In111-transferrin scintigraphy was
reduced by 60% two months later and was
(a) (b) (c)
Fig. 1. Liver biopsies of the patient three months (a) and 24 months (b) after LT, and six months after EBD (30 months after
LT; c). Both upper (trichrome stains, original magnification ·200) and lower pictures (hematoxylin and eosin, original
magnification ·1000) show the diffuse macrovacuolar steatosis and the worsening fibrosis originating from the portal tracts
(*). Six months after EBD, a dramatic improvement of the steatosis can be observed (c).
Fig. 2. Diagram of the surgical procedure of the EBD. The
distal part of the Roux-en-Y loop was disconnected from the
bowel tract and a terminal jejunostomy (*) was open in
the right hypochondrium, allowing the bile flow (arrows) to
be diverted externally. GL, grafted liver; HJ, hepatico-jejun-
ostomy; S, stomach; D, duodenum; JJ, jejuno-jejunostomy.
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absent after six months on both planar abdom-
inal imaging and quantitative assessment. The
child remained well on liposoluble vitamin sup-
plementation, and the post-surgical course was
uneventful at six months post-EBD. The average
bile output was 200 mL/day. The clinical course
and biochemistry results are summarized in
Table 1. Liver biopsy after six months docu-
mented a dramatic improvement of steatosis
(Fig. 1c).
A signed written informed consent, approved
by the local Ethical Committee (Cliniques Uni-
versitaires Saint Luc, Brussels, Belgium), was
provided for the patient.
Discussion
PEBD was introduced in 1998, for the treatment
for PFIC 1, with the purpose of interrupting the
enterohepatic circulation of bile salts by
decreasing the bile acid pool. The procedure
was shown to diminish serum total bile salts and
improve itching, growth, liver function tests,
and lipid metabolism in patients without cir-
rhosis (5, 8). Patients who had undergone
PEBD also showed reversal of histologic mark-
ers of cholestasis and inflammation (9, 10).
However, the long-term outcome of this proce-
dure remains to be demonstrated (11). LT
warrants long-term efficacy and it remains the
only therapeutic option in patients with
advanced liver disease. The potential to receive
a liver graft in younger patients because of the
option of living donation and split liver tech-
nique, as well as an a priori poor acceptance of
the ostomy are further reasons for some centers
to choose LT as the primary option in PFIC
patients.
In the described patient, we performed a LT
because of the presence of early hepatic fibrosis
and of intractable pruritus. However, the occur-
rence of diarrhea has been reported as a specific
complication in such patients. After LT, intesti-
nal FIC1 (the ATP8B1 gene product) defect is
aggravated by the restored bile flow from a
normal liver. This leads to the development of
refractory diarrhea (12–14). The second concern
in the post-transplant course of PFIC 1 patients
is the occurrence of allograft steatohepatitis (6,
13, 15, 16). In one of the largest series, steatosis
occurred in 8/11 transplanted patients, all having
post-LT refractory diarrhea, and seven pro-
gressed to steatohepatitis (6). Possible causes of
fatty change in transplanted livers are refractory
diarrhea and malnutrition secondary to the latter
and/or to pancreatitis. Bile adsorptive resin
therapy has been shown to improve diarrhea
and consequently steatosis, but long-term results
of this medical treatment remain unsatisfactory
(6, 12, 14).
To date, biliary diversion has not been con-
sidered as a cure for these complications after
LT, unlike its use in non-transplanted patients.
Usui et al. reported a single patient who experi-
enced intractable diarrhea and graft failure
because of rejection, in whom EBD was per-
formed at the moment of the retransplantation,
with subsequent good outcome (7).
After LT, our patient experienced malnutrition
secondary to refractory diarrhea with protein-
losing enteropathy, in the absence of pancreatic
exocrine insufficiency. This condition rapidly led
to fatty degeneration of the transplanted liver
with steatohepatitis and worsening fibrosis,
severe weight loss and growth retardation and
Table 1. Clinical course and laboratory tests of the patient with PFIC 1 after LT, before and after EBD
Admission
Age (months) 42 43 44 46 63 68 71 76
Time post-LT (months) ) +1 +2 +4 +21 +26 +29 +34
Time post-EBD (months) ) ) ) ) ) ) +1 +6
ALT, IU/L (NV 14–63) 22 68 156 36 201 102 15 31
GGT, IU/L (NV 7–50) 23 49 35 30 94 103 74 47
TB, mg/dL (NV 0.3–1.2) 3.1 0.4 0.3 0.5 0.5 0.4 0.4 0.7
CB, mg/dL (NV 0–0.2) 1.8 0.1 0.1 0.1 0.1 0.1 0.1 )
aPTT, s (NV 20–33) 27 26 31 24 ) 24 26
PT, s (NV 9–14) 11.1 12.3 12.6 28 ) 11.7 12.5 11.6
PT INR (NV 0.8–1.3) 1.03 1.15 1.18 1.15 ) 1.08 1.16 1.09
Alb, g/dL (NV 3.4–5.2) 3.7 3.5 2.72 3.5 2.1 1.4 3.11 3.7
TP, g/dL (NV 6.1–7.9) 7.8 6.10 5.10 6.2 4.4 3.6 5.73 6.66
Ig, g/dL (NV 0.5–1) 1 0.9 0.89 1.02 ) 0.68 1.01 1.36
Stools/day 1–2 6–7 6–7 4 6–7 6–7 1–2 1–2
Weight/height centile 56 55 ) 91 ) 21 25 85
ALT, alanine aminotransferase; GGT, gamma-glutamyltranspeptidase; TB, total bilirubin; CB, conjugated bilirubin; aPTT, activated partial thromboplastin time; PT,
prothrombin time; Alb, albumin; TP, total proteins; Ig, total immunoglobulins.
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generalized edema because of hypoproteinemia.
Considering the partial response to bile adsorp-
tive resin therapy, we decided to perform an EBD
to improve the diarrhea and nutritional state and
to prevent graft failure. This approach is novel,
and it proved effective in terms of clinical,
histological, and biochemical outcome.
Protein-losing enteropathy, although previ-
ously reported in one patient with PFIC 1
following LT, has not been characterized in these
patients (6). Intestinal protein loss may be due to
causes related to increased interstitial pressure
(such as intestinal lymphangectasia, congestive
heart failure, and portal hypertension) or to
alterations of gastrointestinal mucosa. The rapid
good clinical outcome, documented by scintigra-
phy, suggested that the small bowel defect in bile
acid reabsorption, and not fibrosis or portal
hypertension, was indeed the cause of both
malabsorption and non-erosive mucosal damage
finally leading to protein loss. In this perspective,
all efforts should be performed to characterize
the specific molecular defect among familial
cholestasis, and in case of FIC1 mutations,
PEBD should be further considered as first
treatment option if possible.
A novel ATP8B1 mutation was found in this
patient; an adenine-to-cytosine substitution in
position 1660, leading to a missense aspartate-to-
alanine (p.D734A). This means, in terms of
protein structure, a substitution of a hydrophilic
with a hydrophobic residue in the region encod-
ing the largest and catalytically active cytosolic
domain, carrying the phosphorylation site and
an ATP-binding site. The other mutation carried
is a missense aspartate-to-asparagine p.D554N,
in the same region. The presence of both
mutations in such a key region of ATP8B1 gene
could be related to the dramatic gastrointestinal
disease after LT with graft dysfunction. Muta-
tions in such a region have been described
previously to be associated with post-transplant
steatosis (6).
We conclude that EBD proved to be safe and
effective for the treatment of a PFIC 1 patient
who developed severe diarrhea, protein-losing
enteropathy, and graft steatofibrosis following
LT. In this patient, this intervention restored
normal graft function and allowed a better
quality of life. Internal ileal bypass will be
considered as a safer long-term solution.
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Risk of Perinatal HIV
Infection in Infants Born in
Italy to Immigrant Mothers
To the Editor—Increasing numbers of
human immunodeficiency virus (HIV)–
infected children immigrating from
countries where HIV infection is en-
demic have been reported in Europe
[1–3]. However, information regarding
mother-to-child transmission (MTCT)
in infants born in Western countries
to immigrant mothers is lacking. We
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describe characteristics of infants born to
HIV-infected mothers in Italy, focusing
on potential inequalities between in-
fants born to native and immigrant
women, considered as those originating
from countries where HIV infection is
endemic [4].
Data from 4470 children born in Italy
to HIV-infected mothers during 1996–
2010 and enrolled in the Italian Register
for HIV infection in children from birth,
with an ascertained infectious status,
were analyzed. Details regarding data
collection and status definitions are de-
scribed elsewhere [5]. Factors potentially
associated with MTCT of HIV infection
were explored by logistic regression anal-
ysis. Differences among proportions were
evaluated using the v2 test with Mantel-
Haenzel correction.
Crude total rate of MTCT signifi-
cantly decreased from 5.1% (56 of 1049
cases; 95% confidence interval [CI],
3.98%–6.70%) during 1996–1999 to 2.2%
(46 of 2016 cases; 95% CI,1.63%–2.93%)
during 2000–2005 and 1.0% (13 of 1298
cases; 95% CI, 0.46%–1.55%) during
2005–2010 (P , .0001). The numbers
of children born in Italy to immigrant
mothers increased from 110 (10.0%) of
1105 during 1996–1999 to 522 (25.5%) of
2049 during 2000–2005 and 561 (43.3%)
of 1295 during 2005–2010 (P , .0001);
799 (67.0%) of 1193 immigrant mothers
originated from sub-Saharan Africa.
The rate of MTCT was 2.8% (95% CI,
1.91%–3.79%) among infants born to
immigrant mothers and 1.8% (95% CI,
0.89%–2.68%) among infants born to
native mothers. In multivariable analysis,
being born to an immigrant mother
was associated with increased risk of
MTCT (adjusted odds ratio, 2.269; 95%
CI, 1.115–4.619; P 5 .024) (Table 1).
Immigrant mothers less frequently had
received combined antiretroviral therapy
with $3 drugs (679 [56.9%] of 1193 vs
609 of [71.2%] of 855; P , .0001) and
had less frequently undetectable viral
load at delivery, compared with native
mothers (531 [44.5%] of 1193 vs 529
[61.9%] of 855; P , .0001). A higher
proportion of immigrant mothers
breastfed their infants, compared with
native mothers (1.6% vs 0.3%; P5 .007).
No difference was observed with respect
to the proportion of elective caesarean
delivery, incidence of premature de-
liveries, and receipt of intrapartum or
postnatal prophylaxis.
Considering data from all the 1478
children with perinatal HIV infection
and enrolled in the Italian Register for
HIV Infection in Children from 1985,
followed up or not since birth, the pro-
portion of HIV-infected children born
to immigrant mothers significantly
increased over time from 132 (9.9%) of
1328 before 2000 to 79 (54.5%) of 159
during or after 2000 (P , .0001). This is
consistent with similar findings reported
in US [6], French [1], Spanish [2], UK,
and Irish [3] pediatric cohorts. How-
ever, in our dataset, 115 (54.4%) of 211
infected children born to an immigrant
mother were born in Italy, in contrast
to what has been observed in other
countries, such as the United Kingdom,
where the large majority of these chil-
dren were born abroad [3]. One limit of
our study is lack of detailed information
regarding time of HIV infection di-
agnosis in the mothers, time spent in
Italy, compliance, and resistance profile.
Data regarding mothers’ origins and
viral loads at delivery were missing in
many cases. However, our findings are
indicators for social alarm in Italy and
shed light on possible barriers to ac-
cessing health care facilities, to receiving
appropriate counseling and prophylaxis
measures, and to existence of possible
cultural barriers [7]. Comorbidities may
also be more frequent in immigrant
mothers [7]. Public health interventions
are needed to minimize these missed
opportunities for the prevention of HIV
infection.
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Injection drug user mother
No 76/3182 (2.4) Reference
Yes 38/1260 (3.0) 1.008 (0.627–1.619) .974
Unknown 1/28 (3.6) 0.583 (0.074–4.658) .613
NOTE. aOR, adjusted odds ratio; CI, confidence interval; ZDV, zidovudine.
a OR are adjusted for all other variables included in the table and calculated by logistic regression analysis.
312 d CID 2011:53 (1 August) d CORRESPONDENCE
 at Facoltà Lettere e Filosofia - Bib.Centralizzata on January 25, 2013
http://cid.oxfordjournals.org/
Downloaded from 
and response to treatment by children in the
United Kingdom and Ireland with perinatally
acquired HIV infection during 1996–2006:
planning for teenage and adult care. Clin
Infect Dis 2007; 45:918–24.
4. UNAIDS/WHO. 2010 report on the global
AIDS epidemic. Annex: HIV and AIDS esti-
mates and data, 2009 and 2001. Available at:
http://www.unaids.org/globalreport/Global_
report.htm. Accessed 31 March 2011.
5. Chiappini E, Galli L, Tovo PA, et al. Five-year
follow-up of children with perinatal HIV-1
infection receiving early highly active anti-
retroviral therapy. BMC Infect Dis 2009; 9:140.
6. Rakhmanina NY, Sill A, Baghdassarian A,
et al. Epidemiology of new cases of HIV-1
infection in children referred to the metro-
politan pediatric hospital in Washington,
DC. Pediatr Infect Dis J 2008; 27:837–9.
7. Mepham SO, Bland RM, Newell ML. Pre-
vention of mother-to-child transmission of
HIV in resource-rich and -poor settings.
BJOG 2011; 118:202–18.
Correspondence: Maurizio de Martino, MD, Department of
Sciences for Woman and Child's Health, University of
Florence, Via Pieraccini, 24, I-50139 Florence, Italy
(maurizio.demartino@unifi.it).
Clinical Infectious Diseases 2011;53(3):310–313
! The Author 2011. Published by Oxford University Press on
behalf of the Infectious Diseases Society of America. All
rights reserved. For Permissions, please e-mail: journals.
permissions@oup.com.
1058-4838/2011/533-0023$14.00
DOI: 10.1093/cid/cir344
CORRESPONDENCE d CID 2011:53 (1 August) d 313
 at Facoltà Lettere e Filosofia - Bib.Centralizzata on January 25, 2013
http://cid.oxfordjournals.org/
Downloaded from 
The HIV-1 Transactivator Factor (Tat) Induces Enterocyte
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Abstract
The intestinal mucosa is an important target of human immunodeficiency virus (HIV) infection. HIV virus induces CD4+ T cell
loss and epithelial damage which results in increased intestinal permeability. The mechanisms involved in nutrient
malabsorption and alterations of intestinal mucosal architecture are unknown. We previously demonstrated that HIV-1
transactivator factor (Tat) induces an enterotoxic effect on intestinal epithelial cells that could be responsible for HIV-
associated diarrhea. Since oxidative stress is implicated in the pathogenesis and morbidity of HIV infection, we evaluated
whether Tat induces apoptosis of human enterocytes through oxidative stress, and whether the antioxidant N-
acetylcysteine (NAC) could prevent it. Caco-2 and HT29 cells or human intestinal mucosa specimens were exposed to Tat
alone or combined with NAC. In an in-vitro cell model, Tat increased the generation of reactive oxygen species and
decreased antioxidant defenses as judged by a reduction in catalase activity and a reduced (GSH)/oxidized (GSSG)
glutathione ratio. Tat also induced cytochrome c release from mitochondria to cytosol, and caspase-3 activation. Rectal
dialysis samples from HIV-infected patients were positive for the oxidative stress marker 8-hydroxy-29-deoxyguanosine.
GSH/GSSG imbalance and apoptosis occurred in jejunal specimens from HIV-positive patients at baseline and from HIV-
negative specimens exposed to Tat. Experiments with neutralizing anti-Tat antibodies showed that these effects were direct
and specific. Pre-treatment with NAC prevented Tat-induced apoptosis and restored the glutathione balance in both the in-
vitro and the ex-vivo model. These findings indicate that oxidative stress is one of the mechanism involved in HIV-intestinal
disease.
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Introduction
The intestinal mucosa is a functional barrier against pathogens
being both a physical obstacle with columnar cells linked together by
tight junctions, and the site of mucosal immunological cells. HIV
infection is mainly initiated on the intestinal mucosal surface through
heterosexual or homosexual transmission [1,2] and HIV acutely
induces infiltration of the gut mucosa thereby resulting in the release
of activated effector memory CD4+ and CD8+ T cells, damage to
the intestinal barrier and increased epithelial apoptosis [3]. Clinical
data support a relationship between chronic HIV infection and
intestinal dysfunction including increased permeability, altered
nutrient absorption, diarrhea and reduction of the absorptive surface
[4–10]. Acquired immunodeficiency syndrome (AIDS) enteropathy
is an idiopathic, pathogen-negative diarrhea and is associated with
an increase in inflammation [11], mucosal immune activation,
villous atrophy and crypt hyperplasia that may be observed in all
stages of HIV disease even in the absence of HIV virus [12]. The
detection of viral proteins and/or nucleic acids in enterocytes and in
goblet cells indicated that HIV virus plays a direct pathogenic role at
intestinal level [13,14]. Kotler et al. detected HIV DNA, RNA and
protein antigens in lamina propria mononuclear cells and epithelial
cells of gastrointestinal tract from HIV patients [14].
However, several effects induced by HIV are not mediated by
lytic propagation of viral particles, but rather by viral factors that
are released by infected cells [15]. We previously demonstrated
that the viral protein Tat induces ion secretion in Caco-2 cells and
in human colonic mucosa, and inhibits intestinal cell proliferation.
Tat-induced ion secretion is associated with an increase in
intracellular Ca2+ as a result of extracellular Ca2+ entrance and
mobilization of intracellular stores [16]. A similar effect is induced
by Tat in neurons [17]. In addition, Tat causes an imbalance in
reactive oxygen species (ROS) generation in neurons, which is
neutralized by antioxidants, thereby implicating perturbation of
the intracellular redox status in the pathogenesis of HIV-induced
cell damage [18].
Oxidative stress is implicated in the pathogenesis and morbidity
of HIV infection [19,20]. An increase of ROS and an alteration of
antioxidant defenses have been reported in HIV-infected patients
[21] associated with decreased levels of antioxidants [22]. The
mechanisms involved in HIV-induced oxidative stress are
unknown, but HIV-1 proteins gp120 and Tat have been
implicated in this process [23] because both induce oxidative
stress and cause apoptosis in brain endothelial cells [23].
Antioxidant defenses are also impaired in HIV-infected patients
and, in particular, glutathione metabolism is altered [24]. Reduced
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glutathione (GSH) is the main intracellular thiol molecule
responsible for ROS scavenging and for the maintenance of
oxidative balance. It is also involved in the protection of DNA and
nuclear proteins from oxidative damage. Intracellular GSH
depletion triggers ROS production thereby inducing an arrest in
the intestinal cell cycle [25]. GSH levels are depleted in plasma, in
epithelial lining fluid of the lower respiratory tract, in peripheral
blood mononuclear cells and in monocytes in HIV-infected
patients [26]. Antioxidant deficiency leads to severe degeneration
of intestinal epithelial cells, and even a mild intracellular redox
imbalance inhibits enterocyte proliferation [27].
Interestingly, GSH levels progressively decrease as the HIV-1
viral load increases [28]. A fall in GSH during HIV infection may
result from reduced GSH synthesis or increased catabolism. Tat
blocks transcription of manganese superoxide dismutase, an
enzyme that prevents oxidative stress, and decreases the activity
of glucose-6-phosphate dehydrogenase, a key enzyme in pathways
that maintain GSH in its reduced state [29]. Moreover, Tat
induced oxidative stress in an immortalized endothelial cell line
from rat brain capillaries [30].
In this scenario, we hypothesized that the enteropathogenic
effects induced by Tat are associated with an imbalance of the
redox state in the intestine.
Results
HIV-1 Tat induces intestinal epithelial oxidative stress
thereby increasing reactive oxygen species and impairing
antioxidant defenses
To evaluate whether an altered redox state could be responsible
for the effects induced by Tat, we measured the intracellular levels
of ROS and of two main intracellular antioxidant defense systems,
catalase and glutathione, in intestinal epithelial cells. Fluorescence
microscopy showed that ROS levels were increased in Caco-2 cells
exposed to 0.5 nM of Tat for 1 hour as judged by the fluorescence
green signal produced by the interaction between dichlorodihy-
drofluorescein diacetate (DCFH-DA) and ROS (Fig. 1A). ROS
production was also increased in HT-29 cells stimulated with
HIV-Tat under the same conditions (Fig. 1B). As a positive
control, cells were treated with H2O2, and cells treated with the
same volume of media without Tat protein served as negative
control. Increasing Tat concentrations (0.05–1 nM) were added to
Caco-2 cells. DCFH-DA was used for ROS quantification and
measured 15 min after Tat stimulation. Exposure to Tat protein
resulted in a dose-dependent increase of ROS (Fig. 2A). Since
ROS generation is usually rapid after a toxic stimulus, we
performed time-course experiments in Caco-2 cells exposed to Tat
for 15, 30, 60 and 120 min (Fig. 2B). A ROS increase was evident
as early as 15 min after exposure to Tat; levels returned to control
values after two hours. This suggests that the antioxidant defenses
may be activated to counteract oxidative stress.
We carried out neutralization experiments to ascertain whether
ROS generation is a specific effect induced by Tat. As shown in
Fig. 2C and D, anti-Tat polyclonal antibodies inhibited the increase
of ROS intracellular levels in Caco-2 and HT-29 cells. To see
whether Tat enters into the cells, we stimulated Caco-2 cells from
the same culture with Tat at 1, 24, 48 and 72 hrs and, in parallel, we
evaluated ROS concentrations and Tat intracellular levels (Fig. S1).
In these conditions, Tat was detected inside the cells 1 hour after
stimulation and until at least 72 hours post-exposure (Fig. S1C).
We next investigated whether Tat-induced ROS generation was
associated with a decrease of antioxidant defenses by measuring
Figure 1. Influence of HIV-Tat protein on ROS generation in Caco-2 cells (A) and HT29 cells (B). Immunofluorescent staining of ROS by
DCFH-DA after Tat exposure were compared to H2O2- and untreated cells (control). Representative staining is shown at 1 hour post-exposure.
Magnification: 2006. Data are representative of 3 separate experiments with 3–4 replicates for each experimental condition.
doi:10.1371/journal.pone.0029436.g001
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the levels of glutathione, one of the major intracellular ROS
scavengers. Glutathione is an important cellular antioxidant, and it
plays a major role in protecting cells against oxidative stress. In
fact, the intracellular balance between the reduced (GSH) and
oxidated (GSSG) glutathione forms in healthy conditions was
reported to show a predominantly reducing state being GSH
about 80–90% and GSSG 10–20% [31]. We found that the
GSH/GSSG ratio was lower in Caco-2 cells exposed to Tat than
in controls and that the effect was dose- and time-dependent
(Fig. 3A and B). The reduction of GSH was significant between 0.1
and 1 nM of Tat (Fig. 3A) and was already evident at 1 hour post-
exposure. GSH remained low at 24 hours and returned to basal
level at 48–72 hours (Fig. 3B). Also in this case, anti-Tat polyclonal
antibodies completely inhibited the Tat-induced GSH/GSSG
imbalance in Caco-2 (Fig. 3C) and in HT-29 cells (Fig. S2). The
decreased activity of the enzyme catalase, another component of
the antioxidant defense, after 1 hour of exposure to Tat (Fig. 3D)
indicates that antioxidant defense is a target of Tat.
Intestinal oxidative stress is increased in HIV-infected
children
In nuclear and mitochondrial DNA, 8-hydroxy-29-deoxygua-
nosine (8-OHdG) is one of the predominant marker of free radical-
induced oxidative damage and is therefore widely used as
biomarker for oxidative stress in clinical samples [32–34]. To
investigate whether HIV-infected patients are affected by intestinal
oxidative stress, we measured 8-OHdG concentration in a small
amount of rectal dialysis solution from 20 HIV-positive children
treated in our tertiary care center for patients with AIDS (Fig. 4A).
The characteristics of patients are shown in Table 1. The
concentration of 8-OHdG was higher in HIV-infected children
than in serum-negative children (Fig. 4B). To investigate whether
intestinal oxidative stress was related to virus replication, we
divided the HIV-positive patients in two groups related to plasma
viral load. We identified 9 children with a viral load higher than 40
copies/ml and 11 children with undetectable HIV RNA (,40
copies/ml). The mean 8-OHdG concentration was higher in
children with HIV RNA .40 copies/ml than in children with
HIV RNA ,40 copies/ml and in serum-negative children
(Fig. 4C), which suggests that in children with chronic HIV
infection, oxidative damage measured in rectal mucosa may be
linked with viral replication. However, 8-OHdG concentrations in
urine and serum did not differ between patients and HIV-negative
control children (Fig. S3), suggesting that the oxidative stress is
localized in rectal mucosa. Finally, a significant correlation was
detected between 8-OHdG and viral load (r = 0.4653; p = 0.0009).
Figure 2. Tat-induced ROS generation is dose- and time-dependent. Caco-2 cells were exposed to different concentrations of Tat for 1 hour
(A) and to 0.1 nM for 10, 30, 60 and 120 min (B), and ROS intracellular levels were evaluated by the DCFH-DA fluorometric method. To evaluate the
specificity of the effect, Caco-2 cells (C) and HT-29 (D) were incubated with Tat with or without the anti-Tat polyclonal antibody. Data are
representative of 3 separate experiments. *p,0,05 vs control; #p,0,05 vs Tat.
doi:10.1371/journal.pone.0029436.g002
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Activation of caspase-3 and cytochrome c release in the
cytosol indicates that Tat induces apoptosis through
involvement of the intrinsic pathway
Several viruses induce apoptosis as a strategy to spread the
infection or to induce the breakdown of infected cells, thereby
favoring viral dissemination. To investigate whether Tat induces
intestinal apoptosis, we studied caspase-3 signaling, which is
activated by two fundamentally distinct signaling cascades, namely
the extrinsic and intrinsic (or mitochondrial) pathways [35]. We
found that caspase-3 activity was higher in Caco-2 cells exposed to
Tat for 72 hours than in control cells (Fig. 5A). Caspase-3 is a
critical effector of apoptosis and is responsible for the proteolytic
cleavage of many key proteins including the nuclear enzyme poly
(ADP ribose) polymerase (a-PARP). In a western blot time-course
experiment, we found that the levels of the full-length forms of
caspase-3 protein and a-PARP were reduced after Tat exposure
compared with control cells thereby indicating activation of the
apoptotic molecular mechanisms (Fig. 5B).
Proapoptotic stimuli, including ROS and calcium overload, are
able to activate the intrinsic pathway of apoptosis by inducing
mitochondrial membrane permeabilization and the release of
cytochrome c in the cytosol. Because we previously found that Tat
induced an increase of cytosolic calcium from intracellular stores
[16], we used western blot analysis to test the effects of Tat on the
release of cytochrome c. Twenty-four hours after Tat exposure,
cytochrome c levels in the cytosol of cells were very high and they
continued to increase up to 72 hours (Fig. 5C upper panel).
Cytochrome c was not detected in the cytosol of control cells. The
same filter was reprobed with a monoclonal antibody against
cytochrome oxidase subunit IV (COX IV), which is a mitochon-
drial marker, and then with anti-tubulin antibody, which is a
cytosolic marker. The absence of COX IV in the cytosolic samples
confirmed the absence of mitochondrial contamination in the
cytosolic fraction (Fig. 5C middle panel), and the absence of
tubulin in mitochondrial samples indicates that the mitochondrial
fractions were free from cytosolic content (Fig. 5C lower panel).
Because oxidative stress disrupts the cytoskeleton, we investi-
gated the intracellular actin architecture. The architecture of actin
cytoskeleton was normal in Caco-2 cells, but it became instable
and fragmented after Tat exposure. Disruption of the actin
cytoskeleton was dependent on the time of Tat exposure (Fig. 6A).
To investigate the effects of Tat on microtubules in Caco-2 cells,
we performed experiments of co-immunoprecipitation of Tat and
tubulin. The protein extracts from Caco-2 cells exposed to Tat
Figure 3. Tat induced alteration of intracellular antioxidant defenses. Caco-2 cells were exposed to different concentrations of Tat for
1 hour (A) and to 0.1 nM for 10, 30, 60 and 120 min (B), and the percent of GSH (grey) and GSSG (white) was evaluated as described under ‘‘Methods’’
in the Method section. To evaluate the specificity of the effect, Caco-2 cells (C) were incubated with Tat with or without the anti-Tat polyclonal
antibody. *p,0,05 vs control; #p,0,05 vs Tat. (D) Catalase activity was evaluated in Caco-2 cells after different times of Tat exposure. Data are
representative of 3 separate experiments. *p,0,05 vs time 0.
doi:10.1371/journal.pone.0029436.g003
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were subjected to co-immunoprecipitation with an antibody
against tubulin or with control IgG, and subsequently analyzed
through Western blotting with the anti-Tat polyclonal antibody.
Tat coprecipitated with tubulin indicating that it binds to the
microtubule cytoskeleton (Fig. 6B).
Polar effects by Tat on the apical and basolateral side of
the Caco-2 cell monolayers
To test the hypothesis that Tat induces different effects
depending on its addition to the apical or basolateral side of
the epithelium, Caco-2 cell monolayers were exposed to Tat
0.5 nM for 1, 24 and 48 hours at apical or basolateral side
(Fig. 7). In these conditions Tat reduced the GSH/GSSG ratio at
1–24 hours, with a more potent effect at the basolateral than the
apical side (Fig. 7A). In addition, the activation of caspase-3 was
observed following basolateral but not apical stimulation (Fig. 7B).
The polar effect by Tat is in agreement with our previous data
showing chloride secretion induced by basolateral addition of Tat
[16].
Effects by gp120 on oxidative stress and apoptosis in
Caco-2 cell monolayers
Previous studies investigating the effects of HIV-1 on epithelial
barrier function, demonstrate that both Tat and gp120 (the latter
being a surface envelope glycoprotein) directly increase perme-
ability of brain endothelial cells through a redox-dependent
mechanism [23,30]. In order to investigate the similarities and
differences between the effects induced by gp120 and by Tat, we
evaluated the effects induced by gp120 on oxidative stress and
apoptosis in our experimental system. An imbalance in GSH/
GSSG ratio was observed in response to gp120 with a more potent
effect at apical than basolateral side (Fig. 8A). However, gp120 did
not induce caspase-3 activation (Fig. 8B).
Figure 4. 8-hydroxy-29-deoxyguanosine (8-OHdG) concentration in rectal dialysis in HIV-negative and positive children. The
determinations of rectal 8-OHdG production were performed using a dialysis bag (A) in serum-negative (n = 6, SN) and positive (n = 20, HIV+) children
(B). *p,0.05 vs SN. (C) HIV+ children were divided in two groups and compared with controls (n = 6, white): HIV RNA.40cp/ml (n = 9, black), HIV RNA
,40cp/ml (n = 11, grey). *p,0.05 vs RNA ,40cp/ml and SN groups.
doi:10.1371/journal.pone.0029436.g004
Table 1. Characteristics of the HIV-positive patients.
Age (months)
Mean 6 standard deviation 134.8653.3
Range 26–228
Sex
Male 6
Female 14
CD4+ (cells/ml)
Mean 6 standard deviation 963.856496.43
Range 176–2027
HIV RNA
Patients with HIV RNA ,40cp/ml 11
Patients with HIV RNA .40cp/ml 9
Mean viral load (cp/ml)6 standard deviation 3934.8966776.77
Range 48–14500
doi:10.1371/journal.pone.0029436.t001
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Tat-induced oxidative stress and apoptosis are strongly
inhibited by pretreatment with antioxidants
Our findings demonstrate that Tat induces oxidative stress and
apoptosis in human enterocytes. These two events may be causally
related in several pathogenic conditions [36]. We therefore used
the antioxidant NAC to determine the relationship between
oxidative stress and apoptosis induced by Tat at intestinal level.
Our results demonstrate that oxidative stress is completely
prevented by pretreatment with NAC. In fact, NAC prevented
the Tat-induced ROS increase (Fig. 9A) and preserved the GSH/
GSSG ratio (Fig. 9B).
To verify that the redox imbalance induced by Tat was the
major cause of cell apoptosis, we performed experiments under a
condition of oxidative stress prevention. Pretreatment for
24 hours with NAC completely prevented caspase-3 activity
induced by Tat (Fig. 10A), suggesting that the redox imbalance
caused apoptosis in our experimental model. We also evaluated
caspase-3 and PARP cleavage by western blot and found that
NAC prevented activation of caspase-3 signaling (Fig. 10B).
Similar results were found in HT-29 cell line (Fig. S4). These
results support the hypothesis that oxidative stress induced by Tat
induces programmed cell death.
Intestinal oxidative stress and apoptosis are related and
prevented by the antioxidant NAC in human intestinal
specimens
To determine whether the findings observed in Caco-2 cells
were reproduced in human intestine, we evaluated apoptosis and
redox intracellular homeostasis in duodenal biopsies from
children (Fig. 11A). Western blot analysis for caspase-3 was
performed on human intestinal specimens obtained from 4 HIV-
negative patients. Similar to the findings we obtained in in-vitro
cell models, exposure of human duodenal mucosa to Tat resulted
in caspase-3 activation, as shown by the increase of the
proteolytic 17-kDa fragment from caspase-3. Similar to the
results we obtained in Caco-2 cells, this process was prevented by
NAC (Fig. 11B).
Duodenal biopsies were obtained also from a single HIV-
positive child to evaluate apoptosis and redox mechanisms
in an ex-vivo model. Caspase-3 activation was determined in
basal conditions and in the presence of NAC. Caspase-3
activation in specimens from the child was prevented by NAC
(Fig. 11C).
Finally, we measured the GSH/GSSG ratio in intestinal
biopsies. The ratio was decreased upon Tat exposure and the
Figure 5. Influence of HIV-Tat protein on apoptosis in Caco-2 cells. Caspase-3 activity (A) and full-length protein (B lower panel) were
evaluated in Tat-treated Caco-2 cells. To verify that Tat induced apoptosis, cleaved PARP was evaluated in the same western blot used to evaluate the
activation of caspase-3 (B upper panel). Normalization of western blot was performed with GAPDH in all experiments (B middle panel). *p,0.05
compared with untreated control cells. Protein extracts from cytosol (C lanes) and mitochondria (M lanes) assayed for cytochrome c by western blot
analysis (C); tubulin was used as cytosolic marker, and COX IV as mitochondrial marker. Densitometric acquisitions are shown from three separate
experiments. *p,0,05 vs time 0.
doi:10.1371/journal.pone.0029436.g005
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imbalance was prevented by NAC pretreatment in intestinal
mucosa of HIV-negative patients (Fig. 11D). Interestingly, the
baseline GSH/GSSG ratio in the duodenal tissue of an HIV-
positive child (Fig. 11E) was similar to that observed in HIV-
negative mucosa treated with Tat (Fig. 11D). However, it
decreased after treatment with NAC and became similar to
HIV-negative controls. These data strongly suggest that intestinal
glutathione modifications are directly related to apoptosis in HIV-
patients and that Tat, which was prevented by antioxidant
treatment in human intestine, plays a key role in this condition.
Discussion
Here we demonstrate that HIV-Tat protein directly induces
enterocyte apoptosis by a redox-dependent mechanism. Our
findings indicate that the increase in ROS intracellular level and
impaired antioxidant defenses are associated with epithelial cell
apoptosis and actin destruction. The effect was specific for Tat and
the timing of the events suggested that Tat induced early oxidative
stress followed by apoptosis. The oxidative stress was dose- and
time-dependent reaching its peak at a concentration of 0.1 nM.
Figure 6. Tat-induced disruption of the actin cytoskeleton. (A) Direct immunofluorescence of actin staining by FITC-conjugated phalloidin
(green). The nuclei were stained with Hoerst (blue). Caco-2 cells were exposed to Tat 0.5 nM for 72 hours. Magnification: 10006. Data are
representative of 3 separate experiments with 3–4 replicates for each experimental condition. (B) Cell lysates of Caco-2 cells were stimulated with Tat
0,5 nM for 24 hours and subjected to immunoprecipitation using anti-tubulin antibody or control IgG. Tat protein was detected from
immunoprecipitates by Western blotting with anti-Tat antibody.
doi:10.1371/journal.pone.0029436.g006
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This concentration is similar to that found in sera from HIV
patients [37]. We also show that the antioxidant NAC is able to
prevent intestinal oxidative stress by maintaining ROS and GSSG
intracellular concentrations at a low level. In addition, NAC
counteracted intestinal apoptosis, which supports the hypothesis
that this event depends on a redox mechanism. Further support to
this hypothesis comes from our evaluation of the redox balance
and apoptosis in an ex-vivo experimental model. Caspase-3 cleaved
protein was increased and the GSH/GSSG ratio imbalanced in
intestinal biopsies exposed to Tat, which indicates that the
apoptotic mechanism was triggered by the impairment of
antioxidant defenses. Preincubation with NAC prevented these
events with a pattern similar to that observed in cell lines. We had
the opportunity to examine an intestinal specimen from an HIV-
positive patient. Although we are aware that one HIV-infected
patient is insufficient to make any conclusion, we found that
apoptosis and the GSH/GSSG ratio in this sample were similar to
those in HIV-negative biopsies exposed to Tat. Under these
conditions, NAC decreased the levels of activated caspase-3 and
re-established a GSH/GSSG ratio similar to those recorded in
biopsies of HIV-negative patients. These data demonstrate that a
redox-dependent mechanism is involved in the pathophysiology of
HIV at intestinal level thereby implicating oxidative stress in HIV
enteropathy. It would be interesting to detect Tat in the lamina
propria and correlate the viral protein levels with those used in our
experimental model. However, several authors detected HIV-1
RNA and viral antigens in epithelial intestinal cells in different
stage of infection and in different type of cells [13,14,38].
Therefore it was suggested that the gut mucosa is a reservoir of
HIV-1 infection and it is likely to think that viral proteins,
including Tat, are present locally.
It has recently been demonstrated that the redox state of HIV-
Tat affects its biological activity [39]. In particular, the Tat protein
enters the cell and its reduced isoform reaches the cytoplasm and
nucleus whereas its oxidized form tends to form multi-aggregates
that are less toxic in infected cells. This suggests that the increase
in intracellular ROS is not directly induced by Tat but is rather a
strategy used by the infected cell to reduce the biological activity of
Tat – a process that ultimately leads to programmed cell death.
In clinical studies, the redox balance was severely deranged in
HIV-positive patients without highly active antiretroviral therapy
(HAART) [40]. These studies showed that HIV-infected individ-
uals are exposed to chronic exogenous oxidative stress that causes
perturbations of the antioxidant defense system, including
glutathione, thioredoxin, superoxide dismutase, ascorbic acid,
glutathione peroxidase, tocopherol and selenium. In addition,
hydroperoxidases and elevated levels of malondialdehyde were
found in both pediatric and adult patients [41].
Figure 7. Polar effects by Tat on the apical and basolateral side of the Caco-2 cell monolayers. Tat was added to apical or basolateral side
of Caco-2 cell monolayers and GSH (grey)/GSSG (white) ratio (A) and caspase-3 activation (B) were evaluated after 1, 24 and 48 hours. *p,0,05 vs
control; #p,0,05 vs apical Tat stimulation at the same time. Normalization of western blot was performed with GAPDH in all experiments.
Densitometric acquisitions are shown from three representative separate experiments.
doi:10.1371/journal.pone.0029436.g007
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We first detected oxidative stress at intestinal level in HIV
infection induced directly by Tat in cell models and in human
intestinal epithelium. A marker of oxidative stress was also
increased in rectal dialysis fluid, but not in serum and urine, of
HIV-positive patients seen at our clinical center, which suggests
that the stress event is localized at intestinal level. In addition, we
found a significant correlation between viral load and concentra-
tion of 8-OHdG. We suggest that a specific clinical trial be
conducted to evaluate intestinal damage and the therapeutic use of
antioxidants.
We previously reported that Tat induces Ca2+-dependent
chloride secretion in human intestinal cells [15]. Subsequently,
we found that Tat inhibits glucose absorption in Caco-2 cells, and
this effect was associated with SGLT-1 missorting [42]. Also a-
tubulin staining was drastically decreased in Tat-exposed Caco-2
cells [42], which coincides with the altered actin structure we
observed in Tat-treated Caco-2 and HT-29 cells. It was previously
reported that Tat affects the microtubule cytoskeleton inducing
apoptosis of T cells [43,44]. Similar to what observed in T cells,
Tat induces oxidative stress and destroys the cytoskeleton in
intestinal cells and this is the result of the direct interaction with
the enterocyte. Our findings show a profound disruption of the
enterocyte cytoskeleton in HIV infection. Therefore, Tat induces a
combined enterotoxic and a cytotoxic effect in human intestine.
The data reported herein were obtained in the same
experimental model previously used to evaluate the enteropatho-
genic effects of Tat [16,42] and show that the redox mechanism is
implicated in the enteropathogenic effects of HIV. Tat-induced
apoptosis in enterocytes is supported by our finding of the
mitochondrial release of cytochrome c in the cytosol, the
consequent caspase-3 activation and by increased PARP cleavage.
All these effects are well in agreement with our previous result that
Tat inhibits enterocyte cell proliferation [16,42].
Attene-Ramos and colleagues demonstrated that the mucosal
redox state is linked with intestinal proliferative activity [45].
Proliferating Caco-2 cells are vulnerable to oxidizing agents and a
decrease in GSH levels induces transition to an apoptotic
phenotype [46]. Moreover, an intracellular redox imbalance
results in abnormal expression of genes involved in cell
proliferation and growth, cell cycle progression, cytoskeleton
structure and cell-to-cell adhesion [47], suggesting that redox
alterations impair the enterocyte cycle. We found that Tat
significantly induces oxidative stress and apoptosis in human
intestinal epithelial cells with a specific sequence of events. Tat
induced an early increase of ROS and an imbalance of the GSH/
GSSG ratio that resulted in apoptosis. The two events are
sequential and linked since an antioxidant prevented apoptotic cell
damage.
Previously Nazli et al. demonstrated that gp120, but not Tat,
affects intestinal epithelial integrity in a short time evaluation, with
a major effect at apical side of intestinal epithelium [15]. Our
results indicate that gp120 induces an imbalance in GSH/GSSG
Figure 8. Effects by gp120 on oxidative stress and apoptosis in Caco-2 cell monolayers. gp120 (0.8 nM) was added to apical or basolateral
side of Caco-2 cell monolayers and GSH/GSSG ratio (A) and caspase-3 activation (B) were evaluated after 1, 24 and 48 hours. *p,0,05 vs control;
#p,0,05 vs apical gp120 stimulation at the same time. After gp120 stimulation cells were collected and western blots were performed with anti-
gp120 polyclonal antibody (upper panel) and anti-caspase-3 monoclonal antibody (middle panel). Normalization of western blot was performed with
GAPDH in all experiments (lower panel).
doi:10.1371/journal.pone.0029436.g008
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ratio with a more potent effect at apical side after 1 hour of
stimulation but it does not induce significant caspase-3 activation
suggesting that apoptosis is not induced by this viral protein.
According to the different effects induced by Tat and gp120, we
hypothesize that the two viral proteins act in an integrated mode
with a different timing. gp120 is responsible to damage intestinal
epithelium by luminal side in the early phase of infection allowing
the virus to pass through the intestinal barrier. Subsequently Tat
induces a sustained epithelial damage and oxidative stress which
persists in the long term. These results raise the possibility of a
novel therapeutic strategy for HIV patients, i.e., restoration of
GSH levels. Antioxidants are considered therapeutic agents in
oxidative stress-related diseases. Preliminary data indicate that
NAC improves immunological functions and GSH levels in HIV
patients [48,49]. Our experimental results with NAC support this
concept at intestinal level.
In summary, the results of this study indicate that Tat induces
oxidative stress by increasing ROS levels and impairing the GSH/
GSSG balance in human intestinal epithelial cells suggesting a
possible role in the HIV-enteropathy (Fig. 12). Tat also increases
apoptosis. There is evidence that the intestinal tract, being a major
lymphoid organ, is a source of virus replication [50]. Chun et al.
have recently shown, in ileum biopsies from 8 patients, that gut-
associated lymphoid tissue remains a major reservoir of HIV with
potential residual cryptic replication despite long-term HAART
[50]. In addition, HIV detection in gut mucosa is not influenced
by levels of plasma viral load or antiretroviral therapy [13]. In this
context there is a significant association between CD8+ T-cell
response in rectal mucosa and plasma viral load and blood CD4
count in HIV-infected patients [51,52]. The afore-mentioned
results are fully in keeping with the concept that the intestine plays
a major role in the pathogenesis of HIV infection, even in patients
on successful HAART, and that Tat protein could be a major
mediator of viral effects. Here we show that HIV-Tat protein plays
a key role in inducing intestinal functional alterations including
transepithelial secretion, glucose malabsorption and finally an
oxidative stress condition with apoptosis leading to a compromised
epithelial architecture and pretreatment with the antioxidant NAC
prevented redox imbalance and apoptosis.
Methods
Intestinal cell line cultures
Caco-2 cells were used as small intestinal cell model [53]. At 15
days post-confluence, cells exhibit a well-differentiated brush
border on the apical surface and tight junctions with typical small-
intestinal microvillus hydrolases and nutrient transporters. Caco-2
cells were grown in Dulbecco’s modified Eagle minimum essential
medium (DMEM; Gibco, USA) with a high glucose concentration
(4.5 g/L) at 37uC in a 5% CO2 atmosphere. The medium was
supplemented with 10% fetal bovine serum (FBS, Gibco, USA),
1% non-essential amino acids, penicillin (50 mU/mL) and
streptomycin (50 mg/mL), and changed daily. To verify some
data obtained in Caco-2 cells, we used HT-29 as a supplementary
Figure 9. Effect of NAC on the Tat-induced oxidative stress in Caco-2 cells. Intracellular ROS levels, determined by fluorometric method,
after exposure of Tat with or without pretreatment with NAC (A). Data were represented as percent of controls. Effect of NAC on Tat-induced GSH/
GSSG imbalance (B). Data are represented as percent of GSH (grey) and GSSG (white) vs total glutathione. *p,0.05 vs control; #p,0.05 vs Tat. Data
are representative of 3 separate experiments.
doi:10.1371/journal.pone.0029436.g009
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intestinal cell model. HT-29 were grown in RPMI 1640 cell
culture medium supplemented with 10% fetal bovine serum (FBS,
Gibco, USA), 100 mU/ml penicillin and 100 mg/ml streptomycin.
To evaluate the polar nature of the effects induced by Tat on
Caco-2 cells, monolayers were grown on polycarbonate filter
(Corning Incorporated, NY USA) for 15 days post-confluence and
then exposed to Tat 0,5 nM for 1, 24 and 48 hours at apical or
basolateral side and then GSH/GSSG ratio and caspase-3
activation were evaluated as previously described. Controls were
stimulated with the same volume of medium without Tat.
Fluorescence microscopy
Cells were grown on the chambered cover glass for 3 days. Cells
were exposed to 20 mM 79-dichlorofluorescein diacetate (DCFH-
DA, D6665; Sigma-Aldrich, St. Louis, MO) for 1 hour at 37uC in
the dark. Then, they were treated with Tat (0.5 nM), adding the
protein directly to the cell culture, and incubated at 37uC for
1 hour to detect the ROS. Cells were washed in PBS and after
mounting, the fluorescence images from multiple fields of view
were obtained using a Nikon Eclipse 80i microscopy. The images
were analyzed using NIS Elements D imaging software. A positive
control was obtained by incubating cells with H2O2 10 mM for
5 min.
Reactive oxygen species production
The production of ROS was measured using the DCFH-DA
fluorometric method, which is based on the ROS-dependent
oxidation of DCFH-DA to DCF. Caco-2 cells were grown in 6-
well plates for 15 days post-confluence. Cell monolayers were
treated with Tat 0.05, 0.1 and 1 nM for 15 min or with Tat
0.5 n M for 15, 30, 60 and 120 min at 37uC. Medium was
removed and cells were washed by PBS. Then, cells were treated
with DCFH-DA (20 mM) for 30 min at 37uC in the dark.
Intracellular ROS production was measured with a spetrofluo-
rometer (SFM 25; Kontron Instruments, Japan). A positive
control was obtained by incubating cells with H2O2 10 mM for
5 min. Neutralization experiments were performed incubating
Tat 0.5 nM with 30 ng/ml of anti-Tat polyclonal antibodies
(Tecnogen, Piana di Monte Verna, Italy) at +4uC overnight with
gentle shaking. The preparations were then used to stimulate
cells.
Antioxidant defenses evaluation
GSH and GSSG intracellular levels were measured by method
described by Allen et al. with few modifications [54]. Briefly, cells
were exposed to Tat alone or in combination with NAC and then
lysed with Triton X-100. Protein was precipitated with 1%
Figure 10. Effect of NAC on the Tat-induced apoptosis in Caco-2 cells. Caspase-3 activity (A) and full-length protein (B lower panel) were
evaluated after exposure of Tat with or without pretreatment with NAC. Data were represented as percent of controls. *p,0,05 vs control; **p,0,05
vs Tat. Cleaved PARP was evaluated in the same western blot (B upper panel). Normalization of western blot was performed with GAPDH in all
experiments (B middle panel). Data are representative of 3 separate experiments. (C) Densitometric acquisitions are shown from three separate
experiments. *p,0,05 vs control; #p,0,05 vs control with NAC; 1p,0,05 vs Tat at the same time without NAC.
doi:10.1371/journal.pone.0029436.g010
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sulfosalicylic acid and supernatants used to measure in parallel
total and reduced glutathione. Oxidated glutathione (GSSG) was
determined by subtracting the reduced form from total
glutathione. GSH and GSSG values were normalized for protein
content. All assays were performed three times. Catalase activity,
a well-established indicator of oxidative stress, was measured with
an assay kit from Calbiochem (Gibbstown, NJ) and normalized
for protein content. Neutralization experiments were performed
incubating Tat 0.5 nM with 30 ng/ml of anti-Tat polyclonal
antibodies (Tecnogen, Piana di Monte Verna, Italy) at +4uC
overnight with gentle shaking. The preparations were then used
to stimulate cells. gp120 (ab69717) and goat polyclonal anti-
gp120 antibody (ab21179) were from Abcam plc (Cambridge,
UK).
Oxidative stress evaluation in HIV-positive patients
An aliquot of rectal dyalisis, urine and serum samples from 20
patients infected with HIV and 6 control subjects aged 26–228
months were obtained during a routine check-up. All HIV patients
had been on HAART for more than 3 years. Immediately after
collection, samples were separated into 2 mL aliquots and stored at
280uC until analysis. We used levels of 8-hydroxy-29-deoxyguano-
sine (8-OHdG), as biomarker of DNA oxidative stress. 8-OHdG
was measured in duplicate using a highly sensitive ELISA kit (Li
StarFish Srl, Milan, Italy). The length of dialysis bag is 3 cm and the
concentration of oxidative marker was normalized for the exact
volume inside the bag. Differences were evaluated by the Mann-
Whitney test. The Pearson’s correlation coefficient was applied to
investigate the correlation between 8-OHdG and viral load.
Figure 11. NAC prevented apoptosis and oxidative stress induced by Tat in human intestinal mucosa. Duodenal mucosal specimens
were exposed to Tat alone or combined with NAC in an ex-vivo organ culture model (A). Panels B and C, Western blot on whole cell lysate was
performed using anti-caspase-3 mouse monoclonal antibody (upper panel) and anti-GAPDH mouse monoclonal antibody in 4 HIV-negative children
(B) and in an HIV-positive child (C). Densitometric acquisition of caspase-3 protein was normalized for GAPDH expression. Panels D and E, The GSH
(grey)/GSSG (white) ratio was evaluated as described under ‘‘Methods’’ in intestinal mucosa of 4 HIV-negative children (D) and in an HIV-positive child
(E). *p,0.05 vs control; **p,0.05 vs Tat. Results are expressed as the means SEM.
doi:10.1371/journal.pone.0029436.g011
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Actin staining
One step of fixation and permeabilization was performed with
4% paraformaldehyde and 0.2% Triton X-100 for 30 min at
+4uC. After three washes in PBS, the cells were treated with a
50 mg/ml solution of fluorescein isothiocyanate-phalloidin (Sigma-
Aldrich, Milan, Italy) in PBS for 40 min. Nuclei were stained with
Hoechst 5 mg/ml (Sigma-Aldrich, Milan, Italy) for 5 min at +4uC.
The cells were washed three times with PBS and were mounted
with Mowiol (Invitrogen S.R.L, San Giuliano Milanese, Italy).
The monolayers were examined using a Nikon Eclipse 80i
epifluorescent microscope (FITC filter). The images were analyzed
using NIS Elements D imaging software.
Caspase-3 activity assay
We used caspase-3 as a marker of apoptosis [55]. An apoptosis
assay kit was used to determine caspase-3 activity, according to the
manufacturer’s instructions (Biovision, Mountain View, CA).
Caspase-3 activity was investigated in Caco-2 cells by the release
of the chromophore pNA after substrate cleavage. Modifications of
caspase-3 activity were determined by comparing the sample
optical density (OD) with the control.
Immunoblotting
Total cells lysates were obtained by homogenization of cell
pellets in cold lysis buffer (20 mM Tris, pH 7.5 containing
300 mM sucrose, 60 mM KC1, 15 mM NaC1, 5% (v/v) glycerol,
2 mM EDTA, 1% (v/v) Triton X-100, 1 mM PMSF, 2 mg/ml
aprotinin, 2 mg/ml leupeptin and 0.2% (w/v) deoxycholate) for
1 min at 4uC and further sonication for additional 30 sec at 4uC.
Cytosolic, microsomal and mitochondrial fractions were prepared
with the Qproteome Mitochondria Isolation Kit (Qiagen). Equal
amounts of protein were subjected to 10% (v/v) SDS-PAGE and
transferred to a PVDF membrane (Millipore). The membrane was
blocked with 5% (w/v) skim milk and incubated with primary
antibody, followed by incubation with an HRP-conjugated
secondary antibody. Proteins were visualized with an ECL
detection system (GE-Healthcare). The following antibodies were
used for Western blot analysis: rabbit polyclonal anti-Tat antibody
(Tecnogen, Piana di Monte Verna, Italy), mouse monoclonal anti-
caspase3 antibody (full length protein), mouse monoclonal anti-
PARP antibody, goat polyclonal cytochrome c antibody, mouse
monoclonal anti-COX IV antibody, mouse monoclonal anti-
tubulin antibody, mouse monoclonal anti-GAPDH antibody
(Santa Cruz Biotechnology). gp120 (ab69717) and goat polyclonal
anti-gp120 antibody (ab21179) were from Abcam plc (Cambridge,
UK).
Co-immunoprecipitation
A total of 800 mg of protein lysate from the Caco-2 cells exposed
to Tat 0,5 nM 24 hrs were precipitated with 1 mg of tubulin
antibody. Protein A/G agarose beads (Santa Cruz) were used to
collect the immunoprecipitated complexes and the beads were
washed with PBST before SDS-PAGE and Western blot analysis
with anti-Tat antibody.
Experiments in human small intestinal specimens
Biopsies from the distal part of the duodenum were obtained
from 5 children seen at the Department of Pediatrics and
undergoing endoscopy (84–192 months of the age) for intestinal
disorders. All biopsies were from macroscopically normal areas,
Figure 12. Schematic representation of the mechanism of HIV Tat viral protein-induced oxidative damage to the intestinal mucosa
and the protective role of the antioxidant N-acetylcysteine (NAC). Tat induces oxidative stress by increasing the ROS intracellular level and
deranging the GSH/GSSG ratio. This leads to programmed cell death (apoptosis) and an increase in epithelial damage. Together with ion secretion
[15] and altered glucose transport [39], these steps could represent key mechanisms in HIV enteropathy. Pretreatment with the antioxidant NAC
restores the oxidative stress and cell apoptosis, thus protecting intestinal mucosa from gut dysfunction.
doi:10.1371/journal.pone.0029436.g012
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and intestinal histology was subsequently reported to be normal.
Tissue samples were transported to the laboratory in culture
medium and processed within one hour. Duodenal mucosa
specimens were obtained from 4 HIV-negative children and from
one HIV-positive child. Specimens were washed and observed by
stereomicroscope to exclude tissue necrosis. Organ culture was
performed in DMEM with a high glucose concentration (4.5 g/L)
supplemented with 0.5% FCS, 1% non-essential amino acids, 2%
penicillin (50 mU/mL) and streptomycin (50 mg/mL) and
incubated in 5% CO2/95% air for one hour before treatment.
Short-term experiments were run using high Tat concentrations to
maximize the cytotoxic effect before spontaneous tissue disruption.
Specimens were exposed to Tat alone (0.1 mM) or preincubated
with NAC (10 mM for 4 h). Short-term experiments with an
higher Tat concentration were performed to maximize the effect
before spontaneous tissue disruption. After stimulation, samples
were homogenized and lysed in RIPA buffer: 100 mM Tris-HCL
pH 7.5, 300 mM NaCl, 2% NP40, 1% Na deoxycholic acid, 0.2%
SDS, 100 mg/ml PMSF, 5 mg/mL aprotinin, 1 mg/mL leupeptin,
0.7 mg/ml pepstatin. Whole extracts were centrifuged and protein
content was determined by the Bradford assay. GSH/GSSG
intracellular levels and caspase-3-cleaved protein were evaluated
as described above. For western blot assay we used the mouse
monoclonal anti-caspase-3 cleaved protein (Cell Signaling Inc.,
Danvers, MA). The experiments were undertaken with the
understanding and written consent of each child’s parents and
the study methodologies conformed to the standards set by the
Declaration of Helsinki. The study protocol was approved by the
Ethics Committee of the School of Medicine, University of Naples
Federico II, Italy.
Statistical analysis
We used GraphPad Prism Software (San Diego, CA) to evaluate
the two-tailed unpaired Student t test and a 2-tailed paired Student
t test to evaluate statistical significance. An alpha value of 0.05 was
set for statistical significance. p-Values for each analysis are
indicated in figure legends.
Supporting Information
Figure S1 Fluorescence staining of ROS. ROS intracellular
levels were evaluated in Caco-2 cells by DCF fluorimetric method
(A) and at fluorescence microscope (B). In parallel, cells from the
same culture and in the same conditions were exposed to Tat and
a western blot was performed with anti-Tat polyclonal antibody
(C). *p,0,05 vs control.
(TIF)
Figure S2 The anti-Tat polyclonal antibody blocks the
Tat-induced imbalance of the GSH/GSSG ratio in HT-29
cells. HT-29 cells were incubated with Tat in the presence and
absence of the anti-Tat polyclonal antibody. Data are represented
as percent of GSH (grey) and GSSG (white) vs total glutathione.
Data are representative of 3 separate experiments.*p,0,05 vs
control; **p,0,05 vs Tat.
(TIF)
Figure S3 8-OHdG levels in urine and serum in HIV-
negative and -positive children. 8-OHdG was used as
oxidative stress marker evaluated in urine (A) and serum (B) in
serum-negative (SN) and positive (HIV+) children. There were no
significant differences between the two groups.
(TIF)
Figure S4 Influence of HIV-Tat protein on apoptosis in
HT-29 cells. Caspase-3 activity (A) and full-length protein (B
lower panel) were evaluated in Tat-treated HT-29 cells. To verify
that Tat induced apoptosis, cleaved PARP was evaluated in the
same western blot used to evaluate the activation of caspase-3 (B
upper panel). Normalization of western blot was performed with
GAPDH in all experiments (B middle panel). Data are
representative of 3 separate experiments.
(TIF)
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Time- and Segment-related Changes of Postresected
Intestine: A 4-dimensional Model of Intestinal Adaptation
!Vittoria Buccigrossi, !Carla Armellino, !Arturo Tozzi, !Emanuele Nicastro, yCiro Esposito,
yFrancesca Alicchio, zSantolo Cozzolino, and !Alfredo Guarino
ABSTRACT
Objectives: The aim of the present study was to investigate the segment- and
time-related changes in rat short bowel syndrome and construct a
4-dimensional (4D) geometrical model of intestinal adaptation.
Methods: Sprague-Dawley rats were divided into 3 groups: 2-day, 7-day,
and 15-day postresection groups in which 75% of the jejunoileum was
removed. Histological and morphometrical parameters in the remaining
proximal to distal intestinal segments, from the jejunum to the distal colon,
were comparatively evaluated in the groups. The data were used to construct
a 4D geometric model in which villi were considered as cylinders, and their
surface area was expressed as cylinder lateral area.
Results:Major adaptive changes were observed in the ileum consisting of an
increase in both the diameter of base and the height of villi. A parallel
reduction in their number/mm2 was observed. The resulting ileal
architecture was characterized by a limited number of large villi. An
opposite pattern was observed in the jejunum whose postresection
structure consisted of an increased number of villi. No changes were
observed in the colon. Postresection restructuring was early and faster in
the ileum than in the jejunum resulting in an increase in absorptive area of
81.5% and 22.5% in the ileum and jejunum, respectively.
Conclusions: Postresection adaptation is intestinal segment–specific
because all of the major changes occur in the ileum rather than in the
jejunum. Sparing ileal segments during resection may improve the outcome
of patients undergoing extensive intestinal resection. Our 4D model can
be used to test interventions aimed at optimizing postresection intestinal
adaptation.
Key Words: 4-dimensional model, children, intestinal adaptation,
intestinal failure, surgical short bowel
(JPGN 2013;56: 40–45)
S hort bowel syndrome (SBS) is a clinical condition resultingfrom massive enterotomy and is the most frequent cause of
intestinal failure in children. In children with extensive intestinal
resection, parenteral nutrition is required for survival, but this
procedure is associated with frequent and severe complications
(1). The length of the remnant intestine and the presence of the
ileocecal valve predict the chance of acquiring intestinal sufficiency
(1,2). After extensive small bowel resection, the remaining intestine
undergoes compensatory changes to maintain its absorptive func-
tion (3–5) consisting of an increase in small intestinal mucosal
thickness, villus length, and crypt depth (6,7). Intestinal crypt cells
activate pathways of gene expression of adaptation and develop-
ment resembling the developing immature intestinal tissues (8).
These changes are interpreted as a homeostatic response to increase
the remaining digestive-absorptive surface (9). A crucial factor of
adaptation is the time of changes. When a large part of the intestine
is suddenly removed, a prompt response is needed to ensure
transepithelial ion fluxes, restore the barrier against bacterial trans-
location, and restart motility. Timely changes are essential for
survival; however, intestinal adaptation, its mechanisms, and times
are still largely unknown (10–12). In addition, the role and adaptive
pattern of proximal to distal intestinal segments are also unknown.
Menge et al found that the total mucosal surface of ileal
segments already was increased in the proximal but not in the distal
remnants at the fourth day postresection (13). We tested the
hypothesis that intestinal adaptation in SBS is segment and time
specific and adaptive changes take place with a specific structural
and temporal pattern in proximal to distal intestinal segments. To
this end, we studied the qualitative and quantitative changes of
proximal to distal intestinal epithelial architecture, including villus
area and volume, at 3 time points after resection, in a model of
extensive small bowel resection. Using the morphometric data
obtained in the ileum and jejunum, we constructed a 4-dimensional
(4D) geometric model of epithelial structure. The model provides
an accurate experimental standard for investigations of postresec-
tion structural events and can be used to test the effects of nutrients
and drugs on adaptation.
METHODS
Experimental protocol: Wistar rats weighing between 210
and 270 g were used. The animals were housed in individual cages,
under a 12-hour light-dark regimen and humidity and temperature
control. They were divided into 3 groups: resected animals (n¼ 19),
sham-resected control animals that underwent ileal transection with
subsequent end-to-end anastomosis (n¼ 10), and nonoperated con-
trol animals (n¼ 7). The animals were killed by CO2 inhalation 2, 7,
and 15 days after surgery because adaptive intestinal changes reach
a plateau 15 days after intestinal resection in rats (14–16).
Surgery was performed on animals anesthetized with diaze-
pam, ketamine, and medetomidine. The length of the small intestine
from Treitz ligament to the ileocecal valve was measured in situ,
still attached to the mesentery, under constant tension. Then, 75% of
the mid-small bowel was resected, leaving the proximal 12.5%
corresponding to the remaining jejunum, and the distal 12.5%
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corresponding to the remaining ileum (16,17). A primary end-to-
end anastomosis was performed and the length of remaining small
intestine ranged from 13 to 20 cm. Animals received 5% glucose
solution after surgery, wetted food from the second day after
surgery, and then were allowed free access to food. Postoperative
analgesia and the antibiotic enrofloxacin were given and animals’
weight was recorded daily.
The animals were fed a normal standard diet with no
restriction on food or water supply for 1 week before surgery.
Before surgery, rats were fasted overnight and weighed. On the first
postoperative day, rats had free access to water and rodent diet.
The experimental protocol was approved by the local ethics
committee of the Ospedale Cardarelli (no. 1292/09/CB; February 3,
2009). The animals were treated and housed according to national
and international regulations governing the use of animals in
scientific research.
Tissue sampling: bowel samples were taken 2, 7, and 15 days
postoperatively. Six proximal-to-distal intestinal segments were
obtained from each animal as follows: antrum (1.5 cm proximal
to the pylorus); duodenum (3 cm distal to the pylorus); proximal
jejunum (3 cm proximal to the anastomosis in the resected group
and 10 cm distal to the ligament of Treitz in the control group);
distal ileum (3 cm distal to the anastomosis); right colon (10 cm
distal to the cecum); left colon (proximal to the rectum). All of the
intestinal segments were weighed, measured, and rinsed with ice-
cold saline to remove any luminal contents. Tissue sections measur-
ing 1 cm2 were cut from each segment along the longitudinal axis
and used for histological and morphometric analysis.
Intestinal specimens were fixed in 10% buffered formalin for
24 hours, dehydrated and embedded in paraffin wax using standard
techniques. Four-micrometer sections were cut perpendicular to the
mucosa, placed on gelatin-coated glass, and stained with hematox-
ylin and eosin. At least 10 well-oriented sections from each
intestinal segment were prepared and evaluated by linear quanti-
tative methods using light microscopy. All of the morphometric and
counting procedures were performed by 2 independent, blinded
investigators. The following parameters were obtained for each
segment: total wall thickness (micrometers), total mucosal thick-
ness (micrometers), and inflammatory cells in the mucosa (number
of cells/mm2 of mucosa and degree of inflammatory infiltrate). The
glandular height in the antrum was also measured and is expressed
in micrometers.
Villus height (in micrometers), number of villi (villi/mm2 of
mucosal length), crypt depth (micrometers), and villus/crypt ratio
were recorded in the duodenum, proximal jejunum, and distal
ileum. In the small intestine, only villi and crypts cut throughout
their length were measured. The distance from the tip to the base of
the villus was taken as villus height. The distance from crypt base to
villus-crypt junction was taken as crypt depth. Total mucosal
thickness was measured in the proximal and distal jejunum by
calculating the distance from the tip of the villus to the muscularis
mucosae. Small bowel thickness was determined by calculating the
distance from the villus tip to the serosal extremity of
longitudinal muscle.
An adaptive response consisting of an increase in mucosal
mass may occur through an increase in the number or in the size of
intestinal villi or both. We tested the hypothesis that the adaptive
response is segment-specific and that the specificity is associated
with different mechanisms of adaptation. To address this issue, we
applied the geometry of cylinders to villi and calculated epithelial
surface expressed as cylinder surface lateral area. The formula to
calculate the surface area is the following: surface area -
¼ 2(pr2)þ (2pr)% h, where h is the height of the cylinder and
r is half the measure of the base. Then we constructed a 4D
geometric model using form-Z, version 6.0 software (Auto&Des&Sys
Des&Sys Inc, Columbus, OH) by fitting the villi measures to obtain a
spatial representation of adaptive changes in proximal to distal
segments. This software is a 3D modeling program combining
solids and surface modeling and is used for the first time to construct
a biological model. The fourth dimension is time.
For the statistical analysis, results are mean' standard devi-
ation, with significance determined by analysis of variance test at
the P< 0.05 level.
RESULTS
General Findings
Two rats died 1 day after surgery. Three animals (1 in the
control group and 2 in the 15-day resected group) were excluded
from the study because a stricture developed at the anastomotic site.
At postmortem analysis, both showed a dilated bowel proximal to
the anastomosis. Mean body weight did not differ significantly
before and after intestinal resection or between sham-resected and
resected rats 2, 7, and 15 days after surgery. Data from nonoperated
rats were also identical to the data obtained with the study groups.
Macroscopical Evaluation
The gut reacted to massive resection with a general adaptive
response consisting in catch-up growth of the remaining small
intestine. Fifteen days after surgery, the small intestine showed
an increase in mass of 48.2%' 7.6% over baseline. The adaptive
changes had a well-defined segmental pattern. Figure 1A shows the
major macroscopical findings 15 days postsurgery. Changes were
clearly evident in the ileum: its weight/cm2 was almost 2-fold
higher than in sham-resected animals. The stomach, the duodenum,
and the jejunum underwent minor, not significant modifications,
although there was a consistent trend toward an increase in all 3
segments, which could be interpreted as an expression of minimal
adaptation. Finally, the proximal and the distal colonic segments
were virtually unchanged after small bowel resection 2, 7, and 15
days after surgery compared with sham-resected and control rats.
Total bowel thickness showed a similar segmental pattern with the
ileum undergoing the most evident changes (Fig. 1B).
Microscopical Evaluation
At microscopic evaluation, intestinal adaptation consisted of
an increase in villus height, crypt depth, and mucosal thickness in
the jejunum and ileum. The increase in villus height occurred 7 days
after surgery in the ileum, whereas villus adaptation ceased 15 days
after surgery in the jejunum (Fig. 1C). The crypt adaptive response
was a distinct time-dependent process with a peak at day 15 in both
ileum and jejunum (Fig. 1C). Two days after surgery, no changes
were found in length and crypt depth, in the jejunum, or in the
ileum. Overall, the ileum was the major site of intestinal adaptation;
the major modifications were observed 15 days after surgery, and
consisted of an increase in both villus height and crypt depth. Villus
height and crypt depth were significantly increased also in the
jejunum, albeit to a lesser extent than in the ileum. There were no
substantial changes in the stomach, duodenum, or colon (data not
shown).
To evaluate whether the different adaptive responses of
intestinal segments were linked to segment-specific restructuring
of the intestinal architecture, we analyzed the villus/crypt ratio in all
of the intestinal segments. This ratio was conserved in all of the
intestinal segments and there was a close overlapping of numerical
values between resected and sham-resected animals at 15 days post-
surgery (Fig. 2).
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Light microscopy did not reveal evidence of inflammatory
changes in the ileum or jejunum. This indicates that the observed
changes were because of a true compensatory increase in epithelial
cell mass, rather than to a change in inflammatory mucosal
fluid content.
Morphometric Evaluation
The different adaptive pattern in the jejunum and ileum
supports the hypothesis that adaptation is the result of distinct
mechanisms. To address this issue, we analyzed the segment-
specific morphometric changes of the intestinal structure. The
number of villi per linear millimeter of mucosa was calculated
for each intestinal segment. The area and volume of villi were also
measured in all of the segments. Finally, the overall increase of the
intestinal surface was calculated for each segment. Minor quanti-
tative and qualitative changes were observed 2 days after surgery,
although differences were not significant. Adaptation became
progressively more evident at subsequent observations. The number
of villi in the ileum was significantly lower in resected animals than
in sham-resected animals. In parallel, structural modifications were
found in the ileal villus architecture, that is, there was an increase
both in the diameter of the villus base and in villus height (Fig. 3). In
contrast, the number of villi in the jejunum was similar to that
observed in sham-resected animals; however, jejunal villi were
longer, whereas the diameter of the villus base remained unchanged
(Fig. 3).
We identified a time-related increase in morphometric
parameters in the jejunum and ileum (Table 1), which indicates
that the time course pattern and the type of architectural restructure
were both segment specific. There were no modifications 2 days
after surgery, whereas there was a significant increase in villus
height and crypt depth at day 7 postsurgery in the ileum and at day
15 postsurgery in the ileum and jejunum segments. In both seg-
ments, the area and the volume of the intestinal surface increased,
resulting in an increase of surface area, but the bulk of changes
occurred in the ileum, which suggests that the latter possesses the
highest adaptive plasticity (Fig. 4). Changes were also faster in the
ileum than in the jejunum with an increase of>50% of surface area
7 days after surgery in the ileum versus 5% in the jejunum. The ileal
segment located distally to the anastomosis was the major site of
adaptive changes, which comprised mainly an increase of total
bowel thickness, weight, and volume (Figs. 1 and 4).
Construction of a 4D Model of Segment-
specific Intestinal Adaptation
The adaptive changes in jejunum and ileum were associated
with a segment-specific restructuring of epithelial architecture.
Based on the morphometrical data, a 4D geometric model of
adaptation was constructed that provides a view of segment-specific
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FIGURE 1. A, Total wet weight modifications in different intestinal segments 15 days after extensive small intestinal resection (black bars)
compared with sham-resected animals (white bars);
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!
P<0.001 versus sham resected. C,
Increase in villus height and crypt depth in jejunum and ileum 2 (white bar), 7 (grey bar) and 15 days (black bar) after extensive small intestinal
resection versus sham-resected animals.
!
P<0.05 versus sham resected;
!!
P<0.01 versus sham resected.
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FIGURE 2. Villus/crypt ratio in different small bowel segments 15
days after extensive small intestinal resection (black bars) compared
with sham-resected animals (white bars).
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changes (Fig. 5). Compared to sham-resected rats, the number of
villi/mm2 of mucosa did not change in the jejunum, whereas it
decreased in the ileum. This observation, together with the changes
in bowel thickness, wet weight, height, and diameter of villi,
strongly suggests that adaptation takes place in the jejunum and
ileum with segment-specific events. In the former, the mucosal
increase was associated with an increase in villus height, whereas
their number and diameter did not change. In contrast, in the ileum,
the mucosal increase was the result of a massive increase in villus
height and diameter, whereas the villus number decreased (Fig. 5).
Villus area and volume were much larger in the distal ileum than in
the proximal jejunum; as a result, the nutrient absorptive surface
area was strikingly larger in the distal ileum. In contrast, the
stomach and colon were not involved in the adaption processes.
DISCUSSION
The total intestinal absorptive surface area is approximately
250m2 in adult humans; however, there is a functional and
structural segmental pattern of the intestine, and distinct intestinal
segments have different mechanisms for nutrient absorption and for
the transepithelial flux of electrolytes. In SBS, extensive intestinal
resection suddenly leads to a dramatic reduction in intestinal surface
producing an imbalance of hydroelectrolyte transport and hampered
nutrient absorption. Most patients require parenteral nutrition for
survival (18,19). In recent years, the anatomic definition of
irreversible SBS has changed and, in parallel, the outcome of
patients has improved. The longer survival of children with severe
SBS provided the opportunity to observe the ability of the remain-
ing intestine to adapt over time (20). Adaptation is affected by the
time of refeeding and other clinical variables such as age and
nutritional state (21); however, in our rat model, there was a clear
segment-specific pattern of adaptation. A major difference in the
adaptive responses of jejunum and ileum was the time-related
pattern of adaptation. Two days after resection, the mucosal
morphology of the rat jejunum and ileum did not differ from that
of controls. Adaptation was completed in the ileum within 2 to
7 days, whereas adaptive changes continued in the jejunum at
15 days postsurgery. We do not know whether jejunal changes
were completed at 15 days; however, the adaptive response was
found to reach a plateau after 2 weeks in similar animal models of
short gut (22,23).
The pattern of intestinal adaptation that we observed
resembles the intrinsic development of intestine during embryonic
development. In human infants, the intestine grows more rapidly
during the last trimester of pregnancy, doubling its length by the
40th week or term gestational age (24,25). In contrast, the intestine
in rats is immature at birth, but grows rapidly starting from the time
of weanling at 18 to 22 days until reaching a plateau at 5 weeks of
age (26). In our model, ileal architecture underwent major modi-
fications. A major increase in surface area and volume was
TABLE 1. Comparative morphometric parameters of the adaptive response in jejunum and ileum
Villus height
(mean %'SD)
Crypt depth
(mean %'SD)
No. villi/mm2
(mean %'SD)
Mean absorptive
(mean %'SD)
Jejunum Ileum Jejunum Ileum Jejunum Ileum Jejunum Ileum
2 days þ1' 0.5 0' 0.02 0' 0.1 þ2.8' 0.2 (1.4' 0.7 (8.1' 0.9 þ2.54' 0.8 þ6.5' 0.5
7 days þ6' 0.1 32.7' 0.2! þ15' 0.2! þ12.3!' 0.9 þ1.3' 0.2 (19.5' 0.5! þ5.06' 0.2 þ64.97' 0.6!
15 days þ29' 0.3! 43.9' 0.5! þ30' 0.1! þ39.8' 0.5! þ5.4' 0.3! (20.7' 0.1! þ22.54' 0.9! þ81.50' 0.7!
Data are expressed as % of increase over baseline.!
P< 0.05 versus 2 days.
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Control Resected
Control Resected
200 micron
FIGURE 3. Comparative analytical histology of jejunum and ileum
15 days after extensive small intestinal resection comparedwith sham-
resected animals (control). All of the fields are shown at the same
magnification (Zeiss, original optical magnification %200). In the
jejunum, villus height is increased (black vertical bars). Base diameter
is unchanged (black horizontal bars), and crypt depth is increased
(white bars). The number of villi is unchanged (black circles). In the
ileum, villus height (black vertical bars) and base diameter are
increased (black horizontal bars). Crypt depth is (white bars). The
number of villi is decreased (black circles).
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FIGURE 4. Time-course pattern ofmodifications of villus volume and
area in the jejunum and ileum 2 (white bars), 7 (grey bars) and 15 days
(black bars) after extensive small intestinal resection versus sham-
resected animals.
!
P<0.05 versus sham resected;
!!
P<0.01 versus
sham resected.
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associated with a reduction in villi number. This led to an overall
increase in villi surface. From the functional point of view, these
changes enhance the adaptive response because the ileum is the
main site of absorption of liquids, thereby allowing prompt restor-
ation of transepithelial ion fluxes and of nutrient absorption, which
obviously is an advantage in terms of postresection structural/
functional intestinal modifications.
In an attempt to restore the intestinal functions, the adaptive
response is fully functional in terms of the restructuring because
there is an increase in absorptive surface area in a relatively
short period.
Both drugs and nutrients have been used to stimulate cell
growth and proliferation in SBS, namely, insulin (27), growth
hormone and glucagon-like peptide-2 (28,29), glutamine, arginine,
zinc, and, more recently, lactoferrin (30–32). The 3D model
provides a tool to investigate the type and amount of fuel necessary
to optimize absorptive changes and promote intestinal sufficiency.
The 3D model was approached by other authors. Liao et al (33)
constructed a 3D surface model of different gastrointestinal tracts,
from the stomach to the colon. Their macroscopic model was
developed to study the geometry and the morphology of the visceral
organs to evaluate the visceral distention and curvature during stress
events. The 3D modeling approach is a quantitative method that
could be used as a useful and analytical tool to study the bio-
chemical properties of intestinal mucosa in different physiological
and pathophysiological states.
In conclusion, extensive intestinal resection results in a
differential adaptive response in the remaining proximal and distal
small intestinal segments. The bulk of changes is observed in the
ileum distal to the anastomosis, whereas the adaptive response is
less evident in the jejunum and does not involve the colon. The
responses follow a different time- and segment-related pattern. Our
findings show that the ileum plays a major role in postresection
adaptation. This is reflected in the better outcome observed in
patients with SBS with preserved rather than removed ileocecal
valve (34,35). Sparing even small segments of ileum could result in
adaptive changes that may be eventually associated with restoration
of full intestinal digestive absorptive functions in children under-
going extensive intestinal resection.
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Abstract
Islet and hepatocyte transplantation are associated with tissue factor-dependent activation of coagulation which elicits
instant blood mediated inflammatory reaction, thereby contributing to a low rate of engraftment. The aim of this study
was i) to evaluate the procoagulant activity of human adult liver-derived mesenchymal progenitor cells (hALPCs), ii) to
compare it to other mesenchymal cells of extra-hepatic (bone marrow mesenchymal stem cells and skin fibroblasts) or
liver origin (liver myofibroblasts), and iii) to determine the ways this activity could be modulated. Using a whole blood
coagulation test (thromboelastometry), we demonstrated that all analyzed cell types exhibit procoagulant activity. The
hALPCs pronounced procoagulant activity was associated with an increased tissue factor and a decreased tissue factor
pathway inhibitor expression as compared with hepatocytes. At therapeutic doses, the procoagulant effect of hALPCs
was inhibited by neither antithrombin activators nor direct factor Xa inhibitor or direct thrombin inhibitors individually.
However, concomitant administration of an antithrombin activator or direct factor Xa inhibitor and direct thrombin
inhibitor proved to be a particularly effective combination for controlling the procoagulant effects of hALPCs both in
vitro and in vivo. The results suggest that this dual antithrombotic therapy should also improve the efficacy of cell
transplantation in humans.
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Introduction
Adult mesenchymal stem/progenitor cells are currently under
evaluation in several clinical trials. A main concern for clinicians
and health authorities is the risk of therapy-induced thrombosis,
which has been reported in several patients [1].
We previously showed that hepatocyte transplantation results
in clinical benefits to patients with inborn errors of metabolism,
for whom this technique may be proposed as an alternative or
at least, a bridge to orthotopic liver transplantation [2–7].
However, it was important to increase the degree of cell
engraftment to improve the clinical outcome of this procedure.
One limitation is the finding that isolated hepatocytes exhibit
procoagulant activity (PCA), which was found to be linked to
tissue factor (TF) expression. This in vitro observation has been
found to translate clinically in modifications in coagulation
parameters and D-dimer levels in recipients of liver cell
transplantation, which is suggestive of infraclinical micro-
thrombotic events [8].The TF dependent PCA of hepatocytes
has more recently been confirmed by an independent team
which reported that all the parameters of the instant blood
mediated inflammatory reaction (IBMIR) were documented in
a tubing loop model, whole blood coagulation model mimicking
blood circulation [9]. Furthermore, the activation of the
coagulation cascade was previously shown to be associated with
negative clinical outcome following pancreatic islet transplanta-
tion. PCA not only led to thrombotic events, but also elicited
inflammatory reactions involving the up-regulation of adhesion
molecule expression and chemokine production, two critical
pathways affecting graft success rate [10–13].
Targeting Cell PCA is thus Essential to Improve Safety
and Success of Cell Transplantation
We previously isolated human adult liver-derived mesenchymal
progenitor cells (hALPCs) following human liver enzymatic
digestion [14]. These cells were able to proliferate, but also
differentiate into hepatocyte-like cells both in vitro and in vivo.
Therefore, hALPCs represent an attractive cell source for the
treatment of liver-based metabolic diseases.
In this context, the aim of the present study was to determine
whether hALPCs display PCA and if hALPCs PCA is related to
TF expression. In addition, we compared PCA that of other
mesenchymal cells like bone marrow- mesenchymal stem cells,
skin fibroblats and liver myofibroblasts. Finally, we investigated
how this activity could be modulated by evaluating different
antithrombotic strategies targeting clotting factors IIa and Xa.
PLOS ONE | www.plosone.org 1 August 2012 | Volume 7 | Issue 8 | e42819
Results
Procoagulant Activity of hALPCs
The PCA of hALPCs was determined using thromboelasto-
metry in human whole blood and plasma. The clotting time
(CT) of hALPCs was shorter than that of hepatocytes when
evaluated using the thromboelastogram in both blood and
plasma (116.5633.7 sec [n= 17] vs. 285.8687.0 sec [n = 11] for
blood, p,0.001) (112.6618.4 sec [n= 9] vs. 363.06180.1 sec
[n = 5] for plasma, p,0.05) (Figures 1A and 1B). The control
CT without the addition of cells was measured at
644.86108.8 sec (n = 19) in blood and 781.96150.5 (n = 9) in
plasma. Comparable PCA of hALPCs was observed without
adding extrinsic TF (Figure 1C). No PCA was obtained when
hALPC culture supernatant was placed in the thromboelasto-
gram instead of cells (Figure S1).
The PCA of hALPCs was also evaluated in the tubing loop
model. A decrease in platelet count and increase in D-dimer
levels were observed after the incubation of hALPCs with whole
blood, with a platelet count decreasing from 295 000/ml to 109
000/ml (Experiment 1) and from 310 000/ml to 134 000/ml
(Experiment 2), while D-dimer levels increased from 100 ng/ml
to 700 ng/ml (Experiment 1) and from 95 ng/ml to 740 ng/ml
(Experiment 2).
Procoagulant Activity of Mesenchymal Cells
The PCA of bone marrow mesenchymal stem cells
(279.36108.3 sec [n = 3], p,0.01 as compared to control), skin
fibroblasts (121.8626.53 sec [n = 3], p,0.01 as compared to
control), and liver myofibroblasts (61.767.6 sec [n= 3], p,0.01 as
compared to control) was evaluated using thromboelastometry on
human whole blood. Bone marrow haematopoietic stem cells were
used as a control for non-procoagulant cells (590.7625.3 sec
[n = 3]) (Figure 2).
Figure 1.-hALPCs PCA in ROTEM. Figure 1A-hALPCs PCA in ROTEM (Blood). Clotting time (CT) assayed by ROTEM after recalcification, with added
tissue factor (ExTem 20 mL) of citrated whole blood (300 ml) in presence or not of cells suspended in human albumin 5%. No coagulation was induced
in the absence of recalcification. Hepatocytes (white), human adult liver progenitor cells (hALPCs) (black), control (albumin) (grey). * as compared to
hALPCs f as compared to control hALPCs vs. hepatocytes vs. control. ***p,0.001 (Kruskal-Wallis test). Figure 1B-hALPCs PCA in ROTEM (Plasma).
Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 mL) of plasma (300 ml) obtained from blood incubated
in presence or not of cells suspended in human albumin 5%. Hepatocytes (white), human adult liver progenitor cells (hALPCs) (black), control
(albumin) (grey). * as compared to hALPCs f as compared to control hALPCs vs. hepatocytes vs. control. ***p,0.001 (Kruskal-Wallis test). Figure 1C-
hALPCS PCA in ROTEM (no TF addition). Clotting time (CT) essayed by ROTEM after recalcification, without added Tissue Factor (ExTem 20 mL), of
citrated whole blood (300 ml) in presence or not of cells suspended in human albumin 5%. No coagulation is induced if absence of recalcification.
Hepatocytes (white), hALPCs (black).
doi:10.1371/journal.pone.0042819.g001
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Modulation of Procoagulant Activity of hALPCs
The PCA of hALPCs was first analysed in coagulation factor-
deficient plasma. When using factor VII deficient plasma, the
physiological cofactor of TF, the PCA of hALPCs was only
partially decreased (298.3642.3 sec [n= 3], p,0.01) compared
with the PCA in non-deficient plasma (Figure 3). The PCA of
hALPCs was not observed in factor II (thrombin) or X deficient
plasma, nor in factor V deficient plasma (Figure 3). The PCA of
hALPCs was not fully inhibited by unfractionated heparin
(225.86149.8 sec [n = 15], p,0.001 as compared to control),
low molecular weight heparin (112.3622.5 sec [n = 3], p,0.001
as compared to control), or fondaparinux (209.76149.7 sec
[n = 3], p,0.001 as compared to control) (Figure 4A), even when
using dosage increases up to five times (Figure S2). No coagulation
was observed when heparin was used in the absence of cells.
The direct thrombin inhibitor drugs, hirudin and bivalirudin,
allowed for only a partial control of the PCA of hALPCs
(256.3611.8 sec [n = 3] and 377.76107.2 sec [n = 6], respective-
ly, p,0.01 and p,0.001 as compared to control respectively)
(Figure 4B), even when increasing the dose by two or five times
(Figure S3 and S4). Hepatocyte PCA was controlled by
unfractionated heparin, low molecular weight heparin, the
pentasaccharide fondaparinux (Figure 4C) and the direct
thrombin inhibitor drugs, hirudin, and bivalirudin (Figure 4D).
A control blood sample in the absence of cells had a CT of
1075.06107.2 (n = 6) when bivalirudin was added, while no
measurable coagulation was observed with hirudin.
Anti-vitamin K drugs (using plasma from patients on long-term
anticoagulation when the International Normalized Ratio (INR)
was steady between 2 and 3) had no influence on the
thromboelastometry, even for controls with the absence of cells
(data not shown).
Finally, the concomitant use of bivalirudin with unfractionated
heparin (1240.06338.7 sec [n= 3], p,0.05 as compared to
bivalirudin alone), enoxaparin (725.0690.1 sec [n = 3], p,0.05
as compared to bivalirudin alone), or fondaparinux
(909.06421.4 sec [n = 3], p,0.05 as compared to bivalirudin
alone) was shown to be a synergic combination with antithrombin
activator and thrombin inhibitor, allowing the PCA of hALPCs to
be modulated (Figures 5A and B). However, no complete
modulation of the PCA of hALPCs was obtained when combining
heparin with enoxaparin or fondaparinux (Figure S5).
We also demonstrated the potential of combining of bivalirudin
with a direct anti-thrombotic agent targeting factor-Xa (Rivarox-
aban), while the use of rivaroxaban alone was ineffective on
hALPCs PCA (Figure S6).
Using analogous experiments, we demonstrated that unfractio-
nated heparin was able to control the PCA of bone marrow
mesenchymal cells and skin fibroblasts, but that it remained
inactive on liver myofibroblast PCA (Figure S7). In addition, the
concomitant use of unfractionated heparin and bivalirudin was
shown to modulate the PCA of liver myofibroblasts in contrast
with bivalirudin alone (Figure S8).
Comprehension of the PCA of hALPCs
hALPCs express TF and TFPI. TF expression was first
documented using immunofluorescence. As shown in Figure 6A–
B, we found that all cells expressed TF constitutively (uniform
cytoplasmic staining). Flow cytometry analysis of hALPCs
Figure 2. Mesenchymal cells PCA. Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 mL) of citrated
whole blood (300 ml) with human adult liver progenitor cells (hALPCs), hepatocytes, skin fibroblasts, bone marrow mesenchymal stem cells (BMMSC),
bone marrow haematopoietic stem cells (BMHSC), or liver myofibroblasts suspended in human albumin 5% f as compared to control.
doi:10.1371/journal.pone.0042819.g002
Figure 3. HALPCs PCA in deficient plasma. Clotting time (CT)
assayed by ROTEM after recalcification, with added tissue factor (ExTem
20 mL) of plasma (300 ml) deficient in coagulation factors VII, V, X, and II
(7d Pl, 5d Pl, 10d Pl, and 2d Pl, respectively) in presence of cells
suspended in human albumin 5%. Human adult liver progenitor cells
(hALPCs) (black), control (albumin) (grey). * as compared to normal
plasma f as compared to control.
doi:10.1371/journal.pone.0042819.g003
Mesechymal Cell Procoagulant Activity
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confirmed a positive specific staining for TF (94.961.0% for
membrane bound form and 93.6610.2% for cytosolic form as
compared to control isotype 24.266.1% and 7.665.8%, re-
spectively, and unmarked cells 13.267.1% and 3.764.1%,
respectively; n = 3).
The expression of TF and tissue factor pathway inhibitor (TFPI)
was assessed at the mRNA level using reverse transcription
polymerase chain reaction (RT-PCR) (Figure 6C). Both the
membrane form and alternatively spliced variant of TF mRNA
were expressed in hALPCs, as was TFPI. In further experiments,
we used real-time RT-PCR to quantify TF, alternatively spliced
TF (as-TF), and TFPI mRNA levels. As shown in Figure 6D–E–F,
the membrane TF was predominantly expressed (n = 3). Further-
more, the expression of TF was higher in hALPCs compared to
hepatocytes (n = 3), whereas the expression of TFPI in hepatocytes
was higher than in hALPCs (n= 3).
The role of TF in the induction of PCA was determined by the
pre-incubation of cells with anti-human TF IgG at a concentration
of 0.2 mg/ml. The PCA of hALPCs was partially controlled by
blocking TF (324.8611.4 sec [n = 5], p,0.01 compared to
without the TF antibody), which was in contrast to hepatocytes,
as previously demonstrated (Figure S9) (7).
As shown in Figure 4, only a partial control of the PCA of
hALPCs was obtained in factor VII deficient plasma, possibly
related to the fact that small amounts of residual factor VII were
sufficient to induce coagulation in presence of hALPCs.
HALPCs and heparin. Only minor anti-Xa activity was
observed in plasma obtained after the incubation of hALPCs
(0.0560.03 UI/ml) and heparin at a concentration of 10 UI/ml
(Figure S10), which correlated with the absence of anticoagulant
effect of heparin alone in hALPCs.
Clinical Applications and Anticoagulation Protocol
The anticoagulation protocol was successfully applied, as no
thrombotic or haemorrhagic events occurred in the two patients.
With bivalirudin use, a substantial increase was observed in
Figure 4. Modulation of hALPCs PCA by anticoagulants. Figure 4A Clotting time (CT) assayed by ROTEM after recalcification, with added tissue
factor (ExTem 20 mL) of citrated whole blood (300 ml) in presence or not of human adult liver progenitor cells (hALPCs) suspended in human albumin
5% with heparin (Hepar). In contrast, enoxaparin (Eno) or Fondaparinux (Fond) was extemporaneously added to blood in contact with cells
suspended in albumin. hALPCs (black), Control (albumin) (grey). * as compared to hALPCs f as compared to control Figure 4B Clotting time (CT)
assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 mL) of citrated whole blood (300 ml) in presence or not of human adult
liver progenitor cells (hALPCs) suspended in human albumin 5%. Bivalirudin (Biva) or Hirudin (Hir) was extemporaneously added to blood. hALPCs
(black), Control (albumin) (grey). * as compared to hALPCs f as compared to control Figure 4C Clotting time (CT) assayed by ROTEM after
recalcification, with added tissue factor (ExTem 20 mL) of citrated whole blood (300 ml) in presence or not of hepatocytes suspended in human
albumin 5% with heparin (Hepar). In contrast, enoxaparin (Eno) or Fondaparinux (Fond) was extemporaneously added to blood in contact with cells
suspended in albumin. Hepatocytes (white), Control (albumin) (grey). * as compared to hepatocytes f as compared to control Figure 4D Clotting time
(CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 mL) of citrated whole blood (300 ml) with or without hepatocytes
suspended in human albumin 5%. Bivalirudin (Biva) or Hirudin (Hir) was extemporaneously added to blood. Hepatocytes (white), Control (albumin)
(grey). * as compared to hepatocytes f as compared to control.
doi:10.1371/journal.pone.0042819.g004
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thrombin time (TT), whereas the prothrombin time (PT) remained
virtually unchanged. A small increase in D-dimer levels was noted
in both patients, reaching 1480 ng/ml for the first patient and
1840 ng/ml for the second. An increase in partial thromboplastin
time (PTT) was detected in both patients, which correlated with
detectable anti-Xa activity (Figure 7A and B). There was no
modification in portal flow using liver Doppler ultrasound during
the infusions of both patients.
Discussion
Vein thrombosis at the site of infusion is a potential and major
complication in human cell-based therapies. Our present study
shows the thrombogenic risk of human mesenchymal cells, as
related to the PCA of these cells. We first demonstrated that both
hALPCs and bone marrow mesenchymal stem cells exhibited
significantly measurable PCA. This was further confirmed for
other cells of mesenchymal phenotype like skin fibroblasts and
liver myofibroblasts (activated stellate cells). The risk of thrombosis
related to the infusion of hALPCs was then shown not to be
controlled with antithrombin activator (Heparins, Fondaparinux),
direct factor Xa inhibitor (Rivaroxaban) or thrombin inhibitor
(Hirudin, Bivalirudin) alone. Instead, an innovative specific
anticoagulant protocol acted synergistically to counter this PCA.
This dual antithrombotic therapy effectively prevented the risk of
thrombosis in human clinical practice.
By revealing the PCA of mesenchymal cells, our study
confirmed the previous data from animal studies in which intra-
arterial mesenchymal stem cell infusion led to the occlusion of
distal vasculature. This result was attributed to the relatively large
cell size, and the authors consequently recommended that
mesenchymal stem cells be used cautiously when infused via the
intravascular route [15]. We demonstrated the procoagulant
potential of the cell itself independently of its size.
PCA and subsequent thrombosis events would cause, besides
bloodstream modifications, a cell loss and reduction in cell
engraftment, thus impairing the final efficacy of cell trans-
plantation [10–13]. We thus investigated in-depth the PCA of
hALPCs, as these cells are candidates for curing metabolic diseases
in humans [14,16,17]. PCA was determined using thromboelas-
tometry with or without extrinsic TF addition, which is
a viscoelastometric method for haemostasis testing in whole blood,
measuring the interaction of coagulation factors, inhibitors, and
cellular components during the clotting phase and subsequent clot
lysis. The rheological conditions of this method mimic the sluggish
flow of blood in the veins. The different parameters in
thromboelastometry reflect the synergistic activity of the plasma
coagulation system, platelet function, and fibrinolysis. A limitation
of thromboelastometry is that it only measures part of the process
of thrombin generation. It does not take into account the eventual
inhibition of thrombin by the natural anticoagulants.
In our study, the PCA of hALPCs was revealed in blood as well
as plasma, suggesting that platelet activation did not play a role in
this mechanism. The PCA of hALPCs was further confirmed by
the tubing loop method. The more pronounced PCA of hALPCs
compared to hepatocytes may be explained by the increased TF
expression and decreased TFPI expression. As reported in the
literature, fibroblasts, vascular smooth muscle cells, and cardiac
myocytes, which are all mesenchymal cells, express small amounts
of cell-surface TF under physiologic conditions. Indeed, under
normal conditions, TF expression is confined to the extravascular
sites, separated from the circulating blood by a tissue barrier,
which, when disrupted, allows plasma factor VII/VIIA to be
exposed to TF and initiate clotting. In this study, TF expression of
these extravascular space cells, TF mRNA and antigen, were
increased between eight- and ten-fold by serum stimulation in
culture [18]. TF expression is also increased by other growth
factors, PDGF and EGF, or by non mitogenic agents (bacterial
LPS) [19]. In our study, hALPCs were cultured in serum, with
cells at passages 4 to 6 being examined, as these may increase TF
expression.
We also incubated cells with anti-TF antibody at a concentration
inhibiting HUVEC and hepatocytes PCA to ascertain the role of
TF in inducing PCA of hALPCs. We only obtained a partial
control of hALPCs PCA while using this antibody. This may be
related to a non-saturating concentration of the antibody to
counteract the increased TF expression by hALPCs. We also only
obtained a partial control of hALPCs PCA by using factor VII
Figure 5. Modulation of hALPCs PCA by combination of anticoagulants. Figure 5A Clotting time (CT) assayed by ROTEM after recalcification,
with added tissue factor (ExTem 20 mL) of citrated whole blood (300 ml) in presence or not of human adult liver progenitor cells (hALPCs) suspended
in human albumin 5% with heparin (Hepar), enoxaparin (Eno), or fondaparinux (Fond) extemporaneously added to blood. Combination of
anticoagulant drugs was obtained when bivalirudin (Biva) was extemporaneously added to blood. hALPCs (black), Control (albumin) (grey). * as
compared to hALPCs f as compared to control $ as compared to bivalirudin Figure 5B Clotting time (CT) assayed by ROTEM after recalcification, with
added tissue factor (ExTem 20 mL) of citrated whole blood (300 ml) in presence or not of hepatocytes suspended in human albumin 5% with heparin
(Hepar), enoxaparin (Eno), or fondaparinux (Fond) extemporaneously added to blood. Combination of anticoagulant drugs was obtained when
bivalirudin (Biva) was extemporaneously added to blood. Hepatocytes (white), Control (albumin) (grey). * as compared to hepatocytes f as compared
to control $ as compared to bivalirudin.
doi:10.1371/journal.pone.0042819.g005
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deficient plasma. To interpret these results, we have to consider
that factor VII deficient plasma may contain a small amount of
factor VII, and that coagulation may have been induced when TF,
derived from cells, was exposed to even a small amount of factor
VII.
Surprisingly, the PCA of hALPCs and liver myofibroblasts was
not inhibited by unfractionated heparin alone, which is not the
case for bone marrow mesenchymal stem cells and skin fibroblasts.
The anticoagulant effect of unfractionated heparin predominantly
acts by binding to and increasing the natural anticoagulant activity
of antithrombin and TFPI [20]. Indeed, the release of TFPI into
plasma is induced by heparins but is the lowest for unfractionated
heparin as compared to low molecular weight heparin [20].
Unfractionated heparin is considered the most important antico-
agulant drug used in hepatocyte transplantation, being added to
the infusion medium. The absence or low level of anti-Xa activity
as measured in plasma in contact with hALPCs and unfractio-
nated heparin (except for high doses) may suggest a particular
interaction between cells and heparin.
Heparin is also known to inhibit the proliferation and TF
expression of smooth muscle cells in various vascular smooth
muscle cell tissue cultures [19,21,22]. The exact mechanism by
which heparin inhibits TF expression is still to be elucidated, but it
may be triggered after binding of heparin to a receptor [23–25].
To explain the absence of an effect of heparin on the PCA of
hALPCs, we may hypothesise that heparin is attached to the
binding domain on the cell surface. Heparin is linked to the cell,
being the starting point of several reactions aimed at decreasing
the proliferation of the cell and TF expression, and thus limiting its
availability for a significant blockade of the hALPCs PCA. In
addition, hALPCs can also neutralise heparin, but not by
specifically using ionic charges. Furthermore, data from Xuereb
et al. demonstrated that two downstream pathways could be
activated by TF in smooth muscle cells: one PKC dependent,
heparin insensitive elicited by LPS, and the other ERK dependent,
heparin sensitive elicited by the mitogenic agents but uncoupled to
the pathway for proliferative response [19]. Additionally, other
antithrombin activators, such as low molecular weight heparin
(enoxaparin) or fondaparinux, or direct factor Xa inhibitor did not
inhibit the PCA of hALPCs when used alone and even at high
concentrations.
Following our observation that PCA was absent when using
factor II deficient plasma, we tested the capacity of the direct
thrombin inhibitors, hirudin and bivalirudin, in inhibiting PCA in
our model. It is also known that direct thrombin inhibitors inhibit
clot-bound thrombin more potently than heparins [26]. The PCA
of hALPCs was only partially inhibited by these direct thrombin
inhibitors. In this context, a recent paper demonstrated that
stimulation of human smooth muscle cells with thrombin as well as
factor VIIa/factor X led to a significant induction of both TF
isoforms on mRNA and protein levels, confirming data from the
literature [27], but also to increased TF activity in a chromogenic
assay [28]. In contrast to the thrombin-stimulated TF isoforms
expression and TF activity, treatment with bivalirudin had no
impact on factor VIIa/factor X-induced upregulation of TF and
on increased TF activity in smooth muscle cells. These important
results showed that increased TF expression and activity differed if
obtained after thrombin or factor VIIa/factor X stimulation as
bivalirudin has no effect on factor VIIa/factor X TF expression
and activity [28]. This is in line with our results that showed that
the combination of antithrombotic agents targeting IIa and Xa is
needed to control hALPCs PCA, related to increased TF
expression. As discussed earlier, two different pathways are
probably responsible for increased TF expression, one heparin
sensitive and the other heparin insensitive and thus maybe the
bivalirudin sensitive one.
Combination of a low molecular weight heparin and recombi-
nant hirudin was found to reduce successfully the thrombus
growth in a rabbit jugular vein thrombosis model [29]. Finally, it
was also shown experimentally that following hirudin treatment
discontinuation, a hypercoagulation rebound occurred, possibly
related to the persistence of factor Xa activity in the clot. The
authors subsequently demonstrated the complementary effect of
DX9065a, a clot-bound factor Xa inhibitor, and r-hirudin, which
increased the antithrombotic effect in an in-vitro model for the
measurement of clot-bound thrombin [30]. The combination of an
antithrombin activator and thrombin inhibitor was used in a recent
study on patients with ST-elevation myocardial infarction,
resulting in a reduction in mortality or definite thrombosis
following primary percutaneous angioplasty [31]. Bivalirudin has
a short half-life of 35 to 40 minutes and has a reversible effect,
while hirudin has a non-reversible effect and requires novel
thrombin synthesis in order to return to normal haemostasis status.
Bivalirudin use in children was previously evaluated using an adult
dosage (0.75 mg/kg bolus and 1.75 mg/kg/hr infusion), and safely
provided the expected anticoagulant effect in a paediatric
population undergoing intravascular procedures for congenital
heart disease [32]. For clinical application, we chose unfractio-
nated heparin, typically used in hepatocyte transplantation and
easily added to the infusion medium, and bivalirudin given its
short half-life and available paediatric data.
We successfully tested this anticoagulation protocol in two
hALPC-transplanted recipients, without any side effects being
observed during or following cell transplantation.
The high increase in D-dimer levels that was observed in
previous patients who experienced partial thrombosis was not
found in our two patients, confirming the antithrombotic efficacy
of this anticoagulation protocol. Furthermore, PCA not only
causes local thrombosis and microthrombosis, but also induces
local inflammation, which may lead to cell rejection. Thus, the
proposed anticoagulation combination may optimise engraftment
and repopulation by hALPCs.
To conclude, the original combination of two anticoagulant
drugs, an antithrombin activator or a direct factor Xa inhibitor
and a thrombin inhibitor, can reduce or even prevent the risk of
thrombosis, which is associated with intravascular infusion of cells
in humans. This anticoagulation strategy has probably also an
interest for islet transplantation where TF expression by islets and
Figure 6. TF expression. Figure 6A–B. Tissue factor (TF) expression in hALPCs. Immunofluorescence for TF was performed on human adult liver
progenitor cells (hALPCs) placed on coverslips and fixed by paraformaldehyde (magnification 1006) (A). The nuclei were revealed by DAPI (blue
staining). As a negative control, immunofluorescence was performed on hALPCs without primary antibody (B). Figure 6C Tissue factor (TF) and tissue
factor pathway inhibitor (TFPI) mRNA expression in human adult liver progenitor cells (hALPCs) and hepatocytes evaluated using conventional
reverse transcription polymerase chain reaction. TF, alternatively spliced TF (as-TF), TFPI, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
(technical control). A) hALPCs, B) Hepatocytes, C) Control Figure 6D–E–F Tissue factor mRNA (TF and as-TF), and tissue factor pathway inhibitor (TFPI)
mRNA expression of human adult liver progenitor cells (hALPCs) and hepatocytes evaluated using real-time polymerase chain reaction. Semi-
quantitative expression of the mRNA of the TF gene (A), as-TF (B), and the TFPI gene (C) among hALPCs cells and hepatocytes. CAPAN-2 cells and
HUVEC are the positive control for TF, as-TF, and TFPI.
doi:10.1371/journal.pone.0042819.g006
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Figure 7. HALPCs infusion and anticoagulation protocol. During cell infusion, patients received bivalirudin (1.75 mg/kg). Between consecutive
cell infusions, the dose was decreased to 0.25 mg/kg for 2 to 4 hours. Coagulation tests were repetitively performed before each infusion, 20 min
after beginning and at the end, and included the following: thromboelastometry with clotting time (CT) in the portal vein (port) or via the central line
(centr); platelets (PLT) (normal values: 150–350 10exp3/ml); D-dimer levels (normal values: ,500 ng/ml), thrombin time (TT) (normal values: 15–
24 sec); prothrombin time (PT) (normal values: 9–14 sec); partial thromboplastin time (PTT) (normal values: 20–33 sec). A Crigler Najjar patient. B
Glycogenosis Type 1a patient.
doi:10.1371/journal.pone.0042819.g007
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duct cells plays also a pivotal role in inducing PCA and related
instant blood mediated inflammatory reaction. By preventing
thrombosis, microthrombosis, and inflammation, this anticoagula-
tion should also optimise the safety and success of cell, pancreatic
islet and stem cell transplantation in humans.
Methods
Ethics Statement
The protocol, including all experiments on human samples, as
well as the human off-label anticoagulant protocol use and
informed consent were approved by the institutional ethics review
board (Comission d’e´thique biome´dicale hospitalo-facultaire,
Universite´ Catholique de Louvain, Faculte´ de Me´decine,
commission.ethique@md.ucl.ac.be, chaired by J.M. Maloteaux).
Written informed consent was obtained from the patient (If
applicable) and from the next of kin.
Cell Preparations
hALPCs were obtained from healthy liver donors (n = 6, aged 9
to 44 years) as previously described [14). We studied freshly
trypsinised cells or cells after cryopreservation/thawing at passages
4 to 6, with a viability exceeding 90% at the trypan blue test. Cells
were suspended in an albumin solution with or without heparin at
a concentration of 10 U/mL (or more when specified). As
a control, cryopreserved/thawed human hepatocytes (n = 5, aged
16 to 44 years) were used. Liver isolation and hepatocyte
cryopreservation/thawing procedures were previously published
in detail [4].
Bone marrow samples were collected by the aspiration of
vertebrae or iliac crests of three post-mortem organ donors aged 8
to 67 years. Aspirates were collected into heparinised syringes
containing 10% Hanks’ balanced salt solution (Invitrogen,
Merelbeke, Belgium) and processed within 48 hours according
to a previously described protocol [33].
Human fibroblasts were collected from a skin biopsy (medio-
anterior side of the forearm) of three volunteers aged 18 to 35
years after obtaining written informed consent as previously
described [34].
Human liver non-parenchymal cells were obtained after liver
isolation was performed in our tissue bank, involving filtration and
two low-speed centrifugations of the cell suspension from three
different donors (one neonate liver and two 12-years-old donors).
Next, human stellate cells were isolated using Nycodenz gradient
centrifugation (Myegaard, Oslo, Norway) according to established
protocols and in collaboration with the Department of Cell
Biology-VUB (Prof. LA van Grunsven) [35]. Activated myofibro-
blasts were obtained from the isolated stellate cells.
Blood
Blood was obtained from five male donors aged 29 to 40 years.
Procoagulant Activity of hALPC Suspension
Measurements were performed on a ROTEMH delta analyser
(Pentapharm, Munich, Germany). ROTEMH assessed the kinetics
and quality of clot formation and clot lysis in real time. Clotting
time (CT) was defined as the period of time from the start of
analysis until the start of clot formation, normally until 2-mm
amplitude was reached. Clot formation time was classified as the
period until 20-mm amplitude was reached. The alpha angle was
defined as the angle between the centre line and a tangent to the
curve through the 2-mm amplitude point, which was at the end of
CT. The maximum amplitude of the curve represented the
maximum clot firmness, while the maximum of lysis the maximum
fibrinolysis detected during the measurement. Our analysis
focused on CT.
In short, after a brief rest period, 300 ml of whole blood was
pipetted into a cup preheated to 37uC. Suspended cells were
subsequently added to the whole blood (five 10exp5 cells if not
specified), with 20 ml of trigger reagent containing tissue factor
(Innovin, Siemens, Marburg, Germany; final dilution 1:17000/
0.35 pM) diluted in Owren buffer (Siemens, Marburg, Germany)
then being added to the cell-blood mixture followed by the
necessary addition of 20 ml of 0.2 M CaCl2. After adding calcium,
measurements were initiated automatically. The PCA of cells was
also determined without adding Innovin. Thus, in order to
ascertain the role of TF in this coagulation model, cells were pre-
incubated at room temperature for 10 min with either 0.2 mg/mL
anti-human TF IgG1 monoclonal antibody (mAb) (American
Diagnostica) or 0.2 mg/mL mouse IgG1 mAb (clone11711.11;
RnD Systems, Abingdon, United Kingdom) before extensive
washing with albumin 5% followed by the thromboelastometry
assay, concentration inhibiting HUVEC and hepatocytes PCA
[8,36].
For plasma assays, cells (five 10exp5 cells if not specified) were
incubated in 3.8 ml of citrated blood at 37uC for 30 minutes. After
incubation, whole blood was centrifuged at 4500 rpm for 10
minutes. Consequently, 300 ml of the obtained plasma was ready
for the protocol, pipetted into the cup with the addition or not of
Innovin and CaCl2.
For factor-deficient plasma assays, suspended cells (five 10exp5
cells if not specified) were combined with 300 ml of plasma before
adding Innovin and CaCl2.
For the modulation of PCA assays, cells were suspended in
albumin 5% with or without unfractionated heparin (Heparin
LeoH, Leo) at a concentration of 10 UI/ml. The following were
then added to blood or plasma: low-molecular-weight heparin,
enoxaparin (ClexaneH, Aventis Pharma) at a concentration of
1 UI/ml following published data [37], pentasaccharide anti-
thrombin activator (Fondaparinux, ArixtraH, GSK) at a concen-
tration of 0.34 mg/l and dose extrapolation of 2.5 mg/kg for
adults following published data [38], rivaroxaban (XareltoH, Bayer
Schering) at a concentration of 1 mg/ml following published data
[39], hirudin (RefludanH, Celge`ne Europe Limited) at a concen-
tration of 5.7 mg/ml and dose extrapolation of 0.4 mg/kg, and
bivalirudin (AngioxH, The Medicines Company) at a concentration
of 10.7 mg/ml and dose extrapolation 0.75 mg/kg. Dose extrap-
olation was based on circulating blood volume according to weight
(70 ml/kg).
If no coagulation was observed after 1800 sec, thromboelasto-
metry was arbitrarily stopped.
Tubing Loop
A whole-blood experiment protocol was adapted from a model
previously described [12]. Loops made of polyvinyl chloride tubing
(inner diameter 6.3 mm, length 390 mm) and treated with
a Corline heparin surface were purchased from Corline (Uppsala,
Sweden). Loops were supplemented with cell samples (five 10exp5)
suspended in phosphate buffered saline before adding blood.
Thereafter, 5 mL of non-anticoagulated blood from healthy
volunteers was added to each loop. To generate a blood flow of
approximately 45 mL/minute, loop devices were placed on
a platform rocker inside a 37uC incubator. Blood samples were
collected in tubes containing ethylene diamine tetraacetic acid
(4.1 mmol/L final concentration) and citrate (12.9 mmol/L final
concentration) before and 30 minutes after the start. Platelets were
counted by the XE-2100 automate haematology analyser (Sysmex,
Japan), and D-dimer levels were evaluated using the immuno-
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turbidimetric assay (Innovance D-Dimer, Siemens, Marburg,
Germany) on a CA-7000 system (Sysmex, Japan).
Anti-Xa Activity Measurement
Anti-Xa activity measurement was performed using the
Biophen Heparin (LRT) kit adapted on a CA7000 (Siemens,
Marburg, Germany). In short, the assay was a chromogenic kinetic
method based on the inhibition of a constant amount of factor Xa
by the tested heparin (or other anti-Xa substance) in the presence
of endogenous antithrombin as well as on the hydrolysis of a factor
Xa specific chromogenic substrate by the factor Xa in excess. After
a 30-min incubation of the cells suspended in albumin with or
without heparin (10 UI/ml, 50 UI/ml, and 100 UI/ml) in the
blood, anti-Xa activity was measured in plasma obtained following
blood centrifugation.
TF and TFPI Expression of hALPC Suspension
Immunofluorescence studies were performed in order to
evaluate the presence of TF. Thus, human adult liver-derived
stem cells were placed on coverslips and fixed with paraformal-
dehyde 4% (Merck, Darmstadt, Germany) for 20 minutes. These
cells were then incubated with Triton X-100 (Sigma,Bornem,
Belgium) 1% in Tris-base sodium buffer (50 mmol/L Tris-HCl
pH 7.4 and 150 mmol/L NaCl) (Organics [VWR], Leuven,
Belgium) for 15 minutes and then with 3% milk in Tris-base
sodium buffer for 1 hour. The primary antibody, murine mAb
anti-TF IgG1 (immunoglobulin [Ig]G1 n4508; American Diag-
nostica, Andresy, France), was diluted (1/50) in Tris-base sodium
and incubated with the cells for 1 hour. The secondary antibody
was fluorescein isothiocyanate-conjugated anti-mouse IgG (Sig-
ma). The nuclei were revealed with 4_, 6-diamidino- 2-
phenylindole staining (DAPI; Sigma). Negative experimental
controls were performed relating to the absence of primary or
secondary antibodies. The presence of TF was also confirmed by
flow cytometric analysis. In order to detect the membrane-bound
form of TF, cells were washed in phosphate buffered saline
supplemented with 0.5% bovine serum albumin (FACS buffer)
and incubated for 20 minutes at 4uC with the fluorescein
isothiocyanate-conjugated IgG1 mAb against TF no. 4508CJ
(American Diagnostica) or the corresponding isotype-matched
control mAb (BD Biosciences, Erembogedem, Belgium) diluted in
FACS buffer containing 10% decomplemented pooled human
serum. In order to detect the cytosolic form of TF, cells were
incubated with Cytofix/Cytoperm (BD Biosciences) for 20 min at
room temperature and washed with Perm/Wash (BD Bioscien-
ces).The samples were then incubated for 20 min at room
temperature with fluorescein isothiocyanate-conjugated anti-TF
mAb or the corresponding isotype-matched control mAb (BD
Biosciences) diluted in Perm/Wash. Cell fluorescence was
measured using a BD FACS CANTO II flow cytometer and
analysed with the BD FACS Diva software.
No anti-TFPI antibody was obtained to evaluate the TFPI
expression using immunocytochemistry or flow cytometry analysis.
The two forms of TF and TFPI were analysed by reverse-
transcription polymerase chain reaction (RT-PCR). Messenger
ribonucleic acid (mRNA) was extracted from 0.56106 cells using
the TriPure isolation reagent kit (Roche Applied Science,
Brussels, Belgium) according to the manufacturer’s instructions.
One-step RT-PCR was performed on a Thermocycler in-
strument (Applied Biosystems, Lennik, Belgium) with primers
synthesised at Invitrogen. RT-PCR for TF or glyceraldehyde 3-
phosphate dehydrogenase was conducted with the primers
detailed in Table 1.
Products were separated by electrophoresis on 1% agarose gel
and visualised with ethidium bromide staining and ultraviolet
illumination.
Real-time RT-PCR for TF, as-TF, TFPI, and cyclophilin A was
carried out using the StepOnePlus Real-Time PCR system
(Applied Biosystems, California, USA) with TaqManH Gene
Expression Assays as listed in Table 2. For TF expression, two
assays were used, with one (common TF) amplifying a region
present in both membrane and soluble forms (as-TF), and the
other (membrane TF) amplifying a region present only in
membrane form (standard). The Ct (threshold cycle) parameter
was derived for each cDNA sample and primer pair, with
Cyclophilin A Ct being subtracted in order to obtain the DCt.
DDCt was then obtained by subtracting the Ct calibrator gene,
with the results expressed as the fold change of the mRNA amount
(Figure 6D–E–F). The as-TF expression was calculated as the
difference between the DDCt of the common TF and membrane
TF. The primers are detailed in Table 2.
CAPAN-2 cell line was used as a TF positive control, while
HUVEC cell line as a TFPI positive control.
Infusions of Patients and Anti-coagulation Protocol
A 3-year-old girl, suffering from severe ornithine transcarba-
mylase deficiency (,1% activity), was the first recipient of
hALPCs. The diagnosis was established 12 days after birth and
confirmed by DNA analysis, which indicated a de novo mutation of
exons 6 and 8 on the paternal allele of ornithine transcarbamylase
gene.
The girl received from a male donor two separate infusions of
30 million hALPCs per kg of body weight, with a 2-week interval
between infusions. In total, the patient received 0.9 billion
Table 1. TF, TFPI and GAPDH primers.
Primer Sequence
TF sense primer 5-TGAATGTGACCGTAGAAGATGA-3
TF antisense primer 5-GGAGTTCTCCTTCCAGCTCT-3
as-TF sense primer 5-TCTTCAAGTTCAGGAAAGAAATATTCT-3
as-TF antisense primer 5-CCAGGATGATGACAAGGATGA-3
TFPI sense primer 5-GGAAGAAGATCCTGGAATATCGAGG-3
TFPI antisense primer 5-CTTGGTTGATTGCGGAGTCAGGGAG-3
GAPDH sense primer 5-CGGACTCAACGGATTTGGTCGTAT-3
GAPDH antisense primer 5-AGCCTTCTCCATGGTGGT-3
TF: tissue factor; as-TF: alternatively spliced tissue factor; TFPI: tissue factor
pathway inhibitor; GAPD: glyceraldehyde 3-phosphate dehydrogenase.
doi:10.1371/journal.pone.0042819.t001
Table 2. References for real-time polymerase chain reaction.
Gene
TaqManH Gene
Expression Assays
Amplicon
length
as-TF Hs01076032_m1 69
TF membrane Hs01076029_m1 85
TFPI Hs01041344_m1 78
Cyclophilin A Hs99999904_m1 98
TF: tissue factor; as-TF: alternatively spliced tissue factor; TFPI: tissue factor
pathway inhibitor.
doi:10.1371/journal.pone.0042819.t002
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progenitor cells. The cells were suspended in albumin 5% and
unfractionated heparin (10 UI/ml).
The first hALPC infusion was performed under general
anaesthesia without any premedication. A transcutaneous catheter
was placed in the main portal vein branch under fluoroscopy and
ultrasound guidance after injecting one dose of Cefazolin (40 mg/
kg). Cell infusion was performed using a syringe of 50 ml at a flow
rate of 100 cc/h. Immune suppression was administrated to the
patient using tacrolimus (PrograftH, Astellas Pharma) with the
monotherapy (0.1 mg/kg) corresponding to 2 mg per day in two
divided doses to reach levels of 6–7 ng/ml. Cefazolin (40 mg/kg)
was administrated as prophylactic antibiotherapy twice post-
infusion with an 8-hour interval between the two doses. The
infusion and post-infusion periods were unremarkable, with the
child being discharged from hospital on Day 3 post-infusion.
The second hALPC infusion was performed two weeks later. In
the interim, a partial thrombosis of the intra-hepatic portal vein
branch had occurred and led to stopping the infusion. This
adverse event was treated with heparin and coumarinic anticoag-
ulant (5 mg/day).
D-dimer levels were markedly elevated after both courses of cell
infusion. This adverse event was without consequence for the
patient, but justified a further investigation of the procoagulant
effect of progenitor cells.
The second patient was a 24-year-old man with intermediate
type I/II Crigler-Najjar syndrome, which did not respond to
phenobarbital. The diagnosis was established 1 month after birth
and confirmed by DNA analysis, indicating a mutation on the
UDP-glucuronosyltransferase 1A1 gene with the presence of the
homozygous state for the L443P mutation. The patient received
2.2 billion hALPCs administered in seven infusions over 2 days.
Prior to the placement of the portal catheter, the patient was
administered premedication, including cefazolin (1 gr). The
catheter was under ultrasound control in the portal system.
Solumedrol (80 mg) was injected before the infusion. The
immunosuppression treatment consisted of tacrolimus (PrograftH,
Astellas Pharma), which targeted blood levels of 6–8 ng/ml. A
specific coagulation prophylaxis was prescribed, with cells being
suspended in albumin 5% and heparin at a concentration of
10 UI/ml. During cell infusion, the subject received bivalirudin
(1.75 mg/kg) intraveinously by continuous infusion, while between
consecutive cell infusions, he was given bivalirudin (0.25 mg/kg)
for 2 to 4 hours depending on the thromboelastometry test.
Coagulation tests including thromboelastometry (CT), platelet
counts (normal values: 150–350 10exp3/ml), D-dimer levels
(normal values: ,500 ng/ml), thrombin time (TT, normal values:
15–24 sec), prothrombin time (PT, normal values: 9–14 sec), and
partial thromboplastin time (PTT, normal values: 20–33 sec) were
repetitively performed before each infusion, 20 min after the
beginning, and at the end. A liver Doppler ultra-sound was
conducted after each infusion to assess portal flow. The
signification of coagulation tests was summarised in table 3.
The third patient was a 17-years-old suffering from glycogenosis
type 1a, as documented by genetic analysis (G188R mutation and
380insC insertion) and the absence of glucose-6 phosphatase
activity on a liver biopsy. The patient also received antibiotic
prophylaxis prior to the placement of the portal catheter as well as
steroids before the infusion. The same immunosuppressor regimen
as patient 2 was administered. The patient received 3 billion
progenitor cells administered in seven infusions over 3 days aimed
at controlling recurrent hypoglycemia. The same anticoagulation
protocol and coagulation, including liver Doppler ultrasound
follow-up, was applied.
Statistics
Mann-Whitney tests were used to assess statistically significant
differences (*P,0.05, **P,0.01, ***P,0.001). Any significant
values were adjusted according to the Bonferroni correction in
order to avoid Type 1 errors. The Kruskal-Wallis test was used for
one-way ANOVA analysis.
Supporting Information
Figure S1 Supernatant of hALPCs PCA. Clotting time (CT)
essayed by ROTEM after recalcification, with added Tissue
Factor (ExTem 20 mL), of citrated whole blood (300 ml) in
presence of supernatant of hALPCs culture. No coagulation is
induced if absence of recalcification.
(DOCM)
Figure S2 Modulation of hALPCs PCA by heparin. A)
Clotting time (CT) assayed by ROTEM after recalcification, with
added tissue factor (ExTem 20 mL) of citrated whole blood
Table 3. Coagulation tests.
Coagulation test
D-dimers level D-dimer is a fibrin degradation product, a small protein fragment present in the blood after
a blood clot is degraded by fibrinolysis. It is so named because it contains two crosslinked D
fragments of the fibrinogen protein
Thrombin Time (TT) The Thrombin Time is a blood test which measures the time it takes for a clot to form in the
plasma of a blood sample anticoagulant to which an excess of thrombin has been added. This
test is repeated with pooled plasma from normal patients. The difference in time between the
test and the ‘normal’ indicates an abnormality in the conversion of fibrinogen (a soluble protein)
to fibrin an insoluble protein.
Prothrombin time (PT) and International Normalized Ratio (INR) The Prothrombin time and its derived measures of prothrombin ratio and international
normalized ratio (INR) are measures of the extrinsic pathway of coagulation. They are used to
determine the clotting tendency of blood, in the measure of warfarin dosage, liver damage, and
vitamin K status. PT measures factors I, II, V, VII, and X.
Partial Thromboplastin Time (PTT) The Partial Thromboplastin time or activated Partial Thromboplastin Time is a performance
indicator measuring the efficacy of both the ‘‘intrinsic’’ (now referred to as the contact activation
pathway) and the common coagulation pathways. Apart from detecting abnormalities in blood
clotting, it is also used to monitor the treatment effects with heparin, a major anticoagulant.
Kaolin Cephalin Clotting Time is a historic name for the activated Partial Thromboplastin Time.
doi:10.1371/journal.pone.0042819.t003
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(300 ml) in presence or not of human adult liver progenitor cells
(hALPCs) (Black) suspended in human albumin 5% and with or
without heparin (Hepar) at several concentrations (Hepar-10 UI/
ml, Hepar 56250 UI/ml, and Hepar 1062100 UI/ml) or not
Control (albumin) (grey) f as compared to control. B) Clotting time
(CT) assayed by ROTEM after recalcification, with added tissue
factor (ExTem 20 mL) of citrated whole blood (300 ml) in presence
or not of human adult liver progenitor cells (hALPCs) (Black)
suspended in human albumin 5% and with or without
fondaparinux (Fond) and enoxaparin (Eno) at normal concentra-
tions or increased five times (56) the normal concentration
Control (albumin) (grey) f as compared to control Fond vs. Fond
56, non-significant Eno vs. Eno 56, non-significant.
(DOCM)
Figure S3 Modulation of hALPCs PCA by hirudin.
Clotting time (CT) assayed by ROTEM after recalcification, with
added tissue factor (ExTem 20 mL) of citrated whole blood
(300 ml) in presence or not of human adult liver progenitor cells
(hALPCs) suspended in human albumin 5%. Increased concen-
trations of hirudin (Hir) at two (Hir 2x) or five times the normal
levels (Hir 5x)) was extemporaneously added to blood. hALPCs
(black), Control (albumin) (grey). * as compared to hALPCs f as
compared to control hALPCs Hir vs. hALPCs Hir 2x, n.s.
(DOCM)
Figure S4 Modulation of hALPCs PCA by bivalirudin.
Clotting time (CT) assayed by ROTEM after recalcification, with
added tissue factor (ExTem 20 mL) of citrated whole blood
(300 ml) in presence or not of human adult liver progenitor cells
(hALPCs) suspended in human albumin 5%. Increased concen-
trations of bivalirudin (Biva) two times the normal level (Biva 2x)
was extemporaneously added to blood. hALPCs (black), Control
(albumin) (grey). * as compared to hALPCs f as compared to
control.
(DOCM)
Figure S5 Modulation of hALPCs by antithrombin
activators in combination. Clotting time (CT) assayed by
ROTEM after recalcification, with added tissue factor (ExTem
20 mL) of citrated whole blood (300 ml) in presence or not of
human adult liver progenitor cells (hALPCs) suspended in human
albumin 5% and with or without heparin (Hepar). Enoxaparin
(Eno) or fondaparinux (Fond) was extemporaneously added to
blood with cells suspended in heparin or not hALPCs (black),
Control (albumin) (grey) f as compared to control.
(DOCM)
Figure S6 Modulation of hALPCs by direct inhibition of
factor X in combination or not with bivalirudin. Clotting
time (CT) assayed by ROTEM after recalcification, with added
tissue factor (ExTem 20 mL) of citrated whole blood (300 ml) in
presence or not of human adult liver progenitor cells (hALPCs)
suspended in human albumin 5% with rivaroxaban. Combination
of anticoagulant drugs was obtained when bivalirudin (Biva) was
extemporaneously added to blood. hALPCs (black), Control
(albumin) (grey). * as compared to hALPCs f as compared to
control $ as compared to bivalirudin.
(DOCM)
Figure S7 Modulation of mesenchymal cells PCA by
heparin. Clotting time (CT) assayed by ROTEM after
recalcification, with added tissue factor (ExTem 20 mL) of citrated
whole blood (300 ml) with human adult liver progenitor cells
(hALPCs), hepatocytes, skin fibroblasts, bone marrow mesenchy-
mal stem cells (BMMSC), bone marrow haematopoietic stem cells
(BMHSC), or liver myofibroblasts suspended in human albumin
5% with or without heparin (10 UI/ml) (Hepar) f as compared to
control.
(DOCM)
Figure S8 Modulation of liver myofibroblats PCA.
Clotting time (CT) assayed by ROTEM after recalcification, with
added tissue factor (ExTem 20 mL), of citrated whole blood
(300 ml) in presence or not of liver myofibroblasts suspended in
human albumin 5% with or without heparin (10 UI/ml) (Hepar).
A combination of anticoagulant drugs was obtained when
bivalirudin (Biva) was extemporaneously added to blood in contact
with cells suspended in heparin f as compared to control.
(DOCM)
Figure S9 HALPCs PCA and TF blocking antibody
Clotting time (CT) assayed by ROTEM after recalcification, with
added tissue factor (TF) (ExTem 20 mL) of citrated whole blood
(300 ml) in presence or not of cells suspended in human albumin
5% after the incubation of cells with TF antibody (TF+) or not
(TF-). Hepatocytes (white), human adult liver progenitor cells
(hALPCs) (black), control (albumin) (grey). * as compared to TF-
for hALPCs $ as compared to TF- for hepatocytes f as compared
to control.
(DOCM)
Figure S10 Anti-Xa activity in plasma. After a 30-min
incubation of cells suspended in albumin with or without heparin
(Hepar) (10 UI/ml, 50 UI/ml, and 100 UI/ml) in blood, anti-Xa
activity (UI/ml) was measured in plasma obtained after blood
centrifugation Human adult liver progenitor cells (hALPCs)
(Black), Hepatocytes (Hep) (White), Control (Grey).
(DOCM)
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 CURRENTOPINION Functions of intestinal microflora in children
Vittoria Buccigrossi, Emanuele Nicastro, and Alfredo Guarino
Purpose of review
This review discusses the structural composition of intestinal microbiota, the functional relationship between
the latter and the host, and the role of abnormal microflora in chronic diseases.
Recent findings
A more complete view of the gut microbiota is being developed following the Human Microbiome Project.
The microflora in children is plastic, susceptible to changes in response to diet modifications, antibiotic
treatment and other events, providing the opportunity to study its functional role. Increasing evidence
highlights the role of nutrition in the age-related development of microflora.
Eubiosis, that is, a normal microflora structure, provides protection against infections, educates the immune
system, ensures tolerance to foods, and contributes to nutrient digestion and energy harvest. Changes in
microflora, consisting in the overpresence of harmful species or underpresence of commensal species, or
dysbiosis produce dysfunctions, such as intestinal inflammation or dysmotility. Moreover abnormal pattern
of microflora have been consistently detected in specific diseases.
Summary
A relationship exists between eubiosis and functions and conversely between dysbiosis and dysfunctions or
even diseases. Abnormalities in microflora composition may trigger or contribute to specific diseases. This
raises the hypothesis to target microflora in order to restore eubiosis through the use of antibiotics,
probiotics or nutrients.
Keywords
dysbiosis, enterotype, eubiosis, gut microbiota functions, signature
INTRODUCTION
Intestinal microflora is increasingly considered as
a functional human organ and its structure and
effects are being clarified as a result of the Human
Microbiome Project [1&&]. This project aims to
produce a reference set of microbial genome
sequences and to obtain a preliminary character-
ization of the human microbiome, to explore the
relationship between diseases and changes in the
human microbiome, and to develop new techno-
logies and tools for computational analysis. The
knowledge of intestinal microbiota composition,
how it interacts with the host, and how it causes
or contributes to human diseases have been
enhanced by culture-independent techniques that
allow its phylogenetic investigation and quantifi-
cation [2&].
STRUCTURE OF INTESTINAL MICROFLORA
AND ITS DETERMINANTS
The entire human population can be classified
in three enterotypes on the basis of intestinal
microflora. Enterotype defines the quantitatively
dominating taxa. Enterotype 1 is dominated by
Bacteroides, enterotype 2 by Prevotella and enter-
otype 3 by Ruminococcus [3&,4&&], and each of the
three enterotypes differently affects the host meta-
bolic functions [4&&,5]. The enterotypes are associ-
ated with protein and animal fat (Bacteroides) or
respectively carbohydrates (Prevotella) rich diet and
may change as early as within 24h of initiating a
high-fat/low-fiber or low-fat/high-fiber diet [6&].
However the core structure of enterotypes does
not change and is a lifestyle hallmark of individuals.
The relationship between diet and the intestinal
microflora structure emerged from a comparative
evaluation of bacteria in European children, who ate
a typical western diet, high in animal protein and
fat, and children in Burkina Faso, who were on
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high-carbohydrate/low animal protein diet [7]. The
‘European microbiome’ was dominated by
Bacteroides enterotype, whereas the ‘African micro-
biome’ was dominated by the Prevotella enterotype.
The concept that nutrition is a determinant of
microbiota composition in children was confirmed
in another study [8&].
Features of a healthy microflora are its richness
and evenness. Richness describes the number of
bacterial species in a specific ecosystem not taking
into account their relative abundance. Evenness
indicates the relative abundance of each species in
a specific ecosystem. These two definitions are used
to describe the microbial diversity in the gastro-
intestinal tract [9&].
However, the initial colonization of the
intestine is also important for future microflora
and functions. At birth, the intestine is sterile,
and bacterial colonization begins with amniotic
membrane rupture. Bacteria from the mother’s
intestinal and vaginal sites, and from the outer
environment, colonize the neonatal gut within a
few hours from birth, and appear in feces shortly
thereafter. Vaginally born infants have a greater
abundance of Bacteroides and Bifidobacteria com-
pared with infants born by cesarean section [10]
and, interestingly, the latter are at higher risk of
immunological diseases [11&]. Other important
factors that contribute to build the microbiome
composition are antibiotics, hygiene status and
functional nutrients. The latter are increasingly used
in infancy.
The time of bacterial colonization is also import-
ant as shown in animal models [12&]. In preterm
neonates, bacterial colonization is delayed, and the
number of colonizing species is limited. An increas-
ing diversity of gut microflora was observed in the
first 8 weeks of life in preterm infants, and most
infants had staphylococci in their stools as the main
species, whereas few infants were colonized with
Bifidobacterium spp. [13&&]. The study also showed
a positive relationship between diversity of intesti-
nal microflora and nutrient tolerance and weight
gain, supporting a functional relationship between
humans and their intestinal microbes.
Nutrition plays a major role at birth and after
birth. Breastmilk is important, as it not only pro-
vides a range of substrates for bacterial growth [14&]
but it is also a natural bacterial inoculum that affects
neonatal colonization [15&]. Breastfed infants had
2 times the numbers of Bifidobacteria than formula-
fed infants, and in the latter, Atopobium and
Bacteroides were found in significant counts. More-
over, in formula-fed infants, intestinal microbiota
was less complex (or ‘diverse’) than in breastfed
infants [16&]. Breastfeeding has been associated with
a number of beneficial effects in the short and long
term and it is likely that microflora contributes
many of these effects. The profile of intestinal
bifidobacterial population in infants shows the
simultaneous co-occurrence of a number of bifido-
bacterial species [17&]. Later in life, weaning and the
introduction of solid foods are associated with the
transition toward an adult-like microbiota [18&&]
and nutrients again play a key role in determining
the final microbiota composition [6&,7,9&].
The adult microbiota is relatively stable [19&&].
The temporal stability reflects the resilience of
microbiome in adults and perturbations, such as
antibiotic therapies, have only transient effects on
the dominant microbiota. Overall, the adult micro-
biome is more complex than its infant equivalent,
although being stable over time and similar between
individuals [20&&]. In contrast, infant gut microbiota
possesses a relatively simple structure but is rather
unstable over time. The microflora in children is
intrinsically plastic, affected by few variables and
less exposed to factors that may change its compo-
sition compared with adults, and this provides an
ideal setting to understand the functional roles of
gut microbiome.
FUNCTIONS OF GUT MICROBIOTA
Human microbiota exerts important immune,
metabolic, trophic, and protective functions that
are currently interpreted with a model of symbiosis
between the host and intestinal microbes. Many of
KEY POINTS
! Compared with the complex and resilient adult
microbiome, intestinal microflora in children is
intrinsically plastic, deeply affected by few variables
but less exposed to factors that may change
its composition.
! Human microbiota exerts important immune, metabolic,
trophic, and protective functions as a result of the
symbiosis between the host and intestinal microbes.
! Generally, a reduction in the diversity of gut microflora
is associated with intestinal inflammation, dysmotility,
and atopy.
! Specific aberrations in microflora composition are
microbial ‘signatures’ of selected diseases, suggesting
a specific role of well defined bacterial species in the
pathophysiology of those diseases or also their use as
biomarkers to predict them or to monitor their course.
! Targeting intestinal microflora may be a novel strategy
alone or in combination with traditional treatment for
therapy or prevention of chronic diseases.
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the effects by intestinal microbiota are realized with
mechanisms that derive from coevolution of bac-
teria and in the host (Table 1). The commensal
microflora inhibits colonization by pathogenic bac-
teria through a variety of local mechanisms. It also
interacts with the immune system at local and
systemic level. The immune system in turn protects
the host from potential pathogenicity of microbial
communities that provide metabolic benefits [21&&].
This results in a balanced homeostasis whose histo-
logical counterpart is the ‘physiological inflam-
mation’, defined by the presence of a rich
immune cell population within the intestine. A
key effect of the innate immunity is to confine
bacteria into the intestine preventing them from
reaching the systemic immune compartment
[22&,23&&]. Vaishnava et al. [24&] demonstrated that
RegIIIg, a secreted antibacterial lectin, is a funda-
mental immune mechanism that promotes host–
bacterial mutualism by regulating the spatial
relationships between microbiota and host. Flora
abundant in Bacteroides with consequent intestinal
inflammation was observed in a murine model
deficient in the inflammasome component NLRP6,
supporting the concept of the immune-driven dys-
biosis [25&].
While the host immune system controls the
development of intestinal microflora, also the
opposite is true as the microbiota shapes the
immune system [26&]. Round et al. [27&&] suggest
that the immunologic distinction between patho-
gens and the commensal microbiota is mediated
not solely by direct host mechanisms but also
through specialized molecules evolved by symbiotic
bacteria that enable commensal colonization. The
modulation of mucosal T cells by intestinal bacteria
certainly affects systemic immunity as shown by
the results obtained with different animal models
of microbiota-associated autoimmune diseases
[28&]. Therefore, the intestinal microbiota plays a
major role in driving the immune response and vice
versa. Microflora is under immune control and this
provides the basis of a finely tuned symbiotic
relationship.
A similar mutually beneficial relationship exists
in terms of energy and nutrition supply, between
gut microbiota and the host (Table 1). Bacteria
provide the host with energy from indigestible
dietary substrates in the form of short-chain fatty
acids, whereas the host offers a nutritionally
adequate environment to its commensals. A recent
clinical trial showed clear associations between gut
microbes and nutrient absorption indicating a
possible role of microbiota in the regulation of
nutrient digestion and energy harvest [29&&].
Finally, a novel, fascinating function by micro-
flora is related to neuronal development [30&].
Microbiota is an active player in the brain gut axis
and affects levels of neurotrophins in mice. This
translates in behavior control, brain differentiation,
and neuronal survival [31&&]. However, a recent
study showed that the microbial colonization trig-
gers mechanisms that affect neuronal circuits
involved in motor control and anxiety behavior
[32&&].
DYSBIOSIS IN CHILDREN’S DISEASES
In order to understand the functions and dysfunc-
tions on intestinal microflora, an obvious approach
is to investigate the composition of microflora in
specific diseases. A healthy state of microbiota struc-
ture, in which microorganisms with potential
health benefits predominate in number over those
potentially harmful, is defined ‘normobiosis’ (or
eubiosis). On the contrary, ‘dysbiosis’ is a condition
in which one or more potentially harmful bacterial
species are dominant [33]. In many diseases, the
diversity of microflora is reduced. However, there
are also specific aberrations of microflora in selected
childhood diseases. The specific microflora aberra-
tions that have been detected in specific diseases
are often defined as ‘signature’, indicating that
microbial aberrations may be a hallmark of that
disease (Table 2). An example is provided by celiac
disease in which children show a peculiar microbial
pattern with abundant Firmicutes [34&&]. However,
microbial signatures have been detected in several
Table 1. Physiological functions of intestinal
microbiota
Functions Mechanisms/Effects
Protective functions against
pathogenic bacteria
Pathogen displacement
Nutrient competition
Production of antimicrobial factors
Activation of local immune response
Contribute to the intestinal barrier
function
Immune development IgA production
Control of local and general
inflammation
Tightening of junctions
Induction of tolerance to foods
Digestive and metabolic
functions
Vitamin production
Fermentation of nondigestible
carbohydrates
Dietary carcinogens metabolism
Neuronal development Modulation of brain gut axis during
neuronal development
Motor control and anxiety behavior
IgA, immunoglobulin A.
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chronic diseases such as inflammatory bowel
diseases (IBD). Many studies showed that intesti-
nal microbiome profoundly differs between
patients with IBD and healthy individuals, and
intestinal dysbiosis may contribute to the risk of
IBD or its relapses. Schwiertz et al. [35] showed
that the Firmicutes phylum, and particularly the
species Faecalibacterium prausnitzii, is less
represented in IBD patients than in controls. This
effect may not be confined to IBD, as F. prausnitzii
inversely correlated with the severity of disease in
acute appendicitis [36&]. Interestingly, F. prausnit-
zii has an anti-inflammatory effect and its presence
increases with fiber consumption in adults [37&].
All together, these data suggest that F. prausnitzii
protects against intestinal inflammation.
In a prospective nationwide cohort study
investigating the link between antibiotics and
IBD in children, the relative risk of IBD was
increased for antibiotic users compared with non-
users [38&&]. The association was stronger if only
Crohn’s disease was considered and for antibiotics
given during the early life. In a study in adoles-
cents with IBD, a layered distribution of selected
microbiota components was described with a
decrease in Bifidobacteria, an increase in Strepto-
cocci in Crohn’s disease and in Lactobacilli in
ulcerative colitis. An increase in mucin degra-
dation by bacteria was also described in ulcerative
colitis patients [39&]. This data support the role of
microbiome perturbations in IBD.
Irritable bowel syndrome (IBS), a symptom-
based diagnosis defined by Rome III criteria, is
associated with dysbiosis and the manipulation of
intestinal microbial communities (i.e., probiotics)
may effectively alleviate fastidious symptoms. Inter-
estingly, a close relationship between a specific bac-
terial profile with the severity of symptoms was
recently shown in pediatric IBS [40&&].
Necrotizing enterocolitis (NEC) is a severe and
potentially fatal disease that affects preterm neo-
nates. A decrease in microbiota diversity was
observed for all preterm infants, and NEC children
showed a further reduction in diversity, with a pre-
dominance of Gammaproteobacteria and a
reduction of other bacterial species [41]. However,
others found an opposite pattern, and in a pros-
pective study, bacterial diversity expressed as band
richness was higher in NEC than in controls [42&&].
In a different study, microbiota diversity did not
differ between infants with NEC and controls in the
period before the disease diagnosis, but the authors
found that there is a more heterogeneous microbial
structure in infants developing NEC [43&&]. This
observation supports the concept about the identi-
fication of a pattern of microbiota at high risk
of NEC.
Atopy is also a condition in which microflora
has been implicated. Previous studies, summarized
in a recent review, showed that atopic infants have
lower counts of Lactobacilli, Bifidobacteria, and
Bacteroides species, and an increase in Clostridium
difficile colonization, compared with nonatopic
infants [44&]. Furthermore, prospective studies on
microbiota in early life showed that atopy was
associated with a reduced ratio of Bifidobacteria to
Clostridia and with the presence of C. difficile [45&].
Two recent works showed that reduced microbiome
Table 2. Major changes in the composition of gut microbiome in the intestinal and extraintestinal childhood
diseases
Disease Changes in gut microflora composition
Celiac disease Lack of bacteria of the phylum Bacteroidetes along with an abundance of Firmicutes
Inflammatory bowel disease Low concentrations of Faecalibacterium prausnitzii and Bifidobacteria
Increased levels of Escherichia coli
Reduced diversity of gut microbiota
Inflammatory bowel syndrome Significantly greater percentage of the class Gammaproteobacteria
Presence of unusual Ruminococcus-like microbes
Necrotizing enterocolitis Predominance of Gammaproteobacteria
Reduced diversity of gut microbiota
Atopy Lower counts of Lactobacilli, Bifidobacteria, and Bacteroides
Increased counts of Clostridium difficile
Reduced diversity of gut microbiota
Obesity Increased Firmicutes at expenses of the Bacteroidetes group
Cystic fibrosis Lower species richness
Lower counts of lactic acid bacteria, clostridia, Bifidobacterium spp., Veillonella spp.,
and Bacteroides-Prevotella spp.
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diversity in early life increases the risk of atopic
diseases [46&], thereby suggesting a link between
early microbial colonization and subsequent atopy.
Microflora structure in obesity is amajor focus of
research, and there is increasing evidence that
microflora composition influences the host energy
balance and that western diet profoundly changes
microbiota in humans [7,47&]. A high-carbohydrate
diet affects the composition of intestinal microflora,
which may play an important role in controlling
energy metabolism and favor a state of low inflam-
mation [48&]. Microbial composition differs between
obese and lean patients, and this may be related to
the extraction and use of energy from food in the
intestinal lumen. Changes in gut microbiome are
reflected by an abnormal ratio between Firmicutes
and Bacteroidetes [49&]. Interestingly, breastmilk
differs from mothers with normal or increased
BMI [50&], and this may be linked with a different
microbial imprinting that may become evident in
children up to 10 years of age [51&].
MICROFLORA AS A TARGET FOR
THERAPY
The data summarized above indicate thatmicroflora
plays a role in triggering – or contributing to – a
number of diseases. This raises the hypothesis that
modifications of microflora through antibiotics or –
conversely – with probiotics or also with functional
nutrients (i.e., prebiotics) may have therapeutic
effects. Rifaximin was successful in reducing symp-
toms in a population of adults with IBS without
constipation [52&&]. Consistent evidence of probi-
otic efficacy was obtained in children with IBS
characterized by abdominal pain [53&] and consti-
pation [54]. Interestingly, the administration of
Lactobacillus casei subsp. Rhamnosus to children
at risk of atopy induced a global shift in gut
microbial community composition. This resulted
in modifications of the relative abundance of a large
number of taxa previously associated with either an
increased or decreased risk for the development of
allergy and atopy [55&&]. Overall, the results that are
being obtained with probiotics in IBS and other
diseases further support the concept that microflora
play a role in selected diseases, probably with an age-
related pattern [56&].
However, probiotics should not be regarded as a
therapy to be considered in adjunct to the
traditional treatment or to be used in minor dis-
orders. They may play an important role in very
severe diseases. A general dysbiosis was detected in
children with cystic fibrosis (CF) compared with
their siblings [57&]. This may explain the beneficial
effects observed on intestinal inflammation and also
on respiratory function in children with CF receiv-
ing probiotics [58]. More recently, Scanlan et al.
[59&&] showed a reduced richness, evenness and
diversity of gut microbiota in CF children in a very
small sample-size study. Therefore, dysbiosis may
play a major role in CF and the modulation of gut
microflora with probioticsmay have a positive effect
on intestinal and nonintestinal inflammation.
Finally, a very delicate field is the use of pro-
biotics in NEC. Administration of probiotics to
preterm infants resulted in the reduction of the
incidence of NEC and – even more interestingly –
of mortality for all causes in preterm infants [60&].
The beneficial effects were confirmed in an updated
meta-analysis [61]. Such a dramatic outcome and
the strength of supporting data, led to the indication
to routine administration of probiotics to preterm
infants with the aim of preventing the severe com-
plications associated with this condition [62&]. How-
ever, meta-analysis and recommendations are not
widely shared. There are probiotic products on the
market that cannot be recommended because they
have not been studied sufficiently andmay be harm-
ful. Because NEC also appears to be a highly hetero-
geneous and etiologically multifactorial disease,
targeting the neonates at highest risk with the low-
est potential for harm, rather than routinely pro-
phylaxing all infants appears prudent. Therefore,
further data are expected prior to obtaining a con-
clusive indication in this delicate area [63&,64&].
CONCLUSION
Intestinal microflora is considered a fully functional
human organ and its structure is the result of early
life events such as feeding, illnesses, antibiotic
therapies, and environmental exposure. A healthy
microbiota, or eubiosis, protects from diseases,
whereas an abnormal microflora structure, or dys-
biosis, is linked with the risk of diseases.
A reduced diversity of gut microflora is a fre-
quent hallmark of intestinal inflammation. Consist-
ent abnormalities in the microbial structure have
been detected in populations of children with
specific diseases and have been defined as ‘micro-
biological signatures’ of those diseases. The word
signature provides a double concept: the specific
role of selected bacterial species in causing – or
contributing to – specific diseases and the oppor-
tunity to recognize the disease (or monitoring its
course) by analyzing microflora composition. How-
ever, the changes observed inmicrobial populations
raise the option of targeting microflora for therapy.
This is being done with increasing success in
selected diseases using various strategies, including
administration of probiotics.
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Family Group Psychotherapy to Support the Disclosure
of HIV Status to Children and Adolescents
Emanuele Nicastro, MD, Grazia Isabella Continisio, PsyD, Cinzia Storace, SW,
Eugenia Bruzzese, MD, PhD, Carmela Mango, RN, Ilaria Liguoro,
Alfredo Guarino, MD, and Annunziata Officioso, PsyD
AbstractAU1c
Disclosure of the HIV status to infected children is often delayed due to psychosocial problems in their families.
We aimed at improving the quality of life in families of HIV-infected children, thus promoting disclosure of the
HIV status to children by parents. Parents of 17 HIV-infected children (4.2–18 years) followed at our Center for
pediatric HIV, unaware of their HIV status, were randomly assigned to the intervention group (8 monthly
sessions of family group psychotherapy, FGP) or to the control group not receiving psychotherapy. Changes in
the Psychological General Well-Being Index (PGWB-I) and in the Short-Form State-Trait Anxiety Inventory
(Sf-STAI), as well as the HIV status disclosure to children by parents, were measured. Ten parents were assigned
to the FGP group, while 7 parents to the controls. Psychological well-being increased in 70% of the FGP parents
and none of the control group ( p = 0.017), while anxiety decreased in the FGP group but not in controls (60% vs.
0%, p = 0.03). HIV disclosure took place for 6/10 children of the intervention group and for 1/7 of controls.
Family group psychotherapy had a positive impact on the environment of HIV-infected children, promoting
psychological well-being and the disclosure of the HIV status to children.
Introduction
Positive mental health encompasses diverse aspectsrelated to quality of life and general well-being, and can
be considered as the achievement of emotional resilience.1
Resilience is the psychological process developed in response
to intense life stressors that facilitates healthy functioning,
playing a major role in response to illness and other life
adversities.2 The needs of children living with HIV infection
are progressively shifting from those strictly clinical to those
related to psychosocial issues.3 However, this is in contrast to
the established model of care of HIV-infected children, which
is characterized by a close physician–patient relationship.
Such a model is largely the consequence of the social stigma
with the need of hiding the disease. However, this often re-
sults in delayed disclosure to children and adolescents.4,5
Our Unit has been providing care to children, adolescents,
and young adults with HIV infection since the onset of AIDS
epidemics, in agreement with the guidelines of the National
Institutes of Health.6 In parallel with the evolving aspects of
HIV epidemics, we progressively developed a comprehensive
approach integrating psychological, social, and biomedical
support for the management of HIV. This model provides in-
and outpatient care by the medical staff of the reference cen-
ter, and it also includes home care provided by physicians and
nurses working in the hospital.
Using the International Classification of Functioning, Dis-
ability and Health (ICF), a specific instrument to evaluate the
disabilities and dysfunctions in children, we showed that en-
vironmental factors and psychosocial issues had a major neg-
ative impact on the quality of life of HIV infected children and
their families.7 Interestingly, the greatest impairment reported
by parents was related to the need of hiding the HIV infection
status to their children because of social stigma. This was as-
sociated with delayed disclosure,7 which in turn generated a
vicious cycle of increased anxiety, ultimately leading to further
functional disabilities in HIV-infected children. Therefore,
disclosure has a key role in coping with HIV infection. Current
recommendations regarding the disclosure of HIV infection to
children are based on lessons learned frompediatric oncology.8
Similar to trends observed in oncology, many parents and care
providers of HIV-infected children thought they need to pro-
tect children from emotional burdens and social prejudices
associatedwith their disease. With the advent of new therapies
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in the mid 1990’s, and the dramatic improvements in the
mortality and morbidity of HIV-infected children, changes in
disclosure practices began to take place, and the disclosure of
HIV infection is now a step of care.5 Disclosure is not only
related to psychosocial aspects and eventually resilience, rather
it also affects therapy and its outcome.
In a recent qualitative study, caregivers reported that their
children became more adherent to antiretroviral medications
following disclosure.9 In an interview involving 120 families
in a resource-limited setting, disclosure was perceived as a
step towards self-sufficiency, but also with potential negative
social effects.10 On the contrary, other studies have indicated
that children aware of their HIV status may be less likely to
adhere.11 The conflicting relationship between disclosure and
adherence may be explained by the age-related patterns of
relationship between the child’s age, the type of communi-
cation, and the support to it. Children and adolescents fre-
quently perceive limited communication before, during, and
after disclosure, which is a discrete event rather than a pro-
cess.12 Once children aremade aware of their HIV status, their
care-givers expect them to become able to self-manage treat-
ment, without supervision and reminding.13 However, we
previously showed that adherence was strongly related to
caregivers more than any other factor, such as child’s age or
disease status.12 Disclosure is therefore an important step that
has a broad effect on the HIV infection course and needs to be
accompanied by psychological support.
These issues led us to plan a family group psychotherapy
(FGP) with the families of childrenwith HIV infection, with the
aim of removing barriers that prevent disclosure, and ulti-
mately to increase resilience in the caregivers. The basic concept
was to work with small groups of caregivers and to discuss
common problems and feelings in order to build competence
and self-reliance in families and patients, so that parents and
their children could effectively manage their own health.
The intervention was incorporated in our HIV care plan-
ning. Specific objectives of the intervention were the follow-
ing: to provide information for sound management of the
disease; to offer an empathetic understanding of the problems
and to discuss problems and solutions; and to focus on HIV
disclosure in a timely and appropriate manner, acknowledg-
ing the need for a close interaction between parents of chil-
dren, the medical staff and the team of psychologists.
Methods
Children with HIV and their families, seen at our HIV refer-
ence center for the management of pediatric HIV infection, were
enrolled. Inclusion criteria were the following: age 1–16 years;
diagnosis of vertical HIV infection obtained>1 year before en-
rollment; unawareness of HIV infection status; therapy accord-
ing to the criteria reported in the NIH guidelines for the Use of
Antiretroviral Agents in Pediatric HIV Infection.6 To estimate
adherence quantitatively, each caregiver was asked how many
doses of the total prescribed antiretroviral therapy had been
omitted in the previous 4 days, and children were defined as
non-adherent if they had taken less than 95% of all prescribed
doses of antiretroviral therapy in this period. This method pro-
vides a reliable estimate of adherence to antiretroviral therapy in
children.14 Patients and caregivers were randomly assigned to
either FGP intervention or control group. Parents decided
whether the mother, the father, or the caregiver would partici-
pate in the support group. Written informed consent was ob-
tained for every participant.
The interventionwas structured throughmeetings between
parents of children and the team of psychologists of the ref-
erence center. Eight 2-h group sessions took place once a
month. The first and last meetings were longer to allow test
administration. The content of themeetings is described in the
Appendix. Families in the control group received complete
health assistance but no psychological support and they were
not aware of the intervention.
The following tests were administered before and after the
support group meetings:
! The Psychological General Well-Being Index (PGWB-I)15
that assesses the psychological and mental health status
of an individual through 22 items. The scale consists of
six domains: anxiety, depression, sense of positive and
well-being, self-control, general health, and vitality. The
overall score ranges from 0 to 110 (worst–best states
possible). Scores 91–110 are consistent with high level of
well-being; scores 71–90 with good level of well-being;
scores 51–70 with medium level of well-being; scores 31–
50 with low level of well-being; scores 0–30 with very
low level of well-being.16 Changes in psychological well-
being index were defined according to these ranges.
! The Short-Form State-Trait Anxiety Inventory (Sf- STAI)17
is a six-item version of the Spielberger STAI for the as-
sessment of anxiety state.18 It is a validated instrument for
measuring anxiety in adults. It clearly distinguishes be-
tween a temporary condition of anxiety in a specific sit-
uation and anxiety as a general trait. The results of the
scale range from 20 to 80. A score‡ 60 indicates an ele-
vated level of anxiety; a score between 50–59 indicates a
moderate level of anxiety; a score£ 49 indicates absence
of anxiety.17 Changes in anxiety were defined according
to these ranges. A final self-assessment through rating
was obtained after the last meeting.
Both PGWB-I and Sf-STAI have proven reliable in chronic
conditions, with a high test/retest coefficient.19,20
Results were expressed as number/percent or as mean –
SD. The Student t-test, the Wilcoxon matched-pairs signed
rank test, and the v2 method, or exact Fisher’s test when ap-
propriate, were performed to compare the variables and
p < 0.05 was the cut-off for significance. Data were analyzed
with the SPSS package version 20.
Results
A total of 17 parents of as many children (mean age
11.7 – 3.7 years, range, 4.2–18.0; 7 boys) were enrolled, 13 of
them being biological and 4 foster parents. Ten children were
single orphans, one was a double orphan and entrusted to a
caregiver; 10 childrenwere of Italian origin and 7were of non-
EU origin. Ten caregivers were randomly assigned to support
group intervention and the other 7 to controls. The corre-
sponding children populations were age-matched ( bT1Table 1).
The intervention group had a higher viral load, due to the
presence of three patients with > 100 copies/ml. However, all
patients had < 1000 viral copies/ml. Of note, viral load was
reduced in two children following the intervention (in one
patient the viral load was associated with poor compliance,
and in another with viral resistance).
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Psychological well-being
Baseline PGWB-I scores differed between FGP and controls
(57.4 – 15 vs. 79.7 – 7.3, p= 0.04). The average PGWB-I in-
creased in the intervention group (T0: 57.4 – 15; T1: 72.5 – 21,
p = 0.22), and decreased in controls (T0: 79.7 – 7.3; T1: 48.1 – 9,
p = 0.01) (F1c Fig 1A). Psychological well-being improved in 70%
of the caregivers in the FGP group versus none of the control
group; it decreased in 20% of FGP parents versus 71% of the
controls ( p = 0.01), and finally remained stable in 10% and
29% of the FGP and controls, respectively (T2c Table 2). An as-
sociation was observed between parental schooling and
changes in parental well-being ( p= 0.02) but not with other
social and economic factors (T3c Table 3).
Anxiety
The baseline Sf-STAI scores were not different between
FGP and controls. The average Sf-STAI decreased in the in-
tervention group (T0: 51.7 – 4; T1: 43– 4, p= 0.22), while it in-
creased in controls (T0: 40.6 – 6; T1: 57. – 3, p= 0.01) (Fig 1B).
Anxiety was significantly diminished in 60% of caregivers in
the intervention group versus none of the controls ( p = 0.03)
(Table 2). Similarly to PGWB-I, changes in anxiety were also
associated with parents’ education ( p= 0.01) (Table 3).
Disclosure of HIV infection to children and adherence
to antiretroviral therapy
Disclosure took place in six of 10 (60%) of the group sup-
port caregivers within 12 months following the intervention.
Comparatively only 1 of 7 (14%) of controls achieved this step
( p = 0.59). However, disclosure was correlated neither with
PGWB-I ( p = 0.15) nor with Sf-STAI ( p= 0.45), nor with any
other social, cultural, or economic features ( bT4Table 4).
Changes in adherence to HAART of children were not
correlated to intervention (Table 2) nor to the disclosure of the
HIV status to children by parents.
Assessment of the perceived benefit and efficacy
of the intervention
A final self-assessment of the benefits perceived from the
intervention was obtained after completing all sessions at the
last group meeting: caregivers answered the question ‘To
what extent did the group help you understanding issues
concerning HIV?’, and the level was 7.1 – 2 on a score 0–9 (not
helpful–very helpful). A final self-assessment of the empa-
thetic support received was provided by caregivers answer-
ing the questions ‘How helpful was it to meet other parents of
children with HIV?’ and ‘To what extent did attending the
group help you in feeling less isolated with regard to your
child’s HIV infection?’. On a score 0–9 (not helpful–very
helpful), the perceived helpfulness by empathetic support
was 9 – 0 and 9 – 0, respectively. Only one meeting was mis-
sed by two participants.
Discussion
Our results show that an intervention based on group
psychotherapy delivered to families of HIV-infected chil-
dren improves the quality of life, increases their general well-
being, and reduces their anxiety state, thereby increasing
their resilience. Our observations, even with the limitation of
a wide age range of the patients and of the heterogeneity of
the type of families, show that the support group effectively
breaks the isolation and creates opportunities for carers, by
sharing psychological resources and experiences. These re-
sults also depend on parents’ education, as suggested by the
significant association between carers’ schooling and their
psychological improvement in terms of both general well-
being and anxiety. It is well known that the education
strongly affects the capacity of living with chronic diseases
and that supportive interventions are more effective in high
culture settings. This is demonstrated for diseases such as
diabetes or chronic obstructive pulmonary disease: positive
effects on depression, health-related quality of life, feelings
of mastery, and self-efficacy are confined to patients with
high education, while those with only a primary education
do not benefit from supportive interventions.21 Our data
obtained in a small population of families of low educational
level indicate that interventions tailored to those specific
Table 1. Baseline Psychological Outcomes
and Socioeconomic Features of Patients
and Families of Family Group Psychotherapy
Group (Intervention) and Control Group
Intervention
(n = 10)
Controls
(n = 7) p
Sex n (%)
F 5 (50) 5 (71) 0.622
M 5 (50) 2 (29)
Family n (%)
Natural 7 (70) 6 (86) 0.603
Adoptive 3 (30) 1 (14)
Age mean – SD 12– 4 11 – 2 0.114
Orphanity n (%)
One 5 (50) 5 (71) 0.784
Both 1 (10) 0 (0)
None 4 (40) 2 (29)
Origin n (%)
Italian 5 (50) 5 (71) 0.622
Extra EU 5 (50) 2 (29)
CG education n (%)
Middle school or less 4 (40) 6 (86) 0.134
High school 5 (50) 1 (14)
Graduation 1 (10) 0 (0)
Income n (%)
One 6 (60) 4 (57) 0.59
Both 0 (0) 1 (14)
None 4 (40) 2 (29)
Mother transmission n (%)
Sex 3 (30) 5 (72) 0.486
Blood transfusion 2 (20) 0 (0)
Drug 2 (20) 1 (14)
Adoptive 3 (30) 1 (14)
Adherence to HAART n (%)
Adherent 6 (60) 5 (71) 0.627
Non adherent 4 (40) 2 (29)
CD4 lymphocytes/
lL mean – SD
795 – 415 604– 233 0.124
HIV RNA copies/
mL mean – SD
92– 117 20 – 0.7 0.001
HAART, highly active antiretroviral therapy.
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conditions, with simple peer communication are effective
and contribute to resilience.
Although there are limited data on psychological support
groups in pediatric settings, interventions involving families
of children with HIV are generally delivered with the aim of
improving patients’ care beyond strictly clinical aspects.
However, the effects of interventions are rarely measured.We
did that and also applied disclosure as a secondary outcome
parameter of the intervention. The latter promoted the dis-
closure of HIV status from carers to children. However, the
relationship between psychological support and disclosure
process by the caregivers is complex, and this effect could be
related to cognitive gain rather than to psychological effect.
Table 2. Changes in Psychological and Clinical
Features after the Family Group Psychotherapy
Intervention
(n = 10)
Controls
(n = 7) p
CG PGWB-I n (%)
Improved 7 (70) 0 (0) 0.017
Stable 1 (10) 2 (29)
Worsened 2 (20) 5 (71)
CG Sf-STAI n (%)
Improved 6 (60) 0 (0) 0.037
Stable 2 (20) 2 (29)
Worsened 2 (20) 5 (71)
HIV Disclosure n (%)
Yes 6 (60) 1 (14) 0.134
No 4 (40) 6 (86)
Change in adherence
to HAART n (%)
Improved 3 (30) 2 (29) 0.784
Stable 5 (50) 5 (71)
Worsened 2 (20) 0
Adherence to HAART T1 n (%)
Adherent 7 (60) 7 (71) 0.228
Non adherent 3 (40) 0 (29)
CD4 lymphocytes/
uL T1 mean– SD
863 – 379 665– 271 0.677
HIV RNA copies/
ml T1 mean – SD
92– 150 20 – 1 0.06
CG, caregiver; HAART, highly active antiretroviral therapy;
PGWB-I, Psychological General Well-Being Index; Sf-STAI, Short
form of State-Trait Anxiety Index; T1, after the intervention.
FIG. 1. Psychological general well-being (A) and anxiety (B) scores before and after family group psychotherapy. FGP,
family group psychotherapy; PGWB-I, Psychological General Well-Being Index; Sf-STAI, Short form of State-Trait Anxiety
Index; *p< 0.05.
Table 3. Change in Psychological General Well-Being
and Anxiety of Caregivers After the Intervention
According to Parental Schooling
CG education (n)
Middle or
less (10)
High
(6)
Grad
(1) p
PGWB-I n (%)
Improved 2 (20) 4 (67) 1 (100) 0.021
Stable 1 (10) 2 (33) 0 (0)
Worsened 7 (70) 0 (0) 0 (0)
Sf-STAI n (%)
Improved 2 (20) 4 (67) 0 (0) 0.013
Stable 1 (10) 2 (33) 1 (100)
Worsened 7 (70) 0 (0) 0 (0)
CG, caregiver; PGWB-I, Psychological General Well-Being Index;
Sf-STAI, Short form of State-Trait Anxiety Index.
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Moreover, not all the studies clearly showed an impact of the
disclosure on quality of life, as well as the acceptance of
disclosure appears to be higher in foster parents.22,23 We did
not find any association between disclosure and type of
parents (biological vs. foster), but this might be due to the
heterogeneity of our populations. The group therapy fos-
tered the information about HIV infection in carers, enabling
them to disclose to their children a troublesome truth.
Awareness is a prerequisite to self care and it is a funda-
mental leading force in the construction of personal future.24
Current recommendations by the American Academy of
Pediatrics support disclosure to children as young as 8 years
of age and to all adolescents.25 From this perspective, the
support by the group provided important motivations to
self-management and resilience.
Looking at clinical features, our population was largely
made of children and adolescents with virologically and im-
munologically well-controlled disease, reflecting the high
standards of clinical care in pediatric HIV. No association was
found between either HIV viral load or number of CD4+
lymphocytes and primary or secondary outcomes of our in-
tervention, and only three patients had detectable viral load at
baseline.
Unawareness and psychological discomfort could affect
adherence and hamper effective management of the disease,
especially in adolescents, in whom the lack of responsibility
prevents an effective therapeutic alliance. We previously de-
scribed a changing pattern of adherence over time in HIV-
infected children and adolescents, and demonstrated that
psychosocial features of caregivers and children play a major
role in adherence. Interestingly, children of foster parents had
the highest level of adherence and it may be expected that
depressed and debilitated parents have limited ability in
sustain optimal adherence in their HIV-infected children.14
However, adherence is the result of a complex interplays of
determinants and it is impossible to establish a direct linkwith
psychotherapeutic interventions. In our sample, only 65% of
all children showed an optimal adherence to HAART at
baseline. We observed that adherence increased over the pe-
riod of observation. However, this was also the likely conse-
quence of the higher attention paid by physicians and other
health care professionals to this outcome during the study. In
contrast with the physical well-being, psychological discom-
fort was high in the families enrolled, and the support group
waswell accepted and recognized as effective by families. The
mutual empathetic support among the participants was
perceived as very helpful. These interventions should be in-
tegral part of the standard care for HIV-infected children and
adolescents. Psychosocial issues in young patients should be
carefully considered to ensure clinical success.26 Management
of psychological impairment through a biopsychosocial
model of care may reduce anxiety, depression, and social
isolation by lowering physical tension, increasing a sense of
control and self-efficacy, ultimately increasing resilience in the
parents of infected children.27 The caregivers experienced a
sense of relief and expressed positive feelings for being treated
in a nonjudgmental way. As previously described, the pos-
sibility to freely talk about their own emotions without being
censored is a path of growth for HIV-positive subjects.28
In conclusion, attention needs to be paid to both psycho-
social and biomedical aspects of pediatric AIDS. It is impor-
tant to involve caregivers and family members who are in
close contact with theHIV-infected child.With little effort and
easy to perform and sustainable interventions, the bio-psy-
chosocial state of HIV-infected children and their families
may be substantially improved.
Appendix: Psychotherapy Sessions
First meeting
Apsychologist expert inHIV guided themeeting; a younger
psychologist and a social worker were also actively involved.
All the group members met in a friendly context. Parents were
invited to introduce themselves and their families and share
their expectations. The aims of the group support were pre-
sented, and the participants were asked to fill the standardized
cognitive instruments. Parents reported their fears and feelings
of isolation in relation to their and/or their children’s illness.
Some of the parents reported fear for their own disease. A
major issue was related to the disclosure of the HIV status.
Second meeting
An overall increased acknowledgment of the pain and the
distress related to the issues raised by parents was recorded
and openly discussed. Most interventions focused on the
sense of guilt for having vertically transmitted the infection,
the fear of illness and death, the uncertainty about the future.
Reasons supporting early disclosure to children were gently
introduced.
Third meeting
The inner resources of the parents/carer and the family
resources were explored under the guide of therapists. The
barriers to disclosure were often related to the perceived
misconception of the HIV infection in the ‘outside world’. The
fear of death was strongly rooted in those participants who
already had experienced a death for HIV in the family and
was contained by an element of life expressed by others. The
risk of family break up by a member of the group was coun-
terbalanced by someone else’s confidence as well.
Fourth meeting
A conscious sense of guilt arose for the transmission of the
infection, in association with the idea of having betrayed their
task to be bearers of life rather than death.
Table 4. Rate of Disclosure of HIV Status to Children
by Families According to Psychological Outcomes
of the Intervention
HIV Disclosure (n) Yes (7) No (10) P
PGWB-I n (%)
Improved 5 (71) 2 (20) 0.156
Stable 0 (0) 3 (30)
Worsened 2 (29) 5 (50)
Sf-STAI n (%)
Improved 4 (57) 2 (20) 0.456
Stable 1 (14) 3 (30)
Worsened 2 (29) 5 (50)
PGWB-I, Psychological General Well-Being Index; Sf-STAI, Short
form of State-Trait Anxiety Index.
FAMILY PSYCHOTHERAPY IN PEDIATRIC HIV 5
APC-2012-0465-ver9-Nicastro_1P.3d 04/15/13 11:02am Page 5
Fifth meeting
In this session, the attendeeswere invited to take advantage
from available social services. Particularly, a social worker
provided information on local resources, as well as financial
resources to support HIV-infected subjects. The physicians of
the medical service joined the group, and parents were able to
directly and openly ask questions and make comments. The
physicians stressed the efficacy of HAART in fostering a full
control of the disease, preventing HIV progression, and al-
lowing a full normal life, if optimal adherence to treatment
was reached.
Sixth meeting
This session was named ’Not when, rather how’ and ad-
dressed HIV disclosure, because therapists spoke about the
scattered experiences and built a roleplaying to give simple
explanations to young children or information about the na-
ture and consequences of illness to older children.
Seventh meeting
In this session, the focus was on consolidation of earlier
meetings in order to help the caregiver to find confidence and
language competences to talk to the children.
Eighth meeting
In the final session, tests were administered to caregivers in
order to obtain a feedback on empathetic support and cog-
nitive advance.
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Introduction: Incidence and severity of Clostridium difficile infection (CDI) are
increasing worldwide. Toxins A (TcdA) and B (TcdB) and host immune response
are the major determinates of CD pathogenesis and represent a new, stimu-
lating therapeutic target to control CDI.
Areas covered: The present patent and literature on the pathogenesis and
treatment of CD were critically reviewed. The patent was described and put
into clinical context, highlighting possible advantages and barriers to use. It
consists of a blend of monoclonal antibodies (mAbs) and antigen-binding
portions that neutralize TcdA, targeting the enterocyte-binding domain. It
demonstrated good efficacy in in vivo models and seems promising in clinical
practice. However, recent evidence reshaped the central role of TcdA.
Expert opinion: Current treatments are inadequate to control CDI and recur-
rence. Toxin-targeted mAbs are one of the most promising approaches for
CDI, including infection by hypervirulent strains. At-risk subjects and those
experiencing recurrence are the ideal targets for this second-line treatment;
however CDI epidemiology is fast-changing and mAbs may represent a pow-
erful option also for other patients. The re-evaluation of the pathogenic
role of TcdA may potentially limit the use of this product; however, the
possible administration in combination with other therapeutic agents may
optimize its efficacy.
Keywords: antibiotic-associated diarrhea, Clostridium difficile, Clostridium difficile infection
recurrence, Clostridium difficile Toxin A, immunization, monoclonal antibodies
Expert Opin. Ther. Patents [Early Online]
1. Introduction
1.1 Clostridium difficile infection
Clostridium difficile (CD) is a sporogenic anaerobic Gram-positive organism that
may be responsible for a broad spectrum of diseases in humans, ranging from a
self-limiting secretory diarrhea to life-threatening conditions such as pseudomem-
branous colitis, toxic megacolon, intestinal perforation and septic shock [1].
In the past decade, a dramatic worldwide increase in the incidence of C. difficile
infection (CDI) has been reported [2]. This relevant increase in CDI occurrence
and severity has been related to an injudicious use of antibiotics and other treatment
responsible of microflora disruption and to the concomitant emergence of
hypervirulent epidemic strains and new risk factors.
Although CD still represents the leading cause of diarrhea in health care settings
and at-risk patients (elderly, chronically ill and immune-compromised subjects), it
is fast becoming a cause of community-acquired diarrhea in low-risk populations,
such as children, healthy adults and pregnant women [3-5].
In addition to the change in epidemiology, the report of unacceptably high fail-
ures of traditional first-line treatments (metronidazole and vancomycin) is leading
10.1517/13543776.2013.832203 © 2013 Informa UK, Ltd. ISSN 1354-3776, e-ISSN 1744-7674 1
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to a growing concern and the development of new strategies
to control CDI and its recurrence [2,6].
1.2 Role of toxins in the pathogenesis of CDI
Although not the only virulence factors, CD toxins A (TcdA)
and B (TcdB), play a major role in the pathogenesis of CDI.
Both toxins are glycosyltransferases targeting host GTPases,
including Rac, Rho and Cdc42, leading to cytoskeleton dis-
ruption and apoptosis in enterocytes and immune cells [7].
Moreover, as recently demonstrated, both toxins trigger the
inflammasome-mediated IL-1b production in the gut
mucosa [8]. Historically, TcdA has been thought to be crucial
in the CDI pathogenesis and to have a permissive effect to
TcdB-mediated tissue damage, as suggested by toxicity studies
in hamster and rabbit models [9,10]. More recently, anti-TcdA
IgG titers have been recognized to be protective against the
diarrheal disease in CD colonized patients [11]. However, the
pathogenic role of the TcdA has been recently reshaped. Ham-
ster mortality models demonstrated that the presence of TcdA,
in the absence of TcdB, even at levels higher than in the wild-
type strain was not lethal [12]. In human intestine, TcdB has
proved to be the main trigger to cell inflammatory response
during CDI [13]. The identification of diarrheagenic strains
of CD that do not produce TcdA has further reduced the
role of this toxin and emphasized the importance of TcdB [14].
1.3 Use of antibodies in human CDI
Immune responses to CD and its toxins are central to the
pathophysiology of CDI, and both toxins are highly immuno-
genic. Moreover, an adequate serum antibody response dur-
ing the initial episode of CDI seems to be associated with
protection against recurrence. In fact, asymptomatic carriers
and patients who do not experienced CDI recurrence showed
more robust antitoxin immune responses than those with
symptomatic and recurrent disease. The risk of recurrent
CDI was significantly lower in patients with an enhanced
serum antibody response with high titer of IgG against
TcdA [11,15] and TcdB [16].
The rationale for immunological approaches, including
active vaccination and passive immunotherapy targeting CD
toxins, is essentially based on this evidence [11,16,17].
Intravenous immunoglobulins showed variable efficacy as
adjunctive treatment for recurrent and severe CDI [18,19].
A growing body of evidence suggests that monoclonal
antibodies (mAbs) directed against CD toxins may provide
additional benefit to the standard treatment.
2. Chemistry
The object of the present patent is a biologic agent; hence,
aspects related to chemistry are limited. The content of major
pharmacological and clinical interest is a blend of mouse,
chimeric and humanized mAbs and antigen-binding portions
that specifically bind CD TcdA. Characteristics of different
mAbs are depicted in (Figure 1) and the composition of the
blend under examination are shown in Figure 2. The patent
encompasses the methods of production from the murine
hybridomas and corresponding mAbs, up to the characteriza-
tion of the epitope binding.
Briefly, mice were immunized with TcdA C-terminal
fragment; different clones of lymphocytes were isolated and
fused with immortal myeloma cells to obtain corresponding
hybridomas; and all DNA immunoglobulin sequences, except
complementarity determining region (CDR), were replaced
with human homologue sequences. This technology allows
the production of antibodies with low immunogenicity for
the in vivo use in humans. The patent also provided a phar-
macokinetic analysis in rat models and an evaluation of the
biological effects (survival to CDI) in mice.
3. Biology and action
These mAbs and antigen-binding portions specifically bind
the C-terminal domain of CD TcdA (Figure 3). This domain
vehicles the binding of TcdA (as well as of TcdB) to the enter-
ocyte apical membrane and is critical to the downstream
effects on the host; hence, the blockage through mAbs is a
major mechanism to neutralize toxin action [20-22].
In vitro and in vivomodels demonstrated that mAbs against
C-terminal domain are able to neutralize cytotoxicity and
hamper bowel fluid secretion and systemic toxicity [23]. Never-
theless, results in humans are still questionable, since the
administration of these mAbs to a small group of patients
did not demonstrate difference in recurrence, although a
trend toward delay in time to relapse was reported [24].
Several other mAbs with different target epitopes of the
same domain have been reported in the literature (e.g.,
3359, 3358, PCG4), but some recent evidence suggested
that a combination of different antibodies binding multiple
epitopes may have enhanced neutralizing effects than those
achievable with single targeted antibodies [25,26]. The
Article highlights.
. Current treatments are inadequate to control CDI
spreading and recurrence.
. Pathogenesis of CD is strongly related to the action of
toxins and host immune response.
. The blockage of toxin A C-terminal domain and
consequential inhibition of adhesion to enterocytes may
represent a powerful mechanism to neutralize
toxin activity.
. Toxin-targeted monoclonal antibodies are a promising
therapeutic approaches for the treatment of CDI and
its recurrence.
. Considering the recent re-evaluation of toxin A
pathogenic role, combination of toxin A-targeted
monoclonal antibodies with other treatments (including
neutralization of toxin B) may optimize its efficacy.
This box summarizes key points contained in the article.
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neutralizing effect of multiple mAbs may be due to different
mechanisms, including steric hindrance of TcdA cell receptors
and inhibition of internalization mechanisms. The object of
the present patent suits this evidence, including all antibodies
isotypes and relative subclasses with monospecific and multi-
specific activity; that means that each variable fragment is
capable of specifically bind a separate antigen or a different
epitope on the same antigen.
The patent provides a comparison with the CDA1 mAb,
whose efficacy has been demonstrated in a randomized con-
trolled trial with combined anti-TcdA and TcdB antibodies
in CDI. The blend of mAbs object of the patent binds an epi-
tope bin which is different from CDA1 but has comparable
biological activity in the animal model.
This product may be administered alone or in combination
with other therapeutic agents, including a second monoclonal
antibody (e.g., anti-TcdB), antibiotics (e.g., vancomycin or met-
ronidazole) or probiotics (e.g., Saccharomyces boulardii), through
intravenous, subcutaneous, intramuscular or transdermal routes.
4. Expert opinion
The use of toxin-targeted mAbs is one of the most promising
new therapeutic approaches for the treatment of CDI and its
recurrence. The inhibition of adhesion to enterocytes and the
simultaneous blockage or different domain epitopes may rep-
resent a powerful mechanism to neutralize TcdA activity,
arrest the course of CDI and prevent recurrences.
Administration of monoclonal and policlonal Abs against
TcdA alone, not only failed to protect from CDI, but also
appears to exacerbate the disease in piglets models [27]. The
worldwide prevalence rates of TcdA-negative/TcdB-positive
strains varies considerably (0.2 -- 3%, with picks as high as
97.9%) [14], and more than one outbreak has been
reported [28-30]. This evidence raises doubts on the efficacy
of an exclusive anti-TcdA treatment.
Hamster mortality models suggested that combination of
anti-TcdA and anti-TcdB mAbs can be more efficacious
than the administration of a single mAb [23]. This combined
approach has been recently tested by Lowy et al. who
reported a 72% relative reduction in recurrence rates in
patients receiving two fully human neutralizing mAbs
against CD toxins, compared to placebo. However, this
intervention did not reduce severity of infection, duration
of diarrhea or length of hospital stay for the initial epi-
sode [31]. However, genetic model of CD deficient in TcdA
or TcdB are not conclusive, with a study endorsing the role
of TcdB as the only capable of causing disease in hamster [12],
and another recognizing a significant role to TcdA [32]. Due
to this conflicting evidence, based on studies with different
animal models, bacterial strains and antibodies used, the
desirable strategy in term of immunopharmacologic inter-
vention for CDI still encompasses a combined anti-TcdA/
TcdB approach.
A potential action of anti-TcdA mAbs against hyperviru-
lent CD strains may be hypotizable considering the high level
of identity of the cell wall binding domain among different
CD strains. However, previous clinical trials assessing the
effects of TcdA-targeted mAbs did not reported significant
difference in prevalence of epidemic BI/NAP1/027 strain
between study population and controls [24].
More recently, downstream toxin-triggered mechanisms have
been explored as targets for new treatments, such as empower-
ment of toxins’ nitrosylation (preventing toxin cleavage and
release) [33,34] and dampening of the inflammasome-mediated
tissue damage with other biologic agents (anti-IL1b) [8].
Subjects who experienced CDI recurrence and patients
with underlying chronic conditions, in particular immune
deficiencies, are the ideal targets for this treatment. In addi-
tion, considering the reported changes in epidemiology, chil-
dren and otherwise healthy adults may potentially benefit of
this approach as a second line treatment.
The potential advantages of the passive immunization with
mAbs over other strategies, in adjunct to standard antibiotic
treatment, are the immediate effect of prevention and the
documented effect on primary CD-related diarrhea and
CDI recurrences. High costs may limit applicability of this
approach mainly in comparison to other promising emerging
therapies such as fecal microbiota transplantation [35].
A. B.
C.
Human elements
Murine elements
Complementarity determining regions (CDR)
D.
Figure 1. Different types of monoclonal antibodies (mAbs)
according to origin and method of production. A, murine
mAb; B, chimeric mAb; C, humanized mAb; D, fully
human mAb.
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Figure 2. Different components of the blend object of the patent, beyond the whole immunoglobulins, are depicted. Fab¢,
Fab fragment; F(ab¢)2, Fab fragment dimer; scFv, single-chain fragment variable; di-scFv, disulfide-linked fragment variable.
Clostridium difficile toxin A
Toxin A sequence
C-terminal
ligand-binding domain
Figure 3. Clostridium difficile Toxin A structure. The C-terminal domain is specifically targeted by the mAbs and antigen-
binding portions thereof and naturally binds the enterocyte apical membrane.
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Treatments currently available for CDI are inadequate to
impede the increased spread and virulence of the infection,
avoid recurrence or prevent infection in at-risk populations;
future efforts should focus on optimization of immune
response to CDI and its toxins.
Although available evidence are promising, before consid-
ering mAbs as a routine CDI treatment, several issues should
be addressed, including the duration of mAbs biological
activity, the impact on the host immune response (self-pro-
duction of serum Abs) and long-term effect in case
of recurrence.
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